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Summary 
 
In the last 10 years biocides have been used increasingly and questions have been raised 
about their contribution to the reported increase in biocide and antibiotic resistance in 
pathogenic bacteria. The EU Biocidal Product Regulation (BPR) now requires information on 
the risk of resistance development in organisms targeted by the biocidal product. There is 
no current protocol available to predict the likelihood of bacteria becoming resistant to a 
biocidal product or biocides contained therein. 
 
This study aimed to identify useful markers of biocide resistance and develop a step-by- 
step protocol predictive of bacterial biocide resistance and antibiotic cross-resistance 
following biocide exposure. 
 
A range of experimental techniques with the potential to generate markers of biocide 
resistance were explored. These included minimum inhibitory concentration 
(MIC)/minimum bactericidal concentration (MBC)/antibiotic susceptibility determination, 
flow cytometry, efflux activity measurements, outer membrane protein changes, real-time 
PCR and microarrays. Salmonella enterica serovar Typhimurium strains SL1344 and 14028S, 
and Burkholderia lata strain 383 were exposed to low concentrations of chlorhexidine 
gluconate and benzalkonium chloride as test biocides. Baseline and post-exposure data 
were then compared. Techniques used to understand any change in antimicrobial 
susceptibility were assessed in terms of practicality, cost and ease of use, and a step-by-
step protocol was put together accounting for each of these factors. 
Increases in biocide MIC and MBC of up to 100 fold were observed in SL1344 and 14028S 
after exposure to both biocides. However these changes were not stable after subculture 
of surviving organisms in the absence of either biocide. No such dramatic changes were 
observed within B. lata. Up-regulation of efflux activity was observed as a result of 
CHG/BZC exposure and the efflux regulatory gene acrR underwent a >100 fold down-
regulation in both Salmonella strains after CHG exposure. Flow cytometry experiments 
performed using SL1344 and 14028S indicated that at low CHG/BZC concentrations (0.0001 
– 0.0004 %) greater than 50 % of the population were not killed and that these organisms 
could be sorted and further investigated to determine the mechanisms behind their 
survival. Reduction in the expression of two outer membrane proteins was observed in 
strain SL1344 after exposure to 0.0004 % CHG but further protein sequencing would be 
required to identify these. 
Changes in phenotype and genotype of biocide-exposed bacteria were identified using 
different experimental techniques. Some of these changes e.g. increased MIC/MBC values, 
altered antibiotic susceptibility, up-regulated efflux activity, alterations in the expression of 
specific genes and surviving organisms identified by flow cytometry represent useful 
markers of biocide resistance. A preliminary step by step protocol incorporating these 
techniques was successfully developed and allows for the rapid identification of biocide 
resistance and antibiotic cross-resistance as a result of biocide exposure, and will prove 
particularly useful in light of the recent changes to the BPR.  
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Glossary 
 
Biocide: a chemical agent used to kill living organisms (Maillard, 2005) 
 
Biocidal product: any substance or mixture consisting of/containing/capable of 
generating one or more active substances with the intention of destroying/rendering 
harmless/preventing the action of any harmful organism (BPR (EU) 528/2012 
http://eur-
lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2012:167:0001:0123:EN:PDF 
accessed 11_03_2014) 
 
Biocide resistance: a change in susceptibility to a biocide that renders it ineffective 
against a micro-organism that was previously susceptible to that biocide (Maillard et 
al., 2013) 
 
Reduced biocide susceptibility: an increase in the minimum inhibitory or minimum 
bactericidal concentration of a biocide where the biocide still remains effective for its 
intended purpose (Maillard et al., 2013) 
 
Antimicrobial: an agent that kills/inhibits the growth of microorganisms – can be a 
biocide or antibiotic 
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1.1 General biocide use 
Biocides have been widely used in the control of bacteria for decades, and despite their 
increasing use, bacteria generally remain susceptible to biocides when they are used 
correctly. However, the indiscriminate use of biocides in human medicine, cosmetics, 
agriculture, livestock farming, food production, personal care products and household 
products has raised concerns about the development of bacterial biocide resistance and 
potential cross resistance to antibiotics as a result of biocide exposure. Despite the 
establishment of the European Union (EU) biocidal product regulation (528/2012 – 
discussed in section 1.3), to regulate the authorisation and use of biocidal products 
throughout the EU, the total amount of biocide use in the EU remains unknown (SCENIHR, 
2010). Concerns have also been raised over the release of biocides in to waste water and 
the surrounding environment as a result of their increased use, and the potential effect of 
this on microbial populations in soil and aquatic habitats. Concentrations present in the 
environment may be sufficient to select for bacterial strains with reduced antimicrobial 
susceptibility, and furthermore could result in increased exposure of the human and animal 
population to biocides which could lead to alterations in biocide susceptibility of micro-
flora on humans and animals. 
 
1.2 The EU biocidal product regulation (BPR) 
The aim of the BPR is to improve the free movement of biocidal products throughout the 
EU whilst protecting human, animal and environmental health. Any product used to protect 
humans/animals/other articles against harmful organisms such as bacteria or pests must be 
authorised for use. The new BPR (EU 528/2012) which came in to effect on 01/09/2013 
replaced the previous directive (98/8/EC). The active substance contained within a biocidal 
product must now be authorised for use at both Union level and member state level, 
whereas previously only member state authorisation was required. A further important 
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amendment to the BPR is the requirement by biocidal product manufacturers to provide 
information on the likelihood of resistance development to their product in target 
organisms (http://eur-
lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2012:167:0001:0123:EN:PDF accessed 
11_03_2014) 
“(13) Active substances can, on basis of their intrinsic hazardous properties, be 
designated as candidates for substitution with other active substances, whenever 
such substances considered as efficient towards the targeted harmful organisms 
become available in sufficient variety to avoid the development of resistances 
amongst harmful organisms… 
(25) … The use of low-risk biocidal products should not lead to a high risk of 
developing resistance in target organisms. 
(33) When biocidal products are being authorized, it is necessary to ensure that, 
when properly used for the purpose intended, they are sufficiently effective and 
have no unacceptable effect on the target organisms such as resistance, … When 
deciding whether a biocidal product should be authorized, due consideration should 
be given to the benefits from its use.” 
 
In addition the US Food and Drug Administration (FDA) have issued a proposed rule to 
determine the safety and efficacy of antibacterial soaps 
(http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm378542 accessed 
11/03/14). 
“The U.S. Food and Drug Administration today issued a proposed rule to require 
manufacturers of antibacterial hand soaps and body washes to demonstrate that 
their products are safe for long-term daily use and more effective than plain soap 
and water in preventing illness and the spread of certain infections. Under the 
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proposal, if companies do not demonstrate such safety and effectiveness, these 
products would need to be reformulated or relabelled to remain on the market.” 
 
“…some data suggest that long-term exposure to certain active ingredients used in 
antibacterial products—for example, triclosan (liquid soaps) and triclocarban (bar 
soaps)—could pose health risks, such as bacterial resistance …” 
 
1.3 Factors affecting biocide efficacy 
Biocide efficacy is dependent on numerous factors discussed below. 
 
1.3.1 Concentration 
Biocides are formulated for broad-spectrum activity and use on both inanimate surfaces 
(disinfection) and animated surfaces (antisepsis). Biocide activity can be measured using a 
concentration exponent 'Ƞ'. Biocides that interact strongly with bacterial targets (e.g. 
membrane active agents such as quaternary ammonium compounds and chlorhexidine) 
have a low Ƞ-value (<2) and are more likely to be affected by alterations in concentration 
than those with a high Ƞ-value (>4), e.g. biocides that have a weak physical interaction with 
the lipophilic components of the bacterial cell envelope such as alcohols or phenolics 
(Russell and McDonnell, 2000). Despite the fact that biocides may be affected by changes in 
concentration, some are incorporated in to different products at varying concentrations 
and remain effective. For example chlorhexidine digluconate (CHG) can be used at 
concentrations as high as 4 % in liquid disinfectants, but is incorporated in to hand soaps at 
lower concentrations of approximately 2 % (Larson and Laughon, 1987). However dilution 
of a biocidal product could reduce biocide concentration to a level that is below the 
minimum inhibitory concentration (MIC) for some bacteria (i.e. the lowest concentration 
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required to inhibit bacterial growth). The MIC is a lot more variable between isolates than 
the minimum bactericidal concentration (MBC) (i.e. the lowest concentration required to 
kill bacteria). This suggests that biocide dilution to a sub-lethal concentration could result in 
growth inhibition of only a small proportion of a bacterial population (Russell and 
McDonnell, 2000) resulting in persistence of bacteria with reduced biocide susceptibility. 
Bacteria have also been found to possess the ability to grow and persist in the product 
itself with bacterial survival in biocidal formulations having been reported since the 1950s 
(Maillard, 2005).  
Gilbert and McBain (2003) have proposed that there is likely to be a continuum of biocide 
concentration ranging from in-use to zero present in any environment . This suggests that 
at some point in any environment bacteria may be exposed to low and potentially sub-
lethal concentrations of a particular biocide, creating a pressure that may select for 
bacteria with reduced biocide susceptibility. This may be particularly true for bacteria 
present within the depths of a biofilm found on a surface in the home as it is less likely that 
the same concentration of a biocidal product that reaches the surface of a biofilm will 
reach the deeper layers.  For this reason it is important that the user complies with the 
recommendations of the manufacturer when using the product in order to minimise the 
development of reduced biocide susceptibility. It must also be stressed that biocide 
concentration is one of several factors that can affect biocide efficacy and must therefore 
be critically examined alongside other factors when testing the antimicrobial activity of 
biocidal products (SCENIHR, 2010, Russell and McDonnell, 2000). 
 
1.3.2 Contact time 
 
A longer contact time would usually be associated with increased efficacy of a biocide and 
the killing of a larger number of microorganisms. However Whitehead et al., (2011) 
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reported stable multi-drug resistance in Salmonella enterica serovar Typhimurium isolates  
after 5 hour exposure to the biocides Trigene and Superkill at the recommended in-use 
concentration (1 %). This lengthy exposure time may not have been expected to result in 
the emergence of mutant organisms particularly at a recommended in-use concentration. 
Depending on the application of the biocidal product, there may be a recommended 
minimal contact time when carrying out standard efficacy tests, which may be as short as 1 
min for hand soaps or 5 min for surface disinfectants (Maillard, 2005). However some of 
these products may not be as effective as claimed, even when used for the recommended 
length of time, as demonstrated by Cheeseman et al., (2009) when investigating the 
efficacy of alcoholic hand rubs used in hospitals. They reported that all three hand rubs 
tested did not produce a 4 log10 reduction in CFU/mL of Staphylococcus aureus when tested 
at contact times used in practice (approx 15 sec).  Reports like this are concerning, 
particularly as the biocidal products tested were used in a hospital environment where it is 
of high importance to minimise the spread of microbial contamination and infection. 
It is also important that concentration is taken in to account alongside contact time as 
prolonged exposure of bacteria to a very low concentration of a particular biocide has been 
reported to result in the development of biocide resistance in some bacteria. Mavri et al., 
(2013) reported the in vitro development of reduced susceptibility to triclosan, 
chlorhexidine diacetate and benzalkonium chloride in Campylobacter spp. as a result of 
repeat exposure to sub-lethal concentrations of these biocides. This also resulted in cross- 
resistance to erythromycin and ciprofloxacin. Of further concern are in vivo reports of 
infection outbreaks as a result of repeat exposure of a particular bacterium to a biocidal 
product. Duarte et al., (2009) reported an outbreak of post- surgical infections in 38 
hospitals in Brazil caused by Mycobacterium massiliense that was resistant to 2 % 
glutaraldehyde. They speculated that repeat exposure of these organisms to 2 % 
glutaraldehyde used in the cleaning of surgical instruments, combined with insufficient 
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mechanical cleaning, may have created a selective pressure for glutaraldehyde resistance.  
This highlights the risk of repeat exposure of a particular bacterium to a biocidal product 
and highlights the importance of adherence to proper cleaning procedures in a hospital 
environment. 
 
1.3.3 Interfering materials 
 
The presence of organic materials or quenching agents may affect the activity of a biocidal 
product. Standard efficacy testing protocols such as the BS EN 1276 (2009) suspension 
testing protocol provide guidelines for testing a biocidal product under clean and dirty 
conditions so that comparisons can be made. Reduced biocide efficacy has been observed 
in the presence of other compounds. For example, Benson et al., (1990) found that the use 
of anionic moisturising products on the hands after a chlorhexidine-based hand wash had 
been applied inhibited all residual antimicrobial activity of the hand wash. Otter et al., 
(2012) found that the presence of bovine serum albumin (used to represent dirty 
conditions) reduced the efficacy of hydrogen peroxide vapour against S. aureus in vitro, 
concluding that sub-optimal cleaning may reduce biocide efficacy. The clinical application 
of the biocidal product must therefore be considered and precautions must be taken to 
ensure the efficacy of the product is not affected. 
 
1.3.4 Temperature and pH 
 
Temperature and pH may also have an effect on the activity of a biocide. A specific 
temperature may be required for activation of the biocide in processes such as the 
sterilization of medical equipment (Maillard, 2005). Standard protocols such as the BS EN 
1276 (2009) suspension testing protocol specify that temperature must be controlled for 
the duration of the test performed in order to minimise variability in results due to 
temperature fluctuations. Certain formulations may also have a specific storage 
8 
 
temperature required for preservation of the product. Leung et al., (2004) investigated the 
effect of storage temperature on the efficacy of contact lens solutions against 
Pseudomonas aeruginosa and found that optimum storage temperature ranged between 
25 – 30 °C and that solutions stored at fridge temperature showed reduced efficacy and 
reduced shelf-life. This highlights the importance of correct storage of biocidal products to 
ensure that antimicrobial activity is not reduced. 
pH may affect the overall charge of the biocide which could alter its ability to interact with 
the target microorganism, particularly in the case of Gram-negative organisms that possess 
a cell wall with a negative charge. The activity of cationic biocides such as chlorhexidine can 
be enhanced if the pH is increased (Russell, 2004). The pH can also affect the availability of 
chlorine in biocides such as sodium hypochlorite (Guerreiro-Tanomaru et al., 2011). 
Guerreiro-Tanomaru et al., (2011) reported that lower pH resulted in a reduction in 
available chlorine, but that this did not affect the activity of sodium hypochlorite against 
Enterococcus faecalis. Despite the activity of sodium hypochlorite not being affected in this 
particular case, it is clear that pH should be controlled when testing the efficacy of a 
biocidal product, so that antimicrobial activity is not quenched and the test concentration 
remains accurate and false-negative results are not obtained. 
The nature of the microorganism targeted may also affect the activity and efficacy of the 
biocide. Factors that contribute to bacterial resistance to biocides are discussed in section 
1.4. 
 
1.4 Mechanisms of bacterial resistance to biocides 
 
Antibiotics usually have a specific bacterial cellular target, and antibiotic resistance 
therefore typically occurs due to modification of this particular target. Biocides have 
multiple target sites in bacterial cells and it is therefore less likely that bacteria can become 
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resistant to a particular biocide via the alteration of a target site although there are 
exceptions (Bailey et al., 2009). Biocide resistance therefore generally occurs as a result of 
mechanisms that decrease the concentration of a particular biocide to a level that is not 
lethal to the bacterial cell or prevent the entry of the biocide in to the cell. Examples of 
biocide resistance mechanisms are discussed below. 
 
1.4.1 Cell permeability 
 
Bacterial intrinsic insusceptibility to biocides may be associated with changes to the outer 
layer that alter cell permeability and restrict the uptake of the biocide into the bacterial cell 
(Dubois-Brissonnet et al., 2011, Ferreira et al., 2011). Gram-negative bacteria such as 
Salmonella and Burkholderia spp. tend to be less susceptible to biocides than Gram-
positive bacteria due to the presence of a lipid-rich outer membrane. This membrane is 
composed of phospholipids, fatty acids, lipopolysaccharide (LPS) and porins that aid in 
limiting the uptake of the biocide in to the cell (Mensa et al., 2011). It also possesses a 
negative charge which may result in the repulsion of biocide molecules away from the 
bacterial cell. Figure 1.1 illustrates both the Gram-positive and Gram-negative bacterial cell 
walls.  Mycobacterium spp. possess a lipid-rich cell envelope composed of mycolic acids 
(Portevin et al., 2004) which have been associated with antimicrobial resistance. This layer 
prevents the Gram staining of this species, and maintains the structural integrity of the 
membrane and has been associated with resistance to oxidising agents such as hydrogen 
peroxide (Yuan et al., 1995). 
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Figure 1.1: A comparison of the Gram-positive and Gram-negative bacterial cell walls 
Image taken from (Alberts et al., 2002)  
 
Alteration and modification of the bacterial cell membrane in response to biocide exposure 
has been described on more than one occasion. Dubois-Brissonnet et al., (2011) described 
the modification of membrane fatty acid composition resulting in increased tolerance to 
peracetic acid and dodecyl ammonium bromide in Salmonella enterica serovar 
Typhimurium. They found that exposure to sub-MIC concentrations of natural plant-
derived terpenes used as chemical preservatives in the food industry resulted in the 
increased production of saturated fatty acids throughout all bacterial growth phases. This 
change was thought to stabilise the membrane in the presence of antimicrobials that exert 
their effects on the cell via the partitioning of the lipid membrane.  Tattawasart et al., 
(2000) reported that chlorhexidine diacetate resistant Pseudomonas stutzeri had an altered 
outer membrane protein profile and found the expression of two additional protein bands. 
They also observed changes in LPS that were thought to contribute to cross- resistance to 
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other antimicrobial agents aside from chlorhexidine diacetate, such as polymyxin B 
sulphate and gentamicin. 
Despite the increased biocide susceptibility observed in Gram-positive bacteria (compared 
to Gram-negatives), certain Gram- positive species of bacteria, such as Clostridium spp. and 
Bacillus spp. have the ability to form spores when under environmental stress such as 
nutrient starvation. Bacteria in spore form exist in a dormant state and can survive in this 
state for many years (Leggett et al., 2012). The presence of a spore coat, composed of 
highly cross-linked proteins is thought to contribute to intrinsic resistance to antimicrobials, 
as treatment of spores with chemical disruptors of disulphide bonds has been shown to 
increase spore susceptibility to hydrogen peroxide and lysozyme (Gould, 1970).  
 
1.4.2 Biofilm formation 
 
It has been estimated that > 90 % of bacteria in nature exist as a biofilm (Baugh et al., 
2013). A biofilm is a structured community of bacteria attached to a surface by 
exopolymeric substances (Vickery et al., 2012). Biofilms can consist of monocultures, of 
several diverse species, or of mixed phenotypes of a given species. An environment limited 
in nutrients has been shown to induce a ‘stress’ response where bacteria adopt a resting or 
dormant phenotype similar to that of endospores which are resistant to numerous 
chemical agents (Leggett et al., 2012). Bacteria within a biofilm therefore typically exist in a 
slow growing, nutrient-depleted state, or non-growing state (Gilbert and McBain, 2003) 
and have an altered phenotype in comparison to planktonic (non-biofilm) species.  
In a hospital environment biofilms are generally found on moist surfaces such as catheters, 
disinfecting soap dispensers, instruments regularly immersed in fluid, as well as other 
places including patients which can lead to the increased spread of infection (Vickery et al., 
2012). There are numerous examples of human infections caused by biofilms including 
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Burkholderia in the lungs of cystic fibrosis patients (Peeters et al., 2008) and Legionella 
pneumophilia causing legionellosis (Baugh et al., 2013). 
 
Some biofilm-forming bacteria have been shown to be 10 - 100 fold more resistant to 
antimicrobials in comparison to their planktonic counterparts (Rose et al., 2009, White and 
McDermott, 2001). Furthermore, the exchange of mobile genetic elements between 
bacteria within biofilms has been reported (Antonova and Hammer, 2011). Antonova & 
Hammer (2011) observed that Vibrio cholera present in a biofilm produce an autoinducer 
molecule that allows them to become naturally competent to take up extracellular DNA. 
This demonstrates the possibility of the acquisition of resistance genes amongst bacteria 
present in a biofilm, and may further contribute to the reduced biocide susceptibility of 
these bacteria. Wong et al., (2010b) tested the efficacy of benzalkonium chloride (BZC), 
CHG, citric acid, sodium hypochlorite and ethanol against planktonic S. enterica serovar 
Typhimurium cells and 3 day old S. enterica serovar Typhimurium biofilms at recommended 
in-use concentrations, and found that all biocides were able to reduce the number of 
biofilm cells, but still left some viable cells, whereas all planktonic cells were eliminated. 
This demonstrates the reduced biocide susceptibility of cells present in a biofilm and the 
potential for further spread of infection if a biofilm is not completely eliminated. It has also 
been reported that biofilm age has no effect on the efficacy of the antimicrobial and that 
older biofilms are no more or less susceptible to biocides than new biofilms (Wong et al., 
2010a). Wong et al., (2010b) suggested that an increase in concentration and contact time 
was the only way to ensure 100 % reduction of viable cells present in a biofilm.  The need 
to increase biocide concentrations in order to kill biofilms could result in high 
environmental toxicity and increased costs, and may also create a selection pressure for 
increased biofilm development amongst bacterial species. 
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1.4.3 Metabolism 
 
As biocides generally have multiple targets (e.g. cell wall, cytoplasmic membrane, DNA, 
proteins) in the bacterial cell it is unlikely that biocide resistance would occur due to 
biocide inactivation by bacteria. However, the break down and inactivation of quaternary 
ammonium compounds (QACs) has been reported. Nishihara et al., (2000) showed that 
Pseudomonas fluorescens TN4 isolated from sludge was able to degrade 
didecyldimethylammonium chloride which is a QAC. This isolate was also able to degrade 
other QACs via an N-dealkylation process. The initial parent compound was broken down 
after 24 h and the first metabolite was then further broken down after a period of 7 days. 
This strain was found to be highly resistant to the compounds it could break down 
demonstrating the presence of bacteria that are able to degrade QACs in the environment.  
Biocide use in waste water treatment, industry, building materials and fuel may result in 
the release of biocide residues in to the environment, although the exact quantities are 
unclear (SCENIHR, 2010). Biocide residues in the environment may create a selective 
pressure for the clonal expansion of bacteria with the ability to degrade certain 
compounds, contributing to biocide resistance. 
 
Although there are very few reports of bacteria that are able to directly break down 
biocides, there is evidence of bacteria making alterations to a specific metabolic pathway 
targeted by a biocide in order to prevent damage to the bacterial cell. Bailey et al., (2009) 
described a triclosan-specific alteration in metabolism in S. enterica serovar Typhimurium 
that assisted in the protection of the bacterial cell from the biocide. They demonstrated 
through the use of DNA microarrays that the bacterium was able to down-regulate 
expression of the fab gene cluster associated with fatty acid biosynthesis and up-regulate 
pyruvate synthesis genes in order to by-pass the inhibitory effects of triclosan, which 
inhibits fatty acid biosynthesis at low concentrations, preventing cell membrane synthesis. 
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Due to the specificity of this alteration in response to biocide exposure there is not yet any 
reported evidence of cross -resistance to antibiotics. 
 
1.4.4 Efflux 
 
Efflux is the pumping of a solute out of a cell, and efflux pumps are present in all organisms. 
In bacteria efflux pump genes can be chromosomally encoded or found on mobile genetic 
elements such as plasmids. Efflux pumps are proteins that span the bacterial cell 
membrane and can either transport a single, specific substrate or a range of structurally 
similar compounds (Nikaido and Pages, 2012). Examples of bacterial efflux pump substrates 
include dyes, detergents, antibiotics (e.g. quinolones, fluoroquinolones, chloramphenicol, 
and tetracycline) and biocides (e.g. cetrimide, triclosan). Many bacterial efflux pumps are 
now well characterised and have been associated with a multidrug resistant phenotype 
(Guo et al., 2013, Buroni et al., 2009, Smith and Hunter, 2008). There are five well-
described efflux pump families in bacteria. These are shown in figure 1.2. Pumps are 
classified based on the number of components a pump has, the energy source required for 
the pump to transport substrates, the number of transmembrane spanning regions and the 
type of substrate (Piddock, 2006b). Different species of bacteria can express more than 1 
type of efflux pump. 
In Gram-negative bacteria, the type of efflux pump most commonly associated with multi-
drug resistance is the resistance nodule division (RND) type pump. RND pumps are 
composed of a tripartite system. E.g. the AcrAB-TolC efflux pump in E. coli and S. enterica 
serovar Typhimurium is composed of an inner membrane transporter (AcrB), an accessory 
protein present in the periplasmic space (AcrA) and an outer membrane protein (TolC) 
(Hinchliffe et al., 2013). Substrates of this pump include chloramphenicol, quinolones, 
tetracycline, triclosan, nalidixic acid and triton X-100 (Nikaido and Zgurskaya, 2001). Bailey 
et al., (2009) reported that deletion of this efflux system in S. enterica serovar Typhimurium 
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resulted in a 4 to 10-fold increase in triclosan susceptibility, whereas over-expression of 
this system lead to a 2 to 4-fold decrease in triclosan susceptibility. Guo et al., (2013) also 
attributed BZC resistance in S. enterica serovar Typhimurium BZC- resistant mutants to 
constitutive over-expression of AcrAB-TolC. Of further concern was that inactivation of 
AcrAB-TolC in these mutants resulted in increased expression of AcrEF-TolC in order to 
maintain BZC resistance. 
 
 
Figure 1.2: The 5 classes of bacterial efflux pump 
MATE = multidrug and toxic compound extrusion. MFS = major facilitator superfamily. SMR 
= small multidrug resistance. RND = resistance nodule division. ABC = ATP-binding cassette. 
Figure taken from (Piddock, 2006a) 
 
In Gram-positive bacteria the main class of efflux pump associated with multi-drug 
resistance is the major facilitator superfamily (MFS) (Saidijam et al., 2006). An example of a 
well characterised efflux pump of this type is the chromosomally-encoded pump NorA 
present in S. aureus. Huet et al., (2008) found that repeat exposure of S. aureus isolates to 
sub-lethal concentrations of several biocides including chlorhexidine and BZC resulted in 
mutants over-expressing norA and norC due to mutations in the promoter regions of these 
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genes. They highlighted the concern for hospitalised patients that are treated with 
antibiotics such as ciprofloxacin and norfloxacin that are also substrates for these pumps. 
Bacterial efflux pump genes can also be acquired through horizontal gene transfer. 
Transformation, transduction and conjugation are all types of this process (Koraimann and 
Wagner, 2014). Plasmids and transposons are transferable between bacteria of the same 
species or bacteria of different species and can both carry resistance genes. An example of 
plasmid-borne efflux pump genes is qac genes. Qac efflux pumps confer resistance to 
quaternary ammonium compounds, such as BZC, hence their name but also have further 
substrates including chlorhexidine, intercalating dyes and triclosan (Smith and Hunter, 
2008). Smith and Hunter (2008) reported the presence of multiple qac genes in clinical 
isolates of S. aureus and methicillin-resistant S. aureus (MRSA). These isolates had much 
higher MBCs for the biocides tested than isolates that did not possess qac genes. Plasmid 
transfer of qac genes is not exclusive to Staphylococci. Salmonella spp. can also acquire 
qacE which confers resistance to multiple biocides (White and McDermott, 2001). External 
chemical stress, such as biocide exposure may promote the maintenance of transferable 
resistance genes and increased transfer of these genes. However there is little evidence of 
this, and Pearce et al., (1999) reported that exposure of S. aureus isolates to sub-lethal 
concentrations of chlorhexidine reduced the transfer of a resistance plasmid (pWG613) via 
conjugation or transduction.  
 
Gilbert and McBain (2003) have speculated that the increased use of biocides could 
potentially create a selection pressure for mutant strains that hyper-express these multi-
substrate efflux pumps when exposed. This hyper-expression could occur via a point 
mutation in the efflux gene promoter or a mutation in the global repressor (Baucheron et 
al., 2004a). These mutations may result in over-expression of the gene in the absence of 
the substrate that induces its expression. This would result in reduced susceptibility to any 
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other substrates that come into contact with the bacterial cell, including antibiotics, which 
may lead to limited therapeutic options when treating an infected patient. 
 
1.5 Biocide resistance in the clinical environment 
Biocides have a range of clinical applications including disinfection of both hospital surfaces 
and pre-operative patient skin, sterilisation of medical equipment and general infection 
prevention via incorporation in to hospital bed linens and curtains. Examples of biocides 
commonly used in the hospital environment include cationic biocides such as QACs (e.g. 
BZC), chlorhexidine, cetrimide and triclosan (Bailey et al., 2009, Smith and Hunter, 2008). 
 
Biocides used to control the growth of pathogenic organisms in a clinical environment can 
be categorised based on the level of bacterial inactivation reached. For example, low-level 
disinfectants (e.g. isopropyl alcohol) may only eliminate vegetative bacteria whereas high-
level disinfectants (e.g. hydrogen peroxide) inactivate many microorganisms including 
vegetative bacteria, mycobacteria, viruses and most fungi (Rutala and Weber, 2007). Low-
level disinfectants are commonly used to disinfect ‘non-critical’ hospital devices that come 
into contact with intact skin (e.g. stethoscopes, electrocardiogram cables). These devices 
are unlikely to transmit infectious agents to patients and therefore do not require high-
level disinfection (Dettenkofer et al., 2004). ‘Critical’ devices that penetrate sterile tissues 
(e.g. catheters, needles) are sterilised using high-level disinfectants.  
 
Hospital-acquired infections (HAIs) cause significant morbidity and mortality in the UK with 
approximately 6.4 % (3,360 out of 52,443) of hospital patients in the UK acquiring an 
infection whilst in hospital per year.  Enterobacteriaceae are the most frequently reported 
organisms associated with HAI (English National Point Prevalence Survey on Healthcare-
associated Infections and Antimicrobial Use, 2011 
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http://www.hpa.org.uk/servlet/Satellite?c=HPAweb_C&pagename=HPAwebFile&renderm
ode=previewnoinsite&cid=1317134304594 accessed 11/03/2014). This emphasises the 
requirement for effective disinfection procedures and the correct use of the appropriate 
biocidal products in order to prevent the spread of infection.  One of the main issues is that 
the study of the efficacy, mode of action and mechanisms of resistance to biocides is fairly 
limited when compared to current knowledge of antibiotics. The efficacy of a particular 
biocidal product is usually tested in vitro and experimental conditions may not reflect the 
final application of the product (SCENIHR, 2010) which may result in inaccurate efficacy 
data. Standard tests and protocols that are available for testing bacterial susceptibility to 
antibiotics are not available for biocides and responses to different biocides vary 
enormously between species and strains. 
 
Russell (2004) concluded that biocides are only really required in high risk areas where the 
spread of HAIs is high e.g. in the sterilisation of medical equipment but not perhaps in areas 
that are rarely heavily contaminated such as hospital walls and ceilings. With the increased 
use of biocides it can be assumed that bacteria in the clinical environment are being 
exposed to biocidal products more frequently. Regular exposure to biocide stress could 
lead to genetic, biochemical, functional or physiological changes in the bacterial cell that 
select for bacteria with greater tolerance to these conditions and biocide exposure 
(SCENIHR, 2010). For example Block and Furman (2002) found that in clinical areas of a 
hospital where chlorhexidine was used more intensely, micro-organisms isolated from 
patients showed decreased in susceptibility to this biocide. 
 
It has been argued that bacterial strains showing reduced susceptibility to biocides are still 
not a major health concern as generally biocides are used at high concentrations that are 
lethal to these strains (Thomas et al., 2005). However Duarte et al., (2009) reported an 
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epidemic of rapidly growing Mycobacterium massiliense in patients that had undergone 
surgery in one of 63 hospitals in Rio de Janeiro, Brazil. Five isolates belonging to a specific 
clonal group referred to as BRA100 were resistant to 2 % glutaraldehyde solution which 
had been commercially used in the sterilisation of surgical instruments. All isolates tested 
were also found to be clinically resistant to ciprofloxacin, cefoxitin and doxycycline. This 
finding contradicts the claim that much higher, in-use concentrations of biocides are highly 
effective.   
Despite in vitro studies demonstrating reduced biocide susceptibility as a result of bacterial 
exposure to sub-lethal biocide concentrations, fewer in vivo reports of this exist and a 
concrete relationship between increased biocide use in the clinical environment and 
biocide resistance in bacteria is yet to be established. It remains essential for the users of 
biocidal products to comply with the manufacturers recommendations in terms of 
concentration, application and conditions of use in order for them to remain effective in 
the prevention of contamination and infection. 
 
1.6 Biocide resistance in the domestic environment 
 
It has been suggested that if the use of biocides in the clinical environment is affecting 
antimicrobial resistance, a similar situation could be seen in the domestic environment 
(Gilbert and McBain, 2003). Home hygiene is considered by the public as essential in the 
prevention of the spread of infectious diseases. Regular use of household products such as 
laundry detergents, cleaning products, pet disinfectants and general disinfectants are the 
major sources of bacterial exposure to biocides in home settings (Gilbert and McBain, 
2003). In order to maintain hygiene in the home various cleaning procedures can be carried 
out. The responsible and correct use of biocidal products in the home will contribute to 
reducing the spread of infection. It is therefore important that the use of biocides is not 
discouraged in the home as it is largely beneficial. 
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The International Scientific Forum on Home Hygiene (IFH) (http://www.ifh-
homehygiene.org/ accessed 11_03_14) collected data to determine the lead causes of 
transmission of pathogens in the home. Hands, hand contact surfaces, food contact 
surfaces and cleaning utensils were identified as critical points of transmission in the home, 
as well as clothing and household linens (Bloomfield et al., 2012). The IFH describe a ‘chain 
of pathogen transmission’ and suggest the identification of critical points of intervention 
throughout the chain in order to prevent transmission. Intervention strategies included 
promotion of effective hand hygiene e.g. using alcohol hand gel, and instigating a change in 
behaviour towards home hygiene, e.g. hygienic disposal of household waste (Bloomfield et 
al., 2012).  
Biocidal products that are used to disinfect surfaces in the home, and those used as hand 
washes may leave a low residual concentration after their use (SCENIHR, 2010, Thomas et 
al., 2000). Hand washes typically do not have a contact time of more than one minute with 
the skin before being washed off. It is therefore quite likely that a residual concentration of 
the biocide will remain on the skin. Exposure of bacteria to sub-lethal concentrations of a 
biocide may create a selective pressure for organisms with reduced antimicrobial 
susceptibility (Christensen et al., 2011). However Jones (2000) reported that although the 
frequent use of antimicrobial hand wash products can bring about changes in the human 
skin micro-flora, it has not been associated with increased antimicrobial resistance. As a 
large number of studies focus on the relationship between biocide use and biocide 
resistance in the clinical environment, a concrete relationship between increased biocide 
use in the home and the isolation of biocide-resistant bacteria is yet to be established. 
 
1.7 Test protocols to measure bacterial resistance to biocides 
Different studies use different methodologies when testing bacterial susceptibility to 
biocides, but each of these alone provides limited information on the activity of the 
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biocide, and different microorganisms respond in different ways. Many factors need to be 
considered in biocide susceptibility testing including in vivo conditions such as pH and 
temperature, as well as the concentrations to be tested and their reflection of the 
recommended or in-use concentrations.  
Biocides should be tested at concentrations recommended for use by the manufacturer. 
However in-use concentrations may vary from the recommended concentration intended 
for use due to biocidal product application. The presence of organic load (e.g. dirt) or 
product dilution may alter the in-use concentration and this must also be accounted for 
during susceptibility testing. 
In addition, after biocide use there may be a residual concentration remaining. For example 
if a biocide is incorporated in to a surface cleaner, there may be a lower, residual 
concentration of that biocide remaining after the surface has been wiped clean. This 
remaining concentration may have a different effect on target microorganisms and biocide 
efficacy should also therefore be tested at these residual concentrations. Biocide 
manufacturers do not currently provide information on the effect of bacterial exposure to 
residual biocide concentrations, but it has been reported in the literature that this type of 
exposure can lead to the selection of isolates with reduced antimicrobial susceptibility 
(Christensen et al., 2011, Whitehead et al., 2011). Furthermore, information on the 
likelihood of resistance development now must be provided by product manufacturers 
according to the BPR (http://eur-
lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2012:167:0001:0123:EN:PDF accessed 
11_03_2014).  
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1.7.1. Non-molecular protocols 
1.7.1.1 Minimum inhibitory and minimum bactericidal concentrations 
Many reports on emerging bacterial resistance to biocides are based on the determination 
of minimum inhibitory concentrations (MICs) (Skovgaard et al., 2013, Kastbjerg and Gram, 
2012, Buffet-Bataillon et al., 2011). Using MICs to measure biocide resistance is arguable 
since much higher concentrations of biocides are used in practice and resistance to a 
biocide due to elevated MICs has been deemed unlikely (Russell and McDonnell, 2000). 
Some studies have shown that bacterial strains showing a significant increase in the MIC for 
a particular biocide were nevertheless susceptible to higher (in-use) concentrations of the 
same biocide (Thomas et al., 2005, Lear et al., 2002) and others have shown no change in 
the MIC of a biocide after exposure to an in-use concentration, despite altered antibiotic 
MICs (Whitehead et al., 2011). One study by Carson et al. (2008) found that bacteria with 
high QAC MICs isolated from the domestic environment in which antimicrobial products 
containing QACs had been used for a year, also had high triclosan MICs and were more 
likely to be resistant to an antibiotic. Despite providing limited information on resistance to 
in-use biocide concentrations, MICs may be indicative of a trend towards resistance and 
therefore may be useful in combination with other techniques used to measure biocide 
resistance such as determination of the MBC. 
Concentration is central to biocide efficacy. It may therefore be more appropriate to 
measure bacterial lethality rather than bacterial growth after biocide exposure. 
Determination of the MBC may therefore be considered a more appropriate methodology 
that allows the comparison of lethality between a wild type (normally susceptible) strain 
and potentially resistant strains. It is important that a neutralising agent is used when 
determining the MBC to avoid getting an overestimation of the lethal concentration. 
Several studies have used the MBC as an indication of biocide resistance (Knapp et al., 
2013, Kawamura-Sato et al., 2010, Rose et al., 2009). For example Knapp et al., (2013) 
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compared the MBC of CHG and BZC before and after exposure of Burkholderia lata to low 
concentrations of these biocides, in order to predict biocide resistance in this species. The 
MBC is a simple, straightforward measurement that allows a large number of 
strains/biocidal products to be tested at one time and in a 24 hour time period, allowing 
rapid data generation. It is also simple to compare MBC values and in-use biocide 
concentrations in order to identify resistant strains. 
 
1.7.1.2 Suspension tests & surface disinfection tests 
Suspension tests are a simple way to evaluate the antibacterial activity of a biocide 
allowing the user to determine the effect of concentration and contact time on biocide 
efficacy. There are standard protocols available for suspension tests, e.g. BS EN 1276 (2009) 
that provide guidelines on temperature and pH maintenance, biocide diluents and 
appropriate neutralising agents. One of the biggest limitations of a suspension test is that 
the neutralisation and enumeration steps result in dilution of the bacterial suspension 
which creates a limit of detection with regards to the enumeration of surviving organisms.  
It also must be taken in to account that biocides have a wide variety of applications, and 
that in many cases a suspension test alone may not be efficient in the evaluation of the 
bactericidal activity of a biocide, nor may it be an appropriate reflection of the in vivo 
conditions in which the biocide would be used.  
Alternatively a surface disinfection test could be used to look at the bactericidal activity of 
a biocide against bacteria colonising surfaces rather than those held in suspension. This 
involves the drying of washed bacterial cells before exposure to a particular biocide, in 
order to represent in-use conditions (Ojeil et al., 2013, Thomas et al., 2005). For example 
Ojeil et al., (2013) used a surface disinfection test to determine the efficacy of copper alloy 
and stainless steel surfaces in removing bacterial bioburden. A surface test can also be used 
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to look at the effect of bacterial exposure to residual concentrations of biocide remaining 
after a cleaning procedure has taken place (Thomas et al., 2005). 
 
1.7.1.3 Growth kinetics 
Experiments involving growth kinetics and looking at growth curves cannot directly 
measure bacterial resistance to biocides, but may give an indication of a trend towards 
decreased susceptibility. An extended lag phase before entry in to exponential phase in 
biocide-exposed bacteria may be indicative of the initial inhibitory effects of the biocide on 
the bacterial cell, followed by putative adaptation to the presence of the biocide and the 
ability to of the bacterium grow (Whitehead et al., 2011). The comparison of growth 
kinetics between biocide-exposed and non-biocide-exposed bacteria can also give an 
indication of any inhibitory effects the biocide has on growth and the severity of these. 
Growth curve analysis can therefore be used as an indicator of a trend towards reduced 
susceptibility (Whitehead et al., 2011) to a particular antimicrobial product but may be 
more useful when used in combination with other tests such as MIC and MBC 
determination. 
 
1.7.1.4 Biofilm susceptibility tests 
Bacteria frequently exist in biofilms in situ. Despite this there is no standard protocol for 
measuring the susceptibility of bacteria within a biofilm to biocides (SCENIHR, 2010). This is 
likely to be due to the fact that it is difficult to mimic in situ conditions in the laboratory and 
that there numerous available methods that can be used to grow biofilms (McBain, 2009). 
The use of different methods to grow biofilms is likely to result in variability in results 
obtained from biocide susceptibility tests, and the design of a standard protocol to 
measure the effect of biocide exposure on biofilms would therefore prove useful in 
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providing susceptibility data using parameters representative of in vivo conditions. This 
protocol could include; observation of biofilm development after biocide exposure, 
investigation into the role of persister cells within the biofilm and susceptibility of re-grown 
biofilms after initial biocide exposure (SCENIHR, 2010).  
 
1.7.2 Molecular Protocols 
Alternative methods used to measure or identify biocide resistance in bacteria involve 
looking at changes in the transcriptome or proteome. A change in the transcriptome, i.e. an 
increase or decrease in the amount of mRNA present, may be indicative of increased or 
decreased expression of a particular gene. However, changes in the amount of mRNA 
present do not always lead to changes in the proteome, as the amount of protein present is 
more reflective of the cell conditions and stability of the protein itself. Proteomics allows 
the validation of changes seen in the transcriptome and also allows the investigation of 
post-translational modification of proteins which may have an effect on their activity in the 
cell. 
 
1.7.2.1 Microarrays 
Microarrays allow the user to observe genome wide changes in gene expression and can 
uncover patterns of genetic activity, help provide new understanding of gene functions 
and, in the case of biocide resistance, generate insight into transcriptional processes and 
biological mechanisms (Ricke et al., 2013). Microarray technology involves the fluorescent 
labelling of control and treated cDNA samples that have been reversed transcribed from 
RNA isolated from the relevant organism/sample. The labelled cDNA is then hybridised to a 
microarray slide containing oligonucleotides representing all the genes present in the 
genome of a particular organism (in the case of bacteria) (Leveque et al., 2013). Fold 
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increases and decreases in gene expression in control and biocide-treated samples can be 
compared allowing the user to identify groups of genes associated with a particular 
response to biocide exposure. Microarray data may also provide an insight into putative 
mechanisms of biocide resistance which when combined with data from other 
susceptibility tests may provide more information on how and why a particular bacterium 
has become biocide resistant. Despite providing a large amount of data on genome-wide 
changes after biocide exposure, microarrays are expensive and time consuming 
procedures. Data analysis itself may also prove time consuming and reasons behind 
changes in certain groups of genes may be difficult to ascertain, particularly if the 
mechanism of action of the biocide tested is unknown and putative resistance mechanisms 
in the test organism have not been determined. It may therefore be useful to study 
selected groups of genes that have a potential association with observed biocide 
resistance, using techniques such as real-time and semi-quantitative polymerase chain 
reaction (PCR). 
 
1.7.2.2 Real-time & semi-quantitative PCR 
PCR can be used to validate microarray observations or to investigate changes in the 
expression of specific genes of interest. PCR involves the amplification of a particular gene 
using forward and reverse primers specific to that gene sequence, and a DNA polymerase 
that makes copies of the gene sequence. Semi-quantitative PCR products are 
electrophoresed on an agarose gel and stained with a dye such as ethidium bromide that 
binds DNA, appearing as bands on the gel (Davis, 2014). Semi-quantitative PCR therefore 
does not allow precise quantification of the product. 
Real-time PCR involves the staining of a cDNA copy of extracted RNA with a dye that 
fluoresces when bound to double-stranded DNA (e.g. SYBR green) – i.e. fluorescence occurs 
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in real time, as the gene of interest is amplified by DNA polymerase. An increase in 
fluorescence is therefore associated with increased amplification of the gene. Real-time 
PCR reactions result in the production of Ct values – this is the point where fluorescence 
crosses a threshold level (set by the user) and becomes exponential (Davis, 2014). A 
melting point analysis of PCR products can also be carried out when all reaction cycles are 
complete, to check for contaminants or primer dimers. The PCR product will be a specific 
length and therefore have a specific melting temperature. Fold increases or decreases in 
gene expression can then be calculated, taking in to account the efficiency of the primers 
used (Pfaffl, 2001), therefore making real-time PCR a quantitative method of studying 
changes in gene expression. 
 
1.7.2.3 Proteomics 
Outer membrane or total proteins can be extracted from treated and untreated bacterial 
cells and electrophoresed using sodium dodecyl sulphate polyacrylamide gel 
electrophoresis (SDS-PAGE). Proteins can be separated by mass (one dimension) or mass 
and isoelectric point (2 dimensions). The staining of proteins with stains such as Coomassie 
stain or silver nitrate (binds cysteine) stain allows the visualisation of proteins on the gel. 
Comparisons can then be made between proteins present/absent in biocide- treated and 
untreated bacteria. This technique alone does not allow the identification of proteins. 
However when used in combination with mass spectrometry, proteins can be identified 
(Van Oudenhove and Devreese, 2013). Specific proteins can also be detected using 
Western blotting. This involves gel electrophoresis of proteins, before their transfer to a 
nitrocellulose membrane where they are stained with an antibody specific to the protein of 
interest (Patton, 2002). Western blotting is useful if one has knowledge of particular 
proteins associated with biocide resistance, whereas one or two dimensional SDS-PAGE is 
useful for the identification of changes in total protein. 
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1.7.3 Measuring susceptibility to antibiotics 
There are several standard protocols available for the measurement of bacterial 
susceptibility to antibiotics. These are available from the British Society for Antimicrobial 
Chemotherapy (BSAC) (Andrews, 2009) and the Clinical and Laboratory Standards Institute  
(www.CLSI.org accessed 11_03_14), amongst others. These protocols include susceptibility 
breakpoints that give an indication of how clinically sensitive or resistant an individual 
bacterial species is to a particular antibiotic. The limitations of these guidelines are that 
susceptibility breakpoints are not always provided for certain species of bacteria (e.g. BSAC 
disk diffusion protocol does not provide breakpoints for Burkholderia spp.). There is at 
present no standard protocol available for measuring the capability of biocides to confer 
cross resistance to antibiotics, but such a protocol would be useful due to the numerous 
reports of antibiotic resistance as a result of biocide exposure (Knapp et al., 2013, 
Christensen et al., 2011, Whitehead et al., 2011, Randall et al., 2007). 
 
1.8 Generating bacterial resistance to biocides 
There is no standard protocol for the generation of bacteria that are resistant to a 
particular biocide. The generation of biocide-resistant mutants is useful as it allows the 
exploration of mechanisms behind resistance to a particular biocide, investigation in to the 
effect of the developed resistance on virulence or growth and the identification of any 
cross- resistance to other biocides or antibiotics.  
A common in vitro method that has successfully generated biocide resistant bacteria 
involves the stepwise passaging of bacteria through gradually increasing concentrations of 
a particular biocide, either on agar or in broth. For example Pagedar et al., (2012) produced  
E. coli mutants adapted to BZC via 24 h subculture of isolates in nutrient broth 
supplemented with gradually increasing concentrations of BZC. They reported that 
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resistant isolates showed a significant increase in efflux pump activity and were better at 
biofilm formation than non-resistant isolates. This demonstrates how the in vitro 
generation of biocide resistant mutants provides useful information on the effects of 
biocide exposure and potential mechanisms behind the resistance, and highlights the 
usefulness of developing a standard protocol for the generation of biocide-resistant 
mutants. However it must be noted that the bacterial species and mechanism of action of 
the biocide used may have an effect on the successful generation of resistant mutants. This 
means that a single, universal method may not be possible, as ideally the method would be 
based on conditions under which the biocidal product is used (Maillard and Denyer, 2009). 
Parameters that could be kept consistent could include the preparation of the test 
inoculum, the number of repeats performed, appropriate neutralisation of the test product 
and investigation in to resistance to the in-use concentration of the product (Maillard and 
Denyer, 2009). 
 
1.9 Biocides used in this study 
1.9.1 Chlorhexidine digluconate (CHG) 
Chlorhexidine has been used as a topical antiseptic for over 50 years, and is effective 
against Gram-positive, Gram-negative and non-spore forming bacteria, yeast and lipid 
envelope viruses including HIV (Edmiston et al., 2013). Chlorhexidine is a cationic, 
biguanide molecule and is available in the acetate, gluconate and hydrochloride forms. As 
well as its use as a topical antiseptic it is incorporated in to household disinfectants, hand 
washes, mouthwashes and surgical scrubs at varying concentrations depending on the 
application. For example antibacterial mouthwashes contain 0.2 % w/v CHG whereas 
‘Hibiscrub’ hand disinfectant contains 4 % w/v CHG (Thomas et al., 2000).  
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The mode of action of chlorhexidine is concentration dependent. At lower concentrations it 
is bacteriostatic, causing the leakage of potassium and phosphorus from the bacterial cell 
and inhibiting bacterial growth (Hugo and Longworth, 1964). The positive charge of the 
cationic chlorhexidine molecule is thought to assist its interaction with the negatively 
charged bacterial cell though it is not known exactly how it partitions in to the bacterial cell 
membrane. It is thought to occur via the bending of the molecule which allows it to form a 
wedge shape and interact with the membrane lipids (Komljenovic et al., 2010). This 
ultimately results in cleavage of the lipid matrix and leakage of the cell contents which is 
thought to occur within seconds of the biocide making contact with the cell. At much 
higher concentrations chlorhexidine causes cell death via the precipitation of cell 
cytoplasmic contents (Edmiston et al., 2013).  
 
There are an increasing number of in vivo reports of bacterial resistance to chlorhexidine at 
in-use concentrations in the clinical and domestic environments. Smith et al., (2013) tested 
the efficacy of over the counter mouthwashes containing chlorhexidine against 28 clinical 
MRSA biofilm isolates from the oral cavity of patients. They found that none of the 
mouthwashes tested were able to completely eradicate MRSA biofilms and concluded that 
this observation may result in problems with infection control and the use of chlorhexidine. 
Contamination of chlorhexidine-containing products has also been reported and has 
resulted in outbreaks of bacterial infection. Heo et al., (2008) reported an outbreak of 
Burkholderia stabilis bacteraemia in haematological malignancy patients as a result of the 
contamination of a 0.5 % chlorhexidine-containing solution used to sterilise patient 
catheters. Lepainteur et al., (2013) reported that 12 % of staphylococci isolated from 
neonates with bloodstream S. aureus infections showed reduced susceptibility to 
chlorhexidine. Hassan et al., (2013) recently reported a chlorhexidine-specific energy-
dependent efflux protein (AceI) in Acinetobacter spp. which they stated has orthologs in 
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other proteobacteria such as E. coli. Reports such as these listed above are concerning, 
particularly due to the fact that the chlorhexidine-containing products in question do not 
appear effective at in-use concentrations. 
 
1.9.2 Benzalkonium chloride (BZC) 
BZC is a broad-spectrum, nitrogen-based QAC. QACs are effective against Gram-positive 
and Gram-negative bacteria and are sporistatic.  They also cause membrane damage in 
yeast cells and are effective against lipid and enveloped viruses (Smith and Hunter, 2008). 
BZC is commonly used as a preservative in nasal, ophthalmic and otic products (Marple et 
al., 2004). It is also incorporated in to disinfectants used for surface disinfection and hard 
surface cleaning and used in the disinfection of unbroken, preoperative skin (Nagai et al., 
2003). The concentration at which BZC is used is dependent on the application. Contact 
lens solutions commonly contain low BZC concentrations of 0.002 – 0.01 %. Concentrations 
of up to 0.5 % can be found in strong disinfectants and hard surface cleaning products.  
Concentrations of 10 % or greater are toxic to humans causing irritation to the skin and 
mucosa, and death if ingested (Bernstein, 2000). 
Like chlorhexidine, BZC is a membrane-active biocide (Bragg et al., 2014, Mc Cay et al., 
2010) . The following series of events is thought to occur when a bacterial cell is exposed to 
BZC: (i) cell wall adsorption and penetration; (ii) diffusion of the biocide through the cell 
wall; (iii) binding to the cytoplasmic membrane; (iv) membrane disorganisation; (v) leakage 
of cytoplasmic constituents and (vi) cell death (Nagai et al., 2003). 
There have been several reports of BZC-resistant bacteria. Of particular concern was the 
isolation of a strain of Ps. fluorescens by Nagai et al., (2003) from a 10 % stock solution of 
BZC. The resistance mechanisms were found to be a decrease in bacterial cell membrane 
negative charge to reduce biocide absorption, and activity of an energy- dependent efflux 
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system specific to certain QACs. Frank et al., (1976) and Geftic et al., (1979) both reported 
the contamination of aqueous solutions containing BZC as a preservative agent. 
Furthermore Mc Cay et al., (2010) commented on the theory described by Gilbert and 
McBain (2003) that a bacterium is likely to be exposed to a gradient of biocide 
concentration in any environment and therefore at a given time may be exposed to a sub-
lethal biocide concentration. They reported that Ps. aeruginosa isolates adapted to BZC via 
exposure to sub-lethal concentrations were resistant to fluoroquinolone antibiotics, and 
raised concerns about the possibility of this in vivo. 
 
1.10 Knowledge gaps and suggested studies 
The Scientific Committee on Emerging and Newly Identified Health Risks (SCENIHR) 
produce an annual report that identifies knowledge gaps in antimicrobial research, and 
suggests studies that should be carried out in order to develop knowledge on antimicrobial 
use and develop new ideas for combating antimicrobial resistance in bacteria and other 
microorganisms (SCENIHR, 2010). Some of these are discussed below. 
 
1.10.1 Scientific gaps 
Despite the large number of in vitro laboratory studies carried out investigating the effect 
of biocide exposure on biocide and antibiotic resistance, there are insufficient 
environmental studies being performed that provide epidemiological data on biocide 
resistance and antibiotic cross resistance as a result of biocide miss-use. The concentration 
of active biocidal substances present in any one environment e.g. soil, air, ground water, 
sludge, waste water should be investigated as well as the fate and bioavailability of these 
active substances under different environmental conditions. These investigations will 
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provide information on the concentrations of biocidal substances that target and non-
target organisms are being exposed to. 
A further gap in scientific knowledge is the effect of biocide exposure on the maintenance 
and transfer of extra-chromosomal elements, such as plasmids and transposons that may 
carry genes associated with biocide resistance. Exposure of bovine S. aureus isolates to 
QACs has been shown to favour the dissemination and maintenance of a plasmid carrying a 
smr gene which conferred resistance to a QAC (Bjorland et al., 2001). This data suggests 
that biocide exposure may create a selective pressure for the maintenance and transfer of 
resistance genes between bacteria of the same species or between different species. 
Further investigation in to the long-term effects of biocide exposure on the dissemination 
of resistance genes must be carried out to prevent clonal expansion of resistant organisms. 
 
1.10.2 Technical gaps 
Few studies have been performed investigating the environmental stability of biocides 
under different conditions. Other chemical compounds present in a particular environment 
may bind and interact with biocides and alter the concentration of biocide that is available. 
This may result in exposure of bacteria to low biocide concentrations, creating a selective 
pressure for the survival of resistant organisms. Furthermore, the concentration of biocide 
metabolites present in the environment has not been investigated, nor has the effect of the 
type of environment on the metabolites present. There is also no information on the dose-
response relationship between target and non-target organisms and biocide metabolites. 
This type of information may be difficult to obtain, but over a long period of time would 
help in preventing biocide resistance and potential harm to non-target organisms. 
Despite the fact that bacterial biofilms are very common in the environment, the majority 
of laboratory biocide susceptibility studies are not carried out using biofilms. This may be 
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due to the fact that it is difficult to mimic in situ biofilms in the laboratory. One suggestion 
is the transfer of biofilms to a fermenter to sustain growth (McBain et al., 2003). There is 
no current European standard for testing the efficacy of biocides used in a healthcare 
setting on biofilms. Such a protocol would prove useful as several studies emphasise the 
limited efficacy of biocides against bacterial biofilms compared to planktonic cells (Wong et 
al., 2010a, Wong et al., 2010b, Smith and Hunter, 2008). 
There is no current standard protocol available for the prediction of bacterial resistance to 
biocides and potential cross-resistance to antibiotics as a result of biocide exposure. A 
change in the antimicrobial susceptibility of a bacterium after biocide exposure could 
provide an estimate of the risk of resistance development and this information now must 
be provided by product manufacturers according to the new BPR (528/2012) (http://eur-
lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2012:167:0001:0123:EN:PDF accessed 
11_03_2014). The use of test parameters reflective of the application of the biocidal 
product (concentration, temperature, formulation etc.) would provide realistic data that 
could assist in the prediction of bacterial biocide resistance. The generation of reproducible 
‘baseline’ susceptibility data (e.g. MIC/MBC pre-exposure) from both environmental and 
laboratory strains would provide a useful comparison point for post-exposure MIC/MBC 
values. This type of protocol would allow biocidal product manufacturers to alter the 
formulation of a product or the concentration of the active biocide within the product if a 
high risk of resistance development was predicted. 
 
1.11 Aim of this study 
Having considered the knowledge gaps defined by SCENIHR (2010) and the new 
information on resistance development required by biocidal product manufacturers 
according to the BPR, the aim of this work was to design a protocol that allows the 
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prediction of bacterial resistance to biocides and potential cross-resistance to antibiotics 
after exposure to a particular biocidal product. This was to be achieved via the exploration 
of different techniques that could be used to identify practical markers of biocide 
resistance and antibiotic cross-resistance, with a view to compiling a step-by-step protocol 
that allows the user to predict bacterial resistance to a given biocidal product. 
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Chapter Two: General Materials and Methods 
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2.1 Bacterial samples and cultures 
The bacterial strains used in this study and their origin are shown in table 2.1. These strains 
were selected because their genomes have been fully sequenced (Jarvik et al., 2010, 
Vanlaere et al., 2009) 
(http://www.sanger.ac.uk/resources/downloads/bacteria/salmonella.html accessed 
11/03/2014) making it possible to carry out whole genome analysis.  
 
Table 2.1: Bacterial strains 
Strain Source 
Salmonella enterica serovar Typhimurium 
SL1344 
Department of Infection and Immunity, The 
Medical School, University of Birmingham, 
UK 
Salmonella enterica serovar Typhimurium 
14028S 
Department of Infection and Immunity, The 
Medical School, University of Birmingham, 
UK 
Burkholderia lata 
383 
School of Biosciences, Cardiff University, 
Wales, UK 
 
All culture media was purchased from Fisher Scientific (Loughborough, UK) unless 
otherwise stated. Salmonella enterica serovar Typhimurium strains were cultured on 
tryptone soya agar (TSA) and were incubated for 24 h at 37°C.  Burkholderia lata strain 383 
was cultured on Basal Salts agar (BSA - see table 2.2) and was incubated for 24 h at 30°C. To 
make BSA 15 g of agar was added to 1L of the basal salts media (table 2.2). Plates were 
stored at 4°C (± 1°C). 
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Table 2.2: Basal Salts Media 
All components of the Basal Salts media were purchased from Sigma (Dorset, UK). 
Stock Components Quantity per litre 
Phosphate salts 20x 
stock 
di-Potassium hydrogen orthophosphate 
trihydrate 
 
Sodium di-hydrogen orthophosphate 
monohydrate  
85 g 
 
 
20 g 
Ammonium chloride  
20x Stock  
Ammonium chloride 40 g 
Nitrilotriacetic acid  
100x Stock 
Nitrilotriacetic acid 10 g 
Metal salts 100x Stock  
 
Magnesium sulphate heptahydrate 
Ferrous sulphate heptahydrate 
Manganese sulphate monohydrate  
Zinc Sulphate heptahydrate 
Cobalt sulphate heptahydrate 
20 g 
1.2 g 
0.3 g 
0.3 g 
0.1 g 
CAS amino Acids 5% 
Stock 
CAS amino Acids 50 g 
Yeast extract 5% Stock Yeast extract 50g 
Glucose 200g/L Stock Glucose 4 g 
 
2.1.1 Freezer Storage 
2.1.1.1 Salmonella enterica serovar Typhimurium 
Salmonella enterica serovar Typhimurium strains were stored on protect beads (Fisher 
Scientific, Loughborough, UK) at -80 °C (± 1°C). Briefly, a large loopful of fresh growth was 
taken from an agar plate and added to the protect beads. All liquid was removed from the 
protect bead tube before freezing. 
 
2.1.1.2 Burkholderia lata 
Burkholderia lata strains were stored as follows. A swab of fresh growth was taken from an 
agar plate and re-suspended in 1 mL basal salts broth (BSB) (table 2.2) containing 8 % v/v 
dimethyl sulfoxide (Sigma, Dorset, UK) and stored at -80°C (± 1°C). 
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2.1.2 Overnight broth culture 
All Salmonella enterica serovar Typhimurium strains were cultured in tryptone soya broth 
(TSB). Briefly, a loopful of fresh growth was taken from an agar plate and used to inoculate 
10 mL of TSB, which was incubated for 24 h at 37°C (± 1°C).  
Burkholderia strains were cultured in 3 mL BSB (pH 7 ± 0.2) and incubated horizontally in an 
orbital shaker (150 rpm) for 18 h at 30°C (± 1°C).  
 
2.1.3 Preparation of a bacterial suspension from an overnight culture 
All overnight cultures (1 x 109 – 1 x 1010 CFU/mL) were centrifuged at 5000 x g for 15 
minutes at 18°C (± 1°C). The supernatant was discarded and the pellet re-suspended in 10 
mL of tryptone sodium chloride (TSC) buffer (0.4 g tryptone, 3.4 g sodium chloride, 400 mL 
deionised water (diH20)) unless otherwise stated. 
 
2.1.4 Viable Counts 
Viable counts were performed before and after testing to determine the concentration of a 
bacterial suspension. This was done using the drop count method (Miles et al., 1938). 
Briefly, 100 µL of the neat bacterial suspension was added to a sterile microcentrifuge tube 
containing 900 µL of TSC buffer and vortex mixed.  One hundred µL of this suspension was 
then transferred to another sterile microcentrifuge tube containing 900 µL of TSC buffer. 
This was repeated until ten serial dilutions had been performed. Ten µL of each dilution 
was plated on to the appropriate media in triplicate. Plates were left to dry before 
incubation for 24 h at the appropriate temperature. A mean colony count was determined 
for the dilution that produced between 3 and 50 colonies. 
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2.1.5 Optical density vs. Total viable count 
In order to determine at which optical density (600 nm) 1-5 x 108 CFU/mL were present, an 
optical density vs. total viable count (TVC) experiment was performed for each strain used. 
Briefly, bacterial suspensions were produced from overnight broth cultures and four 1 in 10 
serial dilutions of these suspensions in TSC were prepared. The OD600 of each suspension 
was recorded using an Ultrapro 3000 spectrophotometer (GE Healthcare, UK). Viable 
counts of each suspension were then performed using the drop count method (2.1.4). 
OD600 vs. TVC graphs (shown in figures 2.1 a, b and c) for S. enterica strains SL1344 and 
14028S and B. lata strain 383 were produced and the OD600 range was calculated using the 
equation from the line of best fit displayed on the graph, where y = OD600 and x = log 
CFU/mL. 
 
Figure 2.1 (a): Optical density vs. total viable count for S. enterica strain SL1344 
 
The OD600 range that gave 1-5 x 10
8 CFU/mL for strain SL1344 was calculated as 0.45 – 0.6. 
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Figure 2.1 (b): Optical density vs. total viable count for S. enterica strain 14028 
 
The OD600 range that gave 1-5 x 10
8 CFU/mL for strain 14028S was calculated as 0.4 – 0.57. 
 
Figure 2.1 (c): Optical density vs. total viable count for B. lata strain 383 
 
The OD600 range that gave 1-5 x 10
8 CFU/mL for strain 383 was calculated as 0.85 – 1.1. 
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2.2 Biocides 
The biocides used were chlorhexidine gluconate (CHG) (20 % solution in water) and 
benzalkonium chloride (solid crystals) (BZC) (Sigma, Dorset, UK).  
 
2.3 Neutraliser 
The neutraliser used was composed of Tween 80 (30 g/L) (Fisher Scientific, Loughborough, 
UK), azolectin (3 g/L) (Sigma, Dorset UK) and diH20. 
 
2.3.1 Neutraliser Toxicity 
The toxicity of the neutraliser to all strains of bacteria was tested as follows.  A bacterial 
suspension produced from an overnight culture was standardised to 1 x 108 CFU/mL. One 
mL of this suspension was added to 9 mL of neutraliser, vortex mixed and left for 5 min. A 
control experiment was performed alongside this where 1 mL of bacterial suspension was 
added to 9 mL of diH20.  
Viable counts were performed on test and control suspensions using the drop count 
method (2.1.4). Test and control counts were compared to determine if exposure to 
neutraliser caused any significant decrease in CFU/mL. The neutraliser was considered toxic 
if ≥ 1 log10 decrease was observed in the test colony count according to the BS EN 1276 
(2009) suspension testing protocol. 
 
2.3.2 Neutraliser Efficacy 
The ability of the neutraliser to quench the activity of CHG and BZC was tested as follows: 
One mL of the biocide at the highest concentration used (CHG – 5%, BZC – 12.5%) was 
added to 8 mL of neutraliser and vortex mixed. One mL of a bacterial suspension containing 
43 
 
1 x 108 CFU/mL was then added and the suspension vortex mixed and left for 5 min. A 
control experiment was performed alongside this using 8 mL diH20 instead of neutraliser. 
Viable counts of both control and test suspensions were performed using the drop count 
method (2.1.4). The neutraliser was considered effective if ≤ 1 log10 difference in CFU/mL 
was observed between initial counts and counts taken after bacterial exposure to biocide 
treated with neutraliser according to the BS EN 1276 (2009) suspension testing protocol. 
 
2.4 Biocide minimum inhibitory concentration (MIC) 
The MIC of CHG and BZC was determined for all bacterial strains, following the BS EN ISO: 
20776-1 (2006) protocol.  
In brief, 50 µL of the appropriate broth was added to wells 2-12 of a 96 well microtitre 
plate. Fifty µL of the chosen biocide was then double diluted across wells 1-11. Column 12 
was a control column containing no biocide (see figure 2.2). The concentration range for 
CHG was 1 – 0.0009 % and for BZC was 0.25 – 0.00015 %. These incorporated in-use 
concentrations of both biocides (Berstein, 2000; Thomas et al., 2000). 
Suspensions of all bacterial strains were standardised to 1 x 108 CFU/mL in TSB. Fifty µL of 
an individual strain was then added to all wells in three rows of the plate (i.e. in triplicate). 
The plate was then covered with a sterile lid and incubated for 24 h at the appropriate 
temperature with shaking at 150 rpm. The MIC was the lowest concentration at which no 
bacterial growth was observed on the microtitre plate.  This was observed visually. 
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Figure 2.2: Example MIC plate for S. enterica strains SL1344 and 14028S 
 
2.5 Minimum bactericidal concentration (MBC) 
The MBC of CHG and BZC was determined as follows. Twenty µL of suspension was 
removed from each well of the MIC 96 well plate where no bacterial growth was observed 
and the two lowest concentrations at which growth was observed, and added to 180 µL of 
neutraliser. This was vortex mixed and 25 µL was spotted on to the appropriate agar. Plates 
were incubated for 24 h at the appropriate temperature before being observed for 
bacterial growth. The MBC was the lowest concentration where no bacterial growth was 
observed on the agar plate.  
 
2.6 Antibiotic susceptibility testing 
Susceptibility to clinically relevant antibiotics was determined following the BSAC Disc 
Diffusion Method for Antimicrobial Susceptibility Testing Version 9.1 (Andrews, 2009). All 
antibiotics were purchased from Oxoid, Basingstoke, UK. Briefly, bacterial suspensions in 
diH20 were prepared from overnight cultures of each strain grown in Iso-Sensitest Broth 
and standardised to 1 x 108 CFU/mL. A 1:100 dilution of this suspension in diH20 was then 
1% Control     0.0009 %  
SL1344 
SL1344 
SL1344 
14028S 
14028S 
14028S 
14028S 
Doubling dilutions of CHG 
45 
 
made. A sterile swab was used to inoculate an Iso-Sensitest Agar plate with the diluted 
suspension. The plate was left to dry for no more than 15 min before being inoculated with 
discs containing the relevant antibiotics and incubated for 24 h at the appropriate 
temperature.  Zones of inhibition around the antibiotic disks were then measured and 
values matched up to susceptibility breakpoints provided by the protocol. 
 
2.7 Suspension Testing 
2.7.1 Exposure to the minimum bactericidal concentration 
To observe the effect of contact time on the activity of CHG and BZC, suspension tests were 
carried out following the British Standard EN 1276 protocol (2009). Briefly, bacterial 
suspensions in diH20 produced from overnight cultures were standardised to 1 x 
108CFU/mL. Viable counts were performed on these suspensions using the drop count 
method (2.1.4). One mL of standardised suspension was added to 9 mL of biocide (diluted 
in diH20) at 1.25 times the minimum bactericidal concentration. After exposure for 1, 2.5, 4, 
5, 10, 30, 40 and 60 minutes, 1 mL of this suspension was removed and added to 9 mL of 
neutraliser. Viable counts using the drop count method (2.1.4) were then carried out to 
enumerate surviving organisms. 
 
2.7.2 Exposure to a range of low concentrations 
Suspension tests were carried out as described in section 2.7.1 except the exposure time 
was limited to 5 min.  This contact time was chosen in order to obtain a 2-3 log10 reduction 
in CFU/mL, leaving sufficient survivors for further testing. Concentrations ranged from 
0.00001 – 0.0005 % CHG or BZC. The MIC, MBC and antibiotic susceptibility of test 
organisms were determined before and after 5 min exposure using the methods described 
in sections 2.4, 2.5 and 2.6. 
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2.8 Phenotype stability testing 
The stability of any changes in biocide and antibiotic susceptibility observed after 5 min 
biocide exposure was determined through continuous subculture of surviving bacteria in 
biocide-free broth or broth supplemented with CHG or BZC. Subcultures were made every 
24 h and biocide MIC/MBC and antibiotic susceptibility were determined after 1, 5 and ten 
passages. A culture purity check was performed after each subculture. 
 
2.9 Efflux assays 
The protocol for efflux assays was based on that used by Whitehead et al., (2011). One 
hundred and twenty µL from an overnight culture of each strain was added to 3 mL of fresh 
broth (either biocide-free or supplemented with a low concentration of CHG or BZC). These 
were then incubated at the appropriate temperature with shaking at 150 rpm until mid-
logarithmic growth phase was achieved. Mid-log phase cells were harvested by 
centrifugation at 5000 x g for 10 min at room temperature and the supernatant discarded. 
The remaining cell pellet was re-suspended in 3 mL of TSC buffer. Samples were then 
adjusted to an approximate OD600 of 0.1 (approx 1 x 10
6 CFU/mL), using TSC as a diluent. 
Hoechst 33342 dye (Sigma, Dorset, UK) was added to each of the diluted suspensions to a 
final concentration of 2.5 µM and suspensions were left for 5 min. Cells were then collected 
again by centrifugation at 5000 x g for 10 min at room temperature and the supernatant 
(excess dye) was removed. The cell pellet was then re-suspended in 3 mL TSC buffer or 3 
mL of TSC buffer containing one of the following efflux pump inhibitors (EPIs) (all purchased 
from Sigma, Dorset, UK): phenyl-arginine-β-napthylamide (PaβN) (10 mg/L), verapamil (50 
mg/L), 1-(1-napthylmethyl) piperazine (1-(1-NP) (10 mg/L). The toxicity of the inhibitors to 
each bacterial strain was tested prior to the experiment following the same method used 
for neutraliser toxicity testing (section 2.3.1). PaβN and 1-(1-NP) target RND type efflux 
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pumps and are broad spectrum inhibitors. Verapamil is a calcium ion blocker and inhibits 
ABC transporters. A range of inhibitors were used to cover several types of efflux pump. A 
positive control with no efflux activity (consisting of cells heated to 95 °C for 5 min) was 
included. One hundred and eighty µL of each suspension was then added to a 96 well black 
plate, and the fluorescence (Ex 340 nm, Em 510 nm) was measured using a Fluostar Optima 
(BMG Labtech, Aylesbury, UK). 
 
2.10 Light scattering experiments 
To assess the presence/absence of bacterial aggregates in biocide-treated and untreated 
samples, an N4 Plus Dynamic Light Scattering machine (Coulter, High Wycombe, UK) was 
used. Bacterial suspensions prepared from overnight cultures were standardised to 1 x 108 
CFU/mL in diH20. For untreated samples 1 mL of the suspension was transferred to a 
cuvette with 4 clear sides and placed in the N4 Plus machine. For biocide-treated samples 1 
mL of the suspension was added to 9 mL of the biocide at 1.25 times the minimum 
bactericidal concentration before vortex mixing. After 1 min 1 mL of this suspension was 
transferred to a cuvette and placed in the machine. The N4 Plus measures different particle 
sizes within the sample and produces a mean particle diameter value (nm). Each run lasted 
approx 13 min, making total biocide exposure time 15 min. 
 
2.11 RNA extraction for real-time PCR 
2.11.1 Harvesting bacterial cells 
Flasks containing 25 mL of the appropriate broth were inoculated with 2 x 108 CFU/mL of a 
bacterial strain and incubated at the appropriate temperature with shaking at 150 rpm. For 
biocide-exposed organisms broth was supplemented with a low concentration of CHG or 
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BZC. The OD600 nm was measured hourly and bacterial cells were harvested at mid-
logarithmic growth phase and aliquoted in to microcentrifuge tubes before immediate 
snap-freezing in liquid nitrogen. Aliquots were then centrifuged at 20,000 x g at 4 ˚C for 1 
min. The supernatant was discarded and pellets were frozen at -80 ˚C. In the case of 
bacterial cells exposed to biocides for 5 min (following the method described in section 
2.7.2) tubes were centrifuged at 5000 x g for 10 min and the supernatant discarded. RNA 
was then extracted from the remaining pellet. 
 
2.11.2 RNA extraction  
Total RNA was extracted from bacterial cells using the RibopureTM Bacteria Kit (Ambion, 
Applied Biosystems, Warrington, UK) according to the manufacturer’s instructions. This 
method includes disruption of bacterial cell walls by beating cells mixed with RNAwiz and 
Zirconia beads, a phenol extraction of the lysate and glass-fibre filter purification of the 
RNA. A 2 µL aliquot of extracted RNA was taken and the quantity and purity of the RNA 
present was analysed using a Nanovue spectrophotometer (GE Healthcare, 
Buckinghamshire, UK). 
 
2.12 cDNA synthesis for real-time PCR 
cDNA was synthesised from extracted RNA using an Improm-IITM Reverse Transcription 
System (Promega, Southampton, UK). The kit encompassed controls including a negative 
control (no-RNA) to check for template contamination and a positive control (included in 
the kit) to check the activity of the reverse transcriptase enzyme. For experimental samples 
3 µL of template RNA were combined with 1 µL of random primers (supplied with kit) and 
made up to 5 µL with nuclease free water (NFW). Negative controls contained no RNA 
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template. Experimental reaction mixes were first denatured for 5 min at 70 °C and then 
chilled in ice water for 5 min. cDNA was then synthesised from RNA in the following 
reaction mixture: 4 µL of reaction buffer, 4.8 µL of 25 mM MgCl2, 1 µL dNTP mix, 0.5 µL of 
RNasin ribonuclease inhibitor, 1 µL of Improm–II reverse transcriptase (or NFW for no-RT 
controls). This mixture was made up to 15 µL with NFW. Five µL of the denatured random 
primer/RNA mix was then added to the reaction mixture (except the no-RNA control) and 
placed in a thermal cycler. The programme used was as follows: 5 min at 25 °C, extension 
for 60 min at 42 °C and 15 min at 70 °C. cDNA was stored at -20 °C for further use. 
 
2.13 Real-time PCR reaction conditions 
Reactions were performed in triplicate using an Absolute QPCR SYBR Green Kit (ABgene, 
Epsom, UK). Two µL of cDNA (generated as described in section 2.12) was added to 10 µL of 
SYBR Green mix, 0.4 µL of forward and reverse primers (70 nM) and made up to 20 µL with 
NFW. A standard curve was generated to assess the efficiency of the amplification using 1 
in 5, 1 in 25 and 1 in 50 dilutions of the cDNA template. No-RT and no-cDNA controls were 
included to control for genomic DNA contamination and for primer-dimers respectively. 
Expression levels of a house-keeping gene were used to normalise data. Reactions were run 
on a MJ Research PTC-200 thermal cycler (DNA Engine Opticon, Bio-Rad Laboratories, 
Hertfordshire, UK). The programme used was as follows: 15 min thermal activation of the 
modified Taq-polymerase at 95 °C, 50 cycles of 15 s at 95 °C, 30 s at the appropriate primer 
annealing temperature and 30 s at 72 °C. A melting curve analysis was performed at the 
end of the reaction to test for the specific PCR product. 
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2.14 Real-time PCR analysis – the Pfaffl method 
The Pfaffl method (Pfaffl, 2001) takes in to account the efficiency of the real-time PCR 
reaction and therefore gives a more accurate quantification of mRNA present in the 
original sample compared with methods that assume 100% efficiency of the reaction (e.g. 
delta-delta Ct method). A standard curve was produced from Ct values obtained through 
performing real-time PCR reactions using a range of concentrations of cDNA template. The 
slope of the standard curve is used to calculate the efficiency using the following formula. 
Efficiency (E) = 10 -1/slope 
The difference in gene expression was then calculated using the following formula: 
Ration = (Etarget)
ΔCT Target (control-test) 
               (Ereference) 
ΔCT Reference (control-test) 
Here Etarget is the amplification efficiency of the target gene transcript and Ereference is the 
amplification efficiency of the reference gene transcript. 
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Chapter Three: Salmonella enterica serovar Typhimurium as a 
model organism for predicting biocide resistance 
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3.1 Introduction 
Salmonella enterica is a Gram-negative bacterium commonly associated with salmonellosis or 
‘food poisoning’ in the human population (Wang et al., 2010). Salmonella infection was 
reported as the second most commonly identified gastrointestinal infection in the EU in 2012 
(http://ecdc.europa.eu/en/publications/Publications/Annual-Epidemiological-Report-2012.pdf 
accessed 11/03/2014). Although Salmonella infection is not normally treated with antibiotics, 
severe systemic infections are treated using quinolone and fluoroquinolone antibiotics e.g. 
ciprofloxacin (Rushdy et al., 2013). In the past 30 years there has been an increase in the 
number of multi-drug resistant Salmonella strains reported in the USA and worldwide (Kautz et 
al., 2013).  
 
3.1.1 Salmonella enterica in the clinical environment 
In 2010, 102,323 confirmed cases of salmonellosis were reported by 29 EU countries 
(http://ecdc.europa.eu/en/publications/Publications/Annual-Epidemiological-Report-2012.pdf  
accessed 11/03/2014). When Salmonella spp. come into contact with human intestinal 
epithelial cells, they cause a ruffling of the cell membrane via stimulation of changes to the 
actin cytoskeleton that ultimately results in internalisation of the bacterium into the cell. Once 
inside the cell Salmonella use a type III secretion system to induce the activation of 
transcription factors that stimulate the production of inflammatory cytokines. They also induce 
the secretion of Cl- ions from the cell. This results in subsequent loss of water from the cell, 
and inflammatory diarrhoea that is characteristic of Salmonella infection (Galan, 1998). 
There are over 2,463 serovars of Salmonella enterica, but the two most associated with food-
borne illness are S. enterica serovar Typhimurium and S. enterica serovar Enteritidis (Wang et 
al., 2010). Interestingly these two different serovars have been reported to be associated with 
different food types. S. enterica serovar Enteritidis infections are most often acquired from 
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contaminated eggs whereas S. enterica serovar Typhimurium is more frequently associated 
with the contamination of poultry meat and drinking water (Wang et al., 2010). Figure 3.1 
shows the different serovars of Salmonella reported to the Health Protection Agency (HPA) in 
England and Wales between 2000 and 2010. 
 
 
Figure 3.1: All human Salmonella isolates reported to the Health Protection Agency Centre 
for Infections. England and Wales, 2000 –2010  
 
http://www.hpa.org.uk/Topics/InfectiousDiseases/InfectionsAZ/Salmonella/EpidemiologicalDa
ta/salmDataHuman/ (accessed: 11/03/2014).  
From figure 3.1 it can be seen that the number of reported isolates has decreased over the ten 
year period. S. enterica serovar Enteritidis was responsible for the greatest number of reported 
infections, whereas S. enterica serovar Typhimurium was responsible for a much smaller 
number. Interestingly the number of S. enterica serovar Typhimurium infections has remained 
consistent over the ten year period. The general decline in reported salmonellosis cases is 
thought to be due to the implementation of control programs in the poultry industry, 
particularly in laying hens. This said the majority of cases of Salmonella infection in the EU are 
still associated with contaminated eggs 
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(http://ecdc.europa.eu/en/publications/Publications/Annual-Epidemiological-Report-2012.pdf 
accessed 11/03/2014). For this reason it is essential to control the spread of Salmonella 
amongst farmed livestock and in the food industry. 
 
3.1.2 Salmonella enterica in the industrial environment 
In order to limit the spread of multi-drug resistant isolates in the food chain, regulations have 
now been introduced that prevent the use of antibiotics as growth promoters in livestock 
(Karatzas et al., 2007). This in turn has resulted in the increased use of biocidal products to 
clean/disinfect animal houses, as preservatives in animal feed and in all steps of the food 
production chain (Condell et al., 2012a). This increased biocide use has led to concerns that 
biocide exposure may be selecting for antibiotic-resistant isolates. It has been reported that 
exposure of S. enterica to various biocides (e.g. Virkon, Trigene, triclosan) at the recommended 
in-use concentration has resulted in stable multi-drug resistance in surviving organisms 
(Whitehead et al., 2011) and increased antibiotic MICs (Karatzas et al., 2007). Despite these 
findings being obtained in vitro, there have been numerous reports of multi-drug resistant 
Salmonella spp. isolated from patients in the clinical environment (Rushdy et al., 2013, 
Akiyama and Khan, 2012, Giraud et al., 2012, Yoon et al., 2009). Furthermore, outbreaks of 
serious infections have been observed due to improper biocide use (Duarte et al., 2009) so it is 
possible that increased biocide use may increase the risk of isolating multi-drug resistant 
Salmonella isolates from an industrial environment. 
 
3.1.3 Mechanisms of antimicrobial resistance in Salmonella enterica 
Antibiotic resistance in salmonella, particularly resistance to quinolones and fluoroquinolones 
is often attributed to chromosomal mutations in ‘quinolone resistance-determining regions’ 
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(QRDRs) in gyrA/B (encoding DNA gyrase) or parC/E (encoding topoisomerase IV) (Kautz et al., 
2013). These mutations prevent the inhibition of DNA gyrase and DNA topoisomerase IV by 
quinolone/fluoroquinolone antibiotics allowing DNA super-coiling and synthesis to continue to 
take place in the bacterial cell (Hawkey, 2003).  
Aside from mutations in specific antibiotic cellular targets, multiple antibiotic resistance in S. 
enterica has been attributed to over-expression of efflux systems, particularly the well-
characterised AcrAB-TolC RND type efflux system (Baugh et al., 2013, Rushdy et al., 2013, 
Giraud et al., 2000). This efflux system has also been shown to confer resistance to biocides 
such as QACs and triclosan (Karatzas et al., 2007, Whitehead et al., 2011). Karatzas et al.,  
(2007) showed that over-expression of the acrB gene in S. enterica serovar Typhimurium 
resulted in a 4 fold increase in the MIC of chloramphenicol, tetracycline, ampicillin, acriflavine 
and triclosan, demonstrating that isolates with mutations in efflux-associated genes may be 
particularly difficult to eradicate if they cause infection in humans or animals. Mutations in 
genes associated with the regulation of efflux pumps, such as ramA and ramR have also been 
shown to confer fluoroquinolone resistance in S. enterica serovar Schwarzengrund  (Akiyama 
and Khan, 2012). Salmonella enterica spp. have also been shown to alter outer membrane 
protein composition, and therefore cell permeability to reduce susceptibility to antibiotics 
(Giraud et al., 2000). Due to the lack of specificity of this alteration to the cell, it is likely that 
changes in outer membrane composition may confer reduced susceptibility to multiple 
antimicrobials. 
Salmonella enterica spp. also have the ability to form a biofilm, allowing them to persist in 
industrial and medical settings and on foodstuffs. Biofilms are more difficult to eradicate and 
concentrations of antibiotics and biocides of up to 1000 times greater than those required to 
kill planktonic cells may be required to kill cells in a biofilm (Baugh et al., 2013).  S. enterica 
serovar Typhi has be found to form biofilms on gallstones in the gall bladder, resulting in 
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persistent infection and a reservoir for re-infection (Vaishnavi et al., 2005). Salmonella biofilms 
have also been associated with outbreaks of food poisoning linked to salad leaves (Baugh et 
al., 2013).  
 
3.1.4 Salmonella enterica serovar Typhimurium as a model organism for predicting biocide 
resistance 
S. enterica serovar Typhimurium strains SL1344 and 14028S are wild-type strains of this 
species and were selected for use as a potential model organism to predict biocide resistance. 
These strains were chosen due to the fact that their genomes had been fully sequenced (Jarvik 
et al., 2010)( http://www.sanger.ac.uk/resources/downloads/bacteria/salmonella.html 
accessed 11/03/2014) making whole genome analysis possible. These strains were also chosen 
due to the fact that S. enterica serovar Typhimurium (alongside S. enterica serovar Enteritidis) 
is most commonly associated with food industry contamination and human food poisoning, 
and many multi-drug resistant clinical isolates of this species have been observed. 
Furthermore, the numerous defined resistance mechanisms that S. enterica possesses make it 
a good potential model organism for predicting biocide resistance. 
 
3.1.5 Aims 
The principle aim of this chapter was to determine if short term exposure of S. enterica serovar 
Typhimurium strains SL1344 and 14028S to a low concentration of CHG or BZC resulted in a 
change in the antimicrobial susceptibility of surviving organisms. Further aims were to assess 
the suitability of strains SL1344 and 14028S as model organisms for predicting biocide 
resistance, and to assess to suitability of the techniques used in this chapter for predicting 
biocide resistance.  
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3.2 Materials and Methods 
3.2.1 Suspension testing 
In order to determine the effect of contact time on biocide efficacy, suspension tests were 
carried out following the British Standard EN 1276 protocol (2009) described in chapter 2 
section 2.7. Biocides were tested at the minimum bactericidal concentration to investigate the 
length of time taken to kill all viable bacteria at this concentration. 
 
3.2.2 Antimicrobial susceptibility testing  
3.2.2.1 Baseline data 
The MIC and MBC of CHG and BZC were determined for strains SL1344 and 14028S as 
described in chapter 2 sections 2.4 and 2.5. Susceptibility to the following antibiotics was also 
determined following the BSAC disk diffusion protocol (Andrews, 2009) described in chapter 2 
section 2.6: ciprofloxacin (1 µg), chloramphenicol (30 µg), ampicillin (10 µg), ceftriaxone (30 
µg) and piperacillin (75 µg). 
 
3.2.2.2 Antimicrobial susceptibility of biocide-exposed organisms 
Salmonella strains SL1344 and 14028S were exposed to a range of low CHG and BZC 
concentrations (0.00001 – 0.0005 %) for 5 min according to the BS EN 1276 (2009) suspension 
testing protocol described in chapter 2 section 2.7.2. This contact time resulted in a 2-3 log10 
reduction in CFU/mL, leaving sufficient survivors for further testing. It was also chosen as it 
may reflect the in-use contact time of CHG/BZC (e.g. in surface cleaning).  After neutralisation, 
the neutralised suspension was centrifuged at 5000 x g for 10 min and the resulting 
supernatant discarded. The remaining pellet was then re-suspended in 10 mL TSC buffer. This 
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suspension was then used in the determination of the MIC, MBC and antibiotic susceptibility of 
surviving organisms as described previously in chapter 2 sections 2.4 and 2.5.  
 
3.2.2.3 Phenotype stability testing 
In order to determine the stability of any changes in biocide susceptibility observed after 5 min 
biocide exposure, subculture of surviving bacteria through biocide-free TSB and TSB 
supplemented with CHG or BZC was performed (for SL1344: 0.0004 % CHG and BZC, for 
14028S: 0.0001 % CHG and 0.0004 % BZC. Exposure to these concentrations resulted in the 
greatest changes in MIC and MBC in surviving organisms). Subcultures were made every 24 h 
and CHG and BZC MIC and MBC were determined after 1, 5 and ten subcultures following the 
method described in chapter 2 sections 2.4 and 2.5.  
 
3.2.2.4 Data reproducibility 
In order to determine the reproducibility of the MIC, MBC and antibiotic susceptibility data 
obtained from biocide-exposed bacteria, the experiment described in section 3.2.2.2 was 
performed on 3 separate occasions (each a month apart), each using 3 biological replicates. 
This resulted in 9 MIC, MBC and antibiotic susceptibility readings for each strain at each 
concentration tested. 
 
3.2.3 Efflux assays 
Efflux assays were carried out according to the protocol by Whitehead et al. (2011) described 
fully in chapter 2 section 2.9. Strains SL1344 and 14028S were grown to mid-log phase (OD600 
0.5-0.7) in TSB supplemented with a low concentration of CHG or BZC (for SL1344 0.0004 % 
CHG and BZC, for 14028S 0.0004 % BZC and 0.0001 % CHG) or biocide-free TSB. To ensure the 
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correct growth phase had been reached the optical density of a 1 mL aliquot of each culture 
was read at 600 nm using an Ultrapro 3000 spectrophotometer (GE Healthcare, Amersham, 
UK). The fluorescence was measured in biocide- treated and un-treated cells using a Fluostar 
Optima fluorescent plate reader as an indication of the level of efflux activity taking place in 
the cell. This was also measured in the presence/absence of 3 efflux pump inhibitors (EPIs): 
verapamil (50 mg/L), phenyl-arginine-beta-napthylamide (PAβN) (10mg/L) or 1-(1-
napthylmethyl) piperazine (1-(1-NP)) (10 mg/L) to confirm efflux activity was taking place in 
the cells. The toxicity of the EPIs to both strains was tested prior to the efflux assays being 
performed (see chapter 2 section 2.9).  
 
3.2.4 One Dimensional Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis (SDS-
PAGE) 
One dimensional SDS-PAGE was performed in order to separate outer membrane proteins 
(OMPs) extracted from biocide-treated and untreated S. enterica and make a comparison 
between the OMP composition of biocide-treated and untreated bacteria. 
 
3.2.4.1 Outer membrane protein preparation 
3.2.4.1.1 Crude protein preparation 
S. enterica strains SL1344 and 14028S were grown to mid-log phase (2.5 – 3 h) in TSB in the 
absence or presence of CHG (0.0004 % for SL1344, 0.0001 % for 14028S) or BZC (0.0004 %). 
Cells were harvested by centrifugation and re-suspended in 10 mL diH20. A Complete Mini 
Protease Inhibitor Cocktail tablet (Roche Applied Science, Burgess Hill, UK) was added to this 
suspension. Cells were then broken apart by three cycles of 60 s sonication on ice separated by 
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30 s intervals. Cells suspensions were then centrifuged at 4000 x g for 15 min at 4 °C to remove 
debris, and the supernatant retained.  
 
3.2.4.1.2 Protein preparation 
OMPs were purified from the crude cell extract by addition of sarkosyl solution (Sigma, Dorset, 
UK) at a final concentration of 1 %. The suspension was then incubated for 30 min at room 
temperature with agitation every 10 min. Following incubation, suspensions were centrifuged 
at 26000 x g for 1 h at 4 °C. The resulting supernatant was discarded and the remaining pellet 
washed three times with 1 mL diH20. The pellet was then dissolved in 150 µL collection buffer 
composed of 7 M urea, 1 % ASB-14, 40 mM Tris, 0.5 % ampholytes pH 3-10 (all purchased from 
Sigma, Dorset, UK). Dissolved protein was divided in to 50 µL aliquots and stored at -80 °C (± 1 
°C). 
 
3.2.4.1.3 Protein quantification 
Extracted protein was quantified using a Bicinchoninic Acid (BCA) assay. A series of 11 
standards containing 0 – 0.5 mg/mL bovine serum albumin (BVSA) (Fisher Scientific, UK) in 
phosphate buffered saline (PBS) (Fisher Scientific, UK) were prepared. A BCA working solution 
composed of 1 mL of 4 % (w/v) copper sulphate (Fisher Scientific, UK) and 49 mL BCA (Sigma, 
UK) was also prepared. Protein samples to be quantified were diluted 1 in 10 in PBS. Two 
hundred µL of BCA working solution was added to 25 µL of each standard or protein sample in 
a 96 well plate. The plate was then incubated for 30 min at 37 °C before being placed on ice for 
5 min. Absorbance was then read at OD562 nm using a Fluostar Optima microplate reader (BMG 
LabTech, Aylesbury, UK) and a standard curve was constructed by plotting the mean 
absorbance of the standards against the concentration of protein. The final concentration of 
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protein samples was corrected for the dilution factor (1/10). All protein quantifications were 
performed in triplicate. 
 
3.2.4.2 One Dimensional SDS-PAGE 
Each protein sample was added to 2 x SDS-PAGE loading buffer (0.09 M Tris-HCL, pH 6.8, 20 % 
(v/v) glycerol, 2 % (w/v) SDS, 0.02 % (w/v) bromophenol blue, 0.1 M DTT (all purchased from 
Sigma, Dorset, UK)) at a final concentration of 20 µg in 20 µL. Samples were then heated for 7 
min at 95 °C and 20 µL of each sample was loaded in to a 4 – 20 % CriterionTM Precast Mini gel 
(Bio-Rad, UK). Electrophoresis was carried out in 1 x running buffer (per litre: 14.4 g glycine, 
3.03 g Tris Base, 1 g SDS (all purchased from Sigma, Dorset, UK)) at 150 V, 400 mA, 30 watts for 
approximately 1 h. 
 
3.2.4.3 Colloidal Coomassie Staining 
Following one dimensional SDS-PAGE, gels were washed in diH20 for 2 x 5 min. Gels were then 
fixed in 100 mL of fixing solution (40 % (v/v) methanol, 10 % (v/v) glacial acetic acid (Fisher, 
Basingstoke, UK) in diH20 for 1 h. A 1 x working solution of Brilliant Blue G-Colloidal 
Concentrate (Sigma, Dorset, UK) was prepared according to the manufacturer’s instructions 
prior to staining and stored at 4  C. Just before staining 4 parts working solution was combined 
with 1 part methanol. Gels were stained for 24 h before de-staining with 25 % methanol. 
Images were then taken using a ChemiDock XRS Plus System (Bio-Rad, Herts, UK) and analysed 
using ImageLab Software Version 3 (Bio-Rad). 
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3.2.5 Flow cytometry 
3.2.5.1. Principle 
Flow cytometry was used to separate biocide-treated bacteria according to their light 
scattering and fluorescent properties when stained with different fluorophores. This technique 
did not require bacterial growth on an agar plate and could therefore identify cells that were 
viable but non-culturable. It allowed the observation of ‘shifts’ in a bacterial population as a 
result of biocide exposure and allowed the quantification of bacterial cells that were alive, 
damaged or dead. 
 
3.2.5.2 Fluorescent dyes 
Biocide-treated and untreated bacteria were stained with the fluorescent dyes propidium 
iodide (PI) and Bis (1,3-dibarbituric acid) trimethine oxanol (BOX) (both from Sigma, Dorset, 
UK). PI stains the DNA of bacteria that have lost membrane integrity and BOX stains bacteria 
with collapsed membrane potential. A 200 µg/mL stock of PI in diH2O was produced and stored 
at 4 oC.  This was diluted to a working concentration of 5 µg/mL in Dulbecco’s PBS (Gibco, 
Paisley, UK).  BOX was made up in dimethyl sulfoxide (DMSO) (Sigma, Dorset, UK) to a stock of 
10 mg/mL and stored at -20 oC. This was diluted to a working concentration of 10 µg/mL in 
Dulbecco’s PBS.  One hundred µl of 4 mM ethylenediaminetetraacetic acid (EDTA) (previous 
work carried out indicated no toxicity to cells from EDTA – Webber MA, personal 
communication 25/10/2013) (Sigma, Dorset, UK) was added to 9.9 mL of working 
concentration BOX to aid staining.  Both PI and BOX working stocks were made on the day of 
use and sterilised by passing through a 0.22 µM filter. 
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3.2.5.3 Sample preparation and analysis 
Briefly, strains SL1344 and 14028S were exposed to CHG (SL1344 0.0004 % v/v, 14028S 0.0001 
% ) and BZC (0.0004 %) for 5 min following the BS EN 1276 suspension testing protocol  (2009) 
described in chapter 2 section 2.7, except no neutralisation step was carried out. SL1344 was 
also exposed to 80 % ethanol for 5 min for use as a positive control.  After exposure, bacterial 
suspensions were centrifuged at 5000 x g for 10 min and the resulting supernatant discarded. 
The remaining pellet was re-suspended in 500 µL PBS. Fifty µL of this suspension was added to 
1 mL of FACSFlow buffer (BD, Oxford, UK). Fifty µL of PI and 10 µL of BOX were then added to 
the tube and samples analysed using a FACS ARIA II (BD, Oxford, UK). Cells were illuminated 
with a 488 nm laser and data from 10,000 particles were collected.  Forward- and side-scatter 
data were collected along with PI fluorescence (red, collected through an LP 565 mirror and BP 
610/20 filter) and BOX fluorescence (green, collected through an LP 502 mirror and BP 530/30 
filter).  Data obtained were plotted on graphs using FACSDiva software version 6.0 (BD, Oxford, 
UK). 
 
3.2.5.4 Further data analysis 
Cells were defined from debris and other particles via the comparison of unstained cells with a 
PBS control. Once cells had been defined FACSDiva software was used to exclude events not 
defined as cells so that graphs displayed cells only. Quadrants were defined based on the 
position of stained un-treated cells and stained ethanol-killed cells on the graph; i.e. the 
position of untreated cells defined the ‘alive’ quadrant and the position of killed cells defined 
the ‘dead’ quadrant. Once defined, the quadrants remained in the same position throughout 
the analysis of all samples. 
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3.2.6 Light scattering experiments 
The formation of bacterial aggregates can potentially affect the efficacy of a particular biocide. 
To determine if bacterial aggregates were present in biocide-treated or untreated cells a series 
of experiments measuring particle size were carried out, as described in chapter 2 section 2.10. 
Strain SL1344 was exposed to 0.01 % CHG and 0.003 % BZC and strain 14028S was exposed to 
0.006 % CHG and 0.008 % BZC (MBCs). Particle size was measured using an N4 Plus dynamic 
light scattering machine. 
 
3.2.7 Microarrays 
3.2.7.1 RNA extraction  
One hundred µL of an overnight culture of SL1344 and 14028S was used to inoculate fresh 25 
mL TSB broths (containing 0.0004 % CHG and BZC for SL1344 and 0.0001 % CHG and 0.0004 % 
BZC for 14028S) and incubated at 37°C with shaking at 150 rpm until cells reached mid-
logarithmic growth phase. Four biological replicates were grown for each treatment. An OD 
(600 nm) of 0.5-0.7 was considered an acceptable indication of mid-log phase. Cells were then 
harvested through centrifugation at 5000 x g for 10 min and the supernatant discarded.  RNA 
was then extracted using a SV Total RNA Isolation System (Promega, UK) following the 
manufacturers’ instructions. Briefly, samples were homogenised in RNA lysis buffer before 
transfer to a fresh tube and the addition of RNA dilution buffer. After centrifugation the 
supernatant was retained and 95 % ethanol was added. This sample was then transferred to a 
spin column and centrifuged to deposit RNA on to a filter. RNA was then washed before 
undergoing a DNase treatment to remove any DNA contamination, and then eluted in to a 
fresh tube. Purified RNA was then stored in the freezer at -80 °C.  
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3.2.7.2 RNA Bioanalysis 
3.2.7.2.1 Gel electrophoresis 
Three µL of the resulting RNA was electrophoresed on a 1 % agarose gel. Briefly, 5 µL of 
extracted RNA was added to 2 µL of 5 x sample loading buffer (Bioline, London, UK). This was 
then loaded in to a 1 % agarose gel (1 g agarose in 100 mL) containing 5 µL of ethidium 
bromide (Sigma, Dorset, UK). Seven µL of DNA hyperladder I (Bioline, London, UK) was also 
loaded in to the gel. RNA was then electrophoresed at 120 V for 45 min. RNA was visualised 
using GeneSys image acquisition software (Syngene, Cambridge, UK). (See appendix file name: 
Chapter 3 appendix data > microarray > concentration and purity of extracted RNA). 
 
3.2.7.2.2 Further bioanalysis 
One µL of extracted RNA from each treatment was examined using a Nanovue 
spectrophotometer (GE Healthcare, Buckinghamshire, UK) in order to determine the quality 
(A260/280) and quantity of RNA. Extracted RNA was also bioanalysed by the Functioning 
genomics Lab at The University of Birmingham, UK using an Agilent 2100 Bioanalyzer (Agilent 
Technologies, UK) which gave a more accurate determination of the quality and quantity of the 
RNA extracted for microarray analysis. (See appendix file name: Chapter 3 appendix data > 
microarray > concentration and purity of extracted RNA). 
 
3.2.7.3 Array design and execution 
The array used was an 8 x 15K Agilent eARRAY (Design ID: 029000, Design Name: 
Webber_Salmonella) consisting of 2 oligonucleotides of 60 base pairs for each gene. The array 
contained all coding sequences from Salmonella enterica serovar Typhimurium strains LT2, 
SL1344 and 14028S and was repeated 8 times on each array slide (see appendix file name: 
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Chapter 3 appendix data > Microarray, for full list of genes). cDNA synthesis, labelling and 
hybridisation (of each biological replicate) to the array was performed by the Functioning 
Genomics Lab at the University of Birmingham, UK. Arrays were analysed by Dr Ewan Hunter 
(University of Birmingham) to give lists of genes and pathways with statistically significantly 
changed expression values. Analysis was carried out using GeneSpring software (version 12). 
Further analysis was then carried out in Cardiff University where lists of significantly changed 
genes were compiled (based on a p value of ≤ 0.01) for each strain and treatment. (See 
appendix folder name: Chapter 3 appendix data > Microarray for raw microarray data from Dr 
Ewan Hunter and data analysed at Cardiff). 
 
3.2.8 Real-time PCR 
3.2.8.1 Genes of interest 
Real time PCR reactions were carried out to investigate and confirm changes in the expression 
of specific genes selected from microarray data produced after the exposure of SL1344 and 
14028S to low concentrations of CHG and BZC. Table 3.1 shows the list of genes that were 
selected to be investigated due to their significant up/down regulation observed in the 
microarray work carried out. Genes were also selected based on their possible association with 
results observed in other experiments performed throughout this chapter. rrsH was chosen as 
a reference gene as it has successfully been shown to maintain a consistent level of expression 
after exposure to multiple biocides (Whitehead et al., 2011). 
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Table 3.1: List of S. enterica serovar Typhimurium genes investigated using real time PCR 
Name Function Fold change in Microarray 
ydgF Multi-drug efflux system 
protein MdtJ 
2-fold up-regulated in 
14028S treated with 0.0001 
% CHG 
acrR Transcriptional repressor 
and regulator of the AcrAB 
operon (which is involved 
in efflux) 
0.60-fold down regulated in 
14028S treated with 0.0004 
% BZC 
blc Outer membrane 
lipoprotein 
2-fold up-regulated in 1344  
treated with 0.0004 % BZC 
and CHG 
hybB Hydrogenase 2 large 
subunit 
9.9-fold up-regulated in 
14028S treated with 0.0004 
% BZC 
hycA Formate hydrogenlyase 
regulatory protein 
13.8-fold up-regulated in 
14028S treated with 0.0004 
% BZC 
ompW Outer membrane protein 6.8-fold up-regulated in 
14028S treated with 0.0004 
% BZC 
rrsH 16S ribosomal RNA – 
(reference gene) 
 - 
 
3.2.8.2 Primers 
Primers were designed using Primer 3 software (http://bioinfo.ut.ee/primer3-0.4.0/ accessed 
11/03/2014) and their specificity for each Salmonella gene target was tested using the In Silico 
PCR tool (http://insilico.ehu.es/PCR accessed 11/03/2012). All primers were from Invitrogen, 
Paisley, UK. Primers sequences are listed in table 3.2. 
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Table 3.2: Primers for real-time PCR 
 
3.2.8.3 Real time PCR reactions 
Reactions were performed in triplicate under the conditions described in chapter 2 section 
2.13. Data analysis was carried out using the Pfaffl method (Pfaffl, 2001) described in detail in 
chapter 2 section 2.14. (See appendix folder name: Chapter 3 appendix data > real_time_PCR 
for raw data). 
Primer Name Primer (Forward and Reverse)  
5’ – 3’ 
Product size (bp) Annealing 
temperature (°C) 
rrsH (house-
keeping) 
CAGAAGAAGCACCGGCTAAC 
 
218 Multiple 
GACTCAAGCCTGCCAGTTTC 
 
blc GTTACTGCGGCATTTTTGGT 150 55.2 
TTGTTCCAGTCCACGTTCAA 
hycA TTGGGAAATAAGCGAAAAGG 173 55.2 
GCTCAAACAGGACAAAGCAA 
hybB GGGCGGAAAAATCATCAGTA 153 55.2 
AGGTCAAAGGCAATCCAGAC 
acrR GCCGCTTATTGATGGAGATT 152 56.2 
TTCAGGCAGCATTTTAGCATT 
ompW GCGTGGGGGTGAACTACA 264 55.2 
AGCCTGCCGAGAACATAAAT 
ydgF CTGGCTATCGCGACTGAAAT 184 56.2 
69 
 
3.2.9 Statistical tests 
A Students t-test was used to compare MIC, MBC and zone of inhibition values before and 
after biocide exposure and to compare fluorescence values between biocide-treated and 
untreated cells in efflux assay experiments. A one-way analysis of variance (ANOVA) test was 
used when comparing zone of inhibition values obtained from the phenotype stability tests 
and particle size values from light scattering experiments.  
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3.3 Results 
3.3.1 Suspension testing 
Strains SL1344 and 14028S were exposed to CHG and BZC at the minimum bactericidal 
concentration (0.01 % CHG & 0.006 % BZC for SL1344 and 0.006 % CHG & 0.008 % BZC for 
14028S) for a total time period of 60 min, in order to determine the effect of contact time on 
biocide efficacy. The toxicity and efficacy of the neutraliser was tested prior to the suspension 
test being carried out. Tables 3.3 and 3.4 show the neutraliser toxicity and efficacy data. 
Table 3.3: Neutraliser toxicity data for strains SL1344 & 14028S. N=3 
SD = standard deviation 
Treatment Log CFU/mL ± SD 
Control (diH20) SL1344: 8.48 ± 0.00 
14028S: 8.70 ± 0.00 
Neutraliser SL1344: 8.48 ± 0.00 
14028S: 8.67 ± 0.02 
 
Table 3.4: Neutraliser efficacy data for strains SL1344 & 14028S. N=3 
 
Treatment Log CFU/mL ± SD 
Control (diH20) SL1344: 8.48 ± 0.00 
14028S: 8.70 ± 0.00 
CHG (5 %) SL1344: 0.00 ± 0.00 
14028S: 0.00 ± 0.00 
CHG + Neutraliser SL1344: 8.10 ± 0.04 
14028S: 8.47 ± 0.00 
BZC (12.5 %) SL1344: 0.00 ± 0.00 
14028S: 0.00 ± 0.00 
BZC + Neutraliser SL1344: 8.10 ± 0.05 
14028S: 8.47 ± 0.00 
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The neutraliser was considered non-toxic if ≤ 1 log10 reduction in CFU/mL (compared to 
control) was observed. The neutraliser was considered effective if ≤ 1 log10 reduction in 
CFU/mL was observed in the presence of biocide and neutraliser ((based on BS EN 1276 (2009) 
suspension testing guidelines)). Tables 3.3 and 3.4 show that the neutraliser was not toxic to 
either strain, and that it was effective in neutralising CHG and BZC. 
 
The dilutions performed during the suspension tests resulted in a 4.4 log10 limit of detection 
for SL1344 and a 4.6 log10 limit of detection for 14028S. Figure 3.2 shows the effect of contact 
time on exposure of both strains to CHG. 
 
Figure 3.2: log10 reduction in CFU/mL of strains SL1344 & 14028S after exposure to CHG. 
Contact times of 1, 2.5, 4, 5, 10, 30, 40 and 60 min. N=3 
 
 
After exposure of SL1344 to 0.01% CHG the greatest log10 reduction was observed in the first 
minute of exposure (~2.3 log10). After 10 min a 4.4 log10 reduction was observed. This was the 
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maximum log10 reduction that could be determined due to the 4.4 log10 limit of detection. The 
4.4 log10 reduction corresponded to a plate count of zero. The greatest log10 reduction also 
occurred in the first minute of exposure of strain 14028S to 0.006 % CHG (3 log10). After 10 min 
exposure to 0.006 % CHG a 4.6 log10 reduction was observed in strain 14028S. This was the 
maximum log10 reduction that could be determined due to the limit of detection. 
Figure 3.3 shows the effect of contact time on the efficacy of BZC against SL1344 and 14028S. 
 
 
Figure 3.3: log10 reduction in CFU/mL of strains SL1344 & 14028S after exposure to BZC. 
Contact times of 1, 2.5, 4, 5, 10, 30, 40 and 60 min. N=3 
 
 
In the first minute of exposure of SL1344 to 0.003 % BZC a 2 log10 reduction in log CFU/mL was 
observed. Between 1 and 10 min a further 2.4 log10 reduction was observed. At 10 min a 4.4 
log10 reduction in CFU/mL was observed in SL1344. After exposure of 14028S to 0.008 % BZC 
for 1 min a 2.5 log10 reduction was observed. After 5 min a 4.6 log10 reduction was observed.  
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3.3.2 Antimicrobial susceptibility testing 
The MIC and MBC of CHG and BZC, and susceptibility to the antibiotics ciprofloxacin, 
ceftriaxone, ampicillin, piperacillin and chloramphenicol were determined before and after 5 
min exposure to a range of low CHG and BZC concentrations. Baseline and post-exposure 
values were compared in order to determine if short term exposure to a low concentration of 
CHG or BZC resulted in a change in antimicrobial susceptibility in surviving organisms.  
 
3.3.2.1 Changes in minimum inhibitory and minimum bactericidal concentrations 
Baseline and post-exposure MIC and MBC values for CHG and BZC were compared in order to 
determine if 5 min exposure to CHG or BZC resulted in an increase in the MIC or MBC for either 
of these biocides. Tables 3.5 and 3.6 show baseline and post-exposure MIC and MBC values for 
SL1344 and 14028S. In the case of both strains post-exposure MIC and MBC values for CHG 
and BZC were all significantly different from baseline MIC and MBC values (p≤0.05). For strain 
SL1344 the greatest increases in MIC and MBC were observed after 5 min exposure to 0.0004 
%  CHG and 0.0004 % BZC (table 3.5). For strain 14028S exposure to 0.0001 % CHG and 0.0004 
% w/v BZC resulted in the greatest increases in MIC and MBC in surviving organisms (table 3.6). 
Increases in the MIC and MBC for BZC were observed after 5 min exposure to a low CHG 
concentration in both strains, indicating that short-term exposure to a low concentration of a 
particular biocide can affect the susceptibility of surviving organisms to other biocides. This 
was also true for the MIC and MBC of CHG after 5 min exposure to BZC. Both strains tested 
appeared to respond to 5 min exposure to a low biocide concentration in a similar way. The 
data also appear highly reproducible across all 9 repeats in the case of both strains, as 
indicated by the low standard deviation values.
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Table 3.5: MIC and MBC values of CHG and BZC for strain SL1344 after 5 min exposure to a range of low CHG and BZC concentrations. N=9 
 
 
 
 
 
 
 
 
 
  
Biocide concentration (%) 
MIC/MBC 
(%) 
Baseline 0.0004  
CHG 
0.0001 
CHG 
0.00005 
CHG 
0.00001 
CHG 
0.0004 
BZC 
0.0001 
BZC 
0.00001 
BZC 
CHG MIC 
± SD 
0.003  
± 0.003 
0.08 
± 0.00 
0.08 
± 0.00 
0.04 
± 0.00 
0.08 
± 0.000 
0.05 
± 0.02 
0.04 
± 0.00 
0.08 
± 0.000 
 
CHG MBC 
± SD 
0.010 
± 0.006 
0.20 
± 0.09 
0.20 
± 0.00 
0.04 
± 0.00 
0.10 
± 0.040 
0.30 
± 0.00 
0.20 
± 0.00 
0.20 
± 0.100 
 
BZC MIC 
± SD 
0.003 
± 0.000 
0.20 
± 0.00 
0.03 
± 0.02 
0.01 
± 0.00 
0.07 
± 0.100 
0.30 
± 0.10 
0.08 
± 0.00 
0.07 
± 0.100 
 
BZC MBC 
± SD 
0.003 
± 0.003 
0.20 
± 0.00 
0.05 
± 0.02 
0.20 
± 0.200 
0.13 
± 0.200 
0.80 
± 0.00 
0.20 
± 0.00 
0.30 
± 0.200 
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Table 3.6: MIC and MBC values of CHG and BZC for strain 14028S after 5 min exposure to 
a range of low CHG and BZC concentrations. N=9 
 
 
 
3.3.2.2 Changes in antibiotic susceptibility 
Clinical susceptibility to a range of antibiotics before and after 5 min exposure to a range of 
low CHG and BZC concentrations was determined following the BSAC disk diffusion 
protocol (Andrews, 2009). Tables 3.7 and 3.8 show the mean zone of inhibition sizes for a 
range of antibiotics observed before and after 5 min exposure to low CHG and BZC 
concentrations. Clinical susceptibility (i.e. sensitivity or resistance) was determined using 
the BSAC breakpoints for Enterobacteriaceae (Andrews, 2009).  
Table 3.7 shows that despite the statistically significant decreases in the mean zone of 
inhibition size observed for the antibiotics ciprofloxacin and ceftriaxone, there were no 
changes in clinical susceptibility to any of the antibiotics tested after 5 min exposure to a 
Biocide concentration (%) 
MIC/MBC 
(%) 
Baseline 0.0005  
CHG 
0.0001 
CHG 
0.0015 
BZC 
0.0004 
BZC 
CHG MIC 
± SD 
0.003  
± 0.003 
0.01 
± 0.000 
0.10 
± 0.000 
0.04 
± 0.000 
0.08 
± 0.000 
 
CHG MBC 
± SD 
0.006 
± 0.003 
0.10 
± 0.090 
2.00 
± 0.000 
0.50 
± 0.000 
0.30 
± 0.000 
 
BZC MIC 
± SD 
0.004 
± 0.003 
0.08 
± 0.000 
0.01 
± 0.000 
0.08 
± 0.000 
0.20 
± 0.000 
 
BZC MBC 
± SD 
0.008 
± 0.002 
0.10 
± 0.000 
0.20 
± 0.060 
0.10 
± 0.000 
2.00 
± 0.900 
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range of low CHG and BZC concentrations (according to BSAC susceptibility breakpoints for 
Enterobacteriaceae (Andrews, 2009)). There were no significant changes in mean zone of 
inhibition size for the remaining antibiotics tested. These data suggest that 5 min biocide 
exposure does not result in a change in clinical antibiotic susceptibility.  
 
Table 3.7: Mean zone of inhibition sizes (mm) for a range of antibiotics after exposure of 
strain SL1344 to a range of low CHG and BZC concentrations. N=9 
 
S = clinically sensitive to antibiotic according to BSAC breakpoints for Enterobacteriaceae 
* = significantly different to baseline value (p≤0.05) 
Cip = ciprofloxacin   Cef = ceftriaxone   Chl = chloramphenicol   Amp = ampicillin    
Pip = piperacillin 
 
Mean zone of inhibition size (mm) ± SD 
Antibiotic  
 
Base-
line 
0.0004
% 
CHG 
0.0001
% 
CHG 
0.00005
% 
CHG 
0.00001
% 
CHG 
0.0004
% 
BZC 
0.0001
% 
BZC 
0.00001
% 
BZC 
Cip 
(1µg) 
41.3S 
± 2.3 
 
31.0S* 
± 2.0 
31.0S* 
± 0.0 
34.3S* 
± 0.6 
34.2S* 
± 0.6 
30.3S* 
± 1.5 
30.0S* 
± 1.7 
33.3S* 
± 0.1 
Cef 
(30µg) 
40.7S 
± 0.6 
 
37.0S* 
± 2.0 
30.0S* 
± 0.0 
36.7S* 
± 0.6 
35.2S* 
± 0.5 
33.3S* 
± 2.1 
30.0S* 
± 1.0 
36.0S* 
± 0.0 
Chl 
(30µg) 
27.3S 
± 1.2 
 
27.7S 
± 2.3 
29.0S 
± 1.2 
32.0S 
± 1.7 
27.7S 
± 2.1 
28.7S 
± 0.6 
29.0S 
± 1.7 
28.0S 
± 0.0 
Amp 
(10µg) 
32.0S 
± 2.0 
 
29.7S 
± 0.6 
28.0S 
± 0.5 
32.7S 
± 1.5 
28.7S 
± 1.5 
28.7S 
± 1.5 
29.7S 
± 2.1 
31.0S 
± 0.0 
Pip 
(75µg) 
31.7S 
± 0.6 
31.0S 
± 1.7 
28.0S 
± 0.5 
32.0S 
± 0.0 
29.0S 
± 0.0 
29.3S 
± 1.5 
28.0S 
± 0.6 
32.0S 
± 0.0 
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Table 3.8: Mean zone of inhibition sizes (mm) for a range of antibiotics after exposure of 
strain 14028S to a range of low CHG and BZC concentrations. N=9 
 
S = clinically sensitive to antibiotic according to BSAC breakpoints for Enterobacteriaceae 
* = significantly different to baseline value (p≤0.05) 
Cip = ciprofloxacin   Cef = ceftriaxone   Chl = chloramphenicol   Amp = ampicillin    
Pip = piperacillin 
 
Mean zone of inhibition size (mm) ± SD 
Antibiotic  
 
Baseline 0.0005% 
CHG 
0.0001% 
CHG 
0.0004% 
BZC 
0.0001% 
BZC 
Cip  
(1µg) 
43.3S 
± 1.2 
 
30.3S* 
± 0.5 
31.0S* 
± 0.6 
30.3S* 
± 1.2 
 
27.0S* 
± 0.0 
 
Cef  
(30µg) 
39.3S 
± 1.2 
 
34.7S* 
± 1.2 
30.0S* 
± 0.6 
34.7S* 
± 2.1 
 
34.7S* 
± 1.6 
 
Chl  
(30µg) 
26.7S 
± 2.3 
 
27.7S 
± 0.6 
26.7S 
± 1.5 
27.7S 
± 2.1 
 
26.7S 
± 1.5 
 
Amp  
(10µg) 
31.3S 
± 2.3 
 
31.3S 
± 1.2 
27.7S 
± 1.2 
31.3S 
± 2.3 
 
27.7S 
± 1.2 
 
Pip  
(75µg) 
31.7S 
± 1.5 
29.7S 
± 1.7 
29.0S 
± 1.7 
29.7S 
± 2.5 
29.0S 
± 0.0 
 
As observed in strain SL1344 (table 3.7) there were no clinical changes in susceptibility to 
any of the antibiotics tested according to the BSAC breakpoints for Enterobacteriaceae 
(Andrews, 2009).  
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3.3.2.3 Phenotype stability testing 
The stability of the increases in MBC observed after 5 min exposure to a range of low CHG 
and BZC concentrations was investigated via the 24 h subculture of surviving organisms 
through TSB +/- a low concentration of CHG or BZC. Tables 3.9 and 3.10 show the MBC 
values after 1, 5 and 10 subcultures of surviving organisms through TSB +/- CHG/BZC. 
As shown in tables 3.9 and 3.10, the high MBC values observed after the initial 5 min 
exposure to CHG or BZC were lost after 1 subculture in the absence of CHG or BZC. The 
values obtained after 1 subculture in the absence of CHG or BZC were not significantly 
different from the baseline MBC value. This suggests that in the absence of any selective 
pressure (i.e. removal of biocide), the MBC values reverted to baseline level. These values 
remained stable and at baseline level throughout the remaining subcultures in the absence 
of CHG or BZC in the case of both strains.  
After 1 and 5 subcultures of survivors of strain 14028S in the presence of 0.0001 % CHG or 
0.0004 % BZC there was a significant difference between MBC values obtained and baseline 
MBC values. This indicates that in the presence of these low biocide concentrations an 
elevated MBC was maintained. However there was no significant difference between the 
MBC obtained after 10 passages of survivors of strain 14028S in the presence of 0.0001 % 
CHG or 0.0004 % BZC and the baseline MBC (table 3.10). This shows that despite the 
presence of a low biocide concentration, the elevated MBC values observed after 5 min 
exposure were lost after 10 subcultures. This was also observed in the case of SL1344 
survivors subcultured in the presence of 0.0004 % BZC (table 3.9). The elevated MBC 
observed after the initial 5 min exposure to 0.0001 % CHG had reverted back to baseline 
level after 24 h, even in the presence of the low biocide concentration. The fact that the 
elevated MBCs were not maintained even in the presence of a low concentration of CHG or 
BZC may have been due to accumulative damage from the continuous presence of the 
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biocide. It could also have been due to the fact that the maintenance of an elevated MBC 
was detrimental to the bacterial cell.
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Table 3.9: Mean MBC values for CHG and BZC after 1, 5 and 10 subcultures of surviving SL1344 through TSB +/- 0.0004 % CHG or BZC. N=3 
 
SC = subculture         * = significantly different from baseline (p≤0.05) 
 
  
 
Baseline  
MBC (%) 
5 min CHG 
0.0004 % 
1 SC 
 
5 SC 
 
10 SC 
 
1 SC 
 (CHG) 
5 SC 
(CHG) 
10 SC 
(CHG) 
CHG MBC (%) 
± SD 
 
0.010 
± 0.09 
 
0.500* 
± 0.00 
 
0.008 
± 0.00 
 
0.009 
± 0.00 
 
0.006 
± 0.00 
 
0.015 
± 0.04 
 
0.010 
± 0.04 
 
0.010 
± 0.00 
 
BZC MBC (%) 
± SD 
0.003 
± 0.00 
0.150* 
± 0.00 
0.004 
± 0.00 
0.006 
± 0.00 
0.006 
± 0.00 
0.019* 
± 0.00 
0.050* 
± 0.02 
0.006 
± 0.00 
 
Baseline  
MBC (%) 
5 min BZC 
0.0004 % 
1 SC 
 
5 SC 
 
10 SC 
 
1  SC 
(BZC) 
5  SC 
(BZC) 
10  SC 
(BZC) 
CHG MBC (%) 
± SD 
 
0.010 
± 0.09 
 
0.500* 
± 0.00 
 
0.020 
± 0.03 
 
0.010 
± 0.00 
 
0.009 
± 0.00 
 
0.08* 
± 0.04 
 
0.080* 
± 0.04 
 
0.010 
± 0.00 
 
BZC MBC (%) 
± SD 
0.003 
± 0.00 
0.300* 
± 0.00 
0.006 
± 0.00 
0.006 
± 0.00 
0.006 
± 0.00 
0.078* 
± 0.00 
0.060* 
± 0.02 
0.003 
± 0.00 
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Table 3.10: Mean MBC values for CHG and BZC after 1, 5 and 10 subcultures of surviving 14028S through TSB +/- 0.0001 % CHG or 0.0004 % BZC. N=3 
 
SC = subculture        * = significantly different from baseline (p≤0.05)
 
Baseline  
MBC (%) 
5 min CHG 
0.0001 % 
1 SC 
 
5 SC 
 
10 SC 
 
1 SC 
(CHG) 
5 SC 
(CHG) 
10 SC 
(CHG) 
CHG MBC (%) 
± SD 
 
0.006 
± 0.003 
 
0.500* 
± 0.00 
 
0.001 
± 0.00 
 
0.006 
± 0.00 
 
0.009 
± 0.00 
 
0.080* 
± 0.04 
 
0.080* 
± 0.04 
 
0.006 
± 0.00 
 
BZC MBC (%) 
± SD 
0.008 
± 0.002 
0.300* 
± 0.00 
0.006 
± 0.00 
0.007 
± 0.00 
0.006 
± 0.00 
0.019* 
± 0.00 
0.020* 
± 0.00 
0.006 
± 0.00 
 
Baseline  
MBC (%) 
5 min BZC 
0.0004 % 
1 SC 
 
5 SC 
 
10 SC 
 
1 SC 
 (BZC) 
5 SC 
 (BZC) 
10 SC 
(BZC) 
CHG MBC (%) 
± SD 
 
0.006 
± 0.003 
 
0.500* 
± 0.00 
 
0.006 
± 0.00 
 
0.005 
± 0.00 
 
0.006 
± 0.00 
 
0.040* 
± 0.02 
 
0.070* 
± 0.07 
 
0.006 
± 0.00 
 
BZC MBC (%) 
± SD 
0.008 
± 0.002 
0.300* 
± 0.00 
0.007 
± 0.00 
0.004 
± 0.00 
0.006 
± 0.00 
0.019* 
± 0.00 
0.020* 
± 0.00 
0.006 
± 0.00 
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3.3.3 Efflux assays 
The accumulation of fluorescent Hoechst dye was measured in SL1344 or 14028S cells 
grown to mid-log phase in the presence/absence of CHG or BZC, and in the 
presence/absence of 3 different efflux pump inhibitors (EPIs). This gave an indication of the 
level of efflux activity taking place in the bacterial cell as a result of biocide exposure. The 
toxicity of the EPIs was tested prior to the efflux assays. Table 3.11 shows the toxicity 
testing data. 
Table 3.11: EPI toxicity data for strains SL1344 & 14028S 
 
EPI Log10 CFU/mL before 
exposure ± SD 
Log10 CFU/mL after 
exposure ± SD 
Log10 reduction in 
CFU/mL after EPI 
exposure 
Verapamil (50 mg/L) SL1344: 8.26 ± 0.01 
14028S: 8.60 ± 0.02 
SL1344: 7.39 ± 0.13 
14028S: 8.10 ± 0.09 
0.87 ± 0.13 
0.50 ± 0.09 
PAβN (10 mg/L) SL1344: 8.26 ± 0.01 
14028S: 8.24 ± 0.01 
SL1344: 7.67 ± 0.15 
14028S: 7.29 ± 0.06 
0.59 ± 0.15 
0.95 ± 0.06 
1-(1-NP) (10mg/L) SL1344: 8.26 ± 0.01 
14028S: 8.23 ± 0.04 
SL1344: 7.31 ± 0.06 
14028S: 7.28 ± 0.10 
0.95 ± 0.06 
0.95 ± 0.10 
 
The EPIs were considered non-toxic if ≤ 1 log10 reduction was observed after exposure 
(according to BS EN 1276 2009 protocol). Table 3.11 shows that none of the EPIs used were 
toxic to strains SL1344 and 14028S at the concentrations chosen. 
Figure 3.4 shows mean fluorescence values in biocide-treated and untreated SL1344 cells in 
the presence/absence of verapamil (50 mg/L) or PAβN (10 mg/L) or 1-(1-NP) (10 mg/L). 
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Figure 3.4: Mean fluorescence values observed in biocide-exposed and untreated SL1344 
before and after the addition of different efflux pump inhibitors (EPIs). N=3 
* = significantly different from untreated 
CHG and BZC treated SL1344 accumulated significantly less (p≤ 0.05) Hoechst dye than 
untreated cells, as indicated by the lower fluorescence reading (figure 3.4 blue bars). This 
reduced accumulation of dye in biocide-treated cells may have been due to the up-
regulation of efflux-associated genes or increased efflux pump activity.  This suggests that 
biocide treatment may have had an effect on the efflux activity taking place in SL1344 cells. 
All three EPIs tested caused an increase in the fluorescence reading observed across all 
three treatments (figure 3.4). This suggests that the EPIs were inhibiting efflux activity, 
resulting in an increased accumulation of Hoechst dye in the cells. 1-(1-NP) and PAβN had a 
greater inhibitory effect on efflux, as indicated by the greater increase in fluorescence in 
figure 3.4 (green and purple bars). Both inhibit RND type efflux pumps, suggesting that a 
large proportion of the efflux pump activity taking place may have been due to this type of 
pump. Verapamil also caused an increase in the fluorescence reading across all treatments. 
Verapamil is an inhibitor of ABC type efflux pumps. This suggests that more than one type 
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of efflux pump was present and that Hoechst dye may be a substrate of more than one 
type of efflux pump present in SL1344. 
Figure 3.5 shows mean fluorescence values in biocide-treated and untreated 14028S cells 
in the presence/absence of verapamil (50 mg/L) or PAβN (1 0mg/L) or 1-(1-NP) (10 mg/L). 
 
 
Figure 3.5: Mean fluorescence values observed in biocide-exposed and untreated 14028S 
before and after the addition of different efflux pump inhibitors (EPIs). N=3 
* = significantly different from untreated 
 
CHG treated 14028S cells accumulated significantly less (p≤0.05) Hoechst dye than 
untreated cells as indicated by the lower fluorescence reading in figure 3.5 blue bars. This 
response to CHG exposure was also observed in SL1344 and is suggestive of increased 
efflux pump activity as a result of biocide exposure. Exposure of 14028S to 0.0004 % BZC 
did not result a significant change in the fluorescence reading observed (blue bars figure 
3.5) suggesting that BZC exposure did not result in a significant alteration in efflux pump 
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activity in this strain. The EPIs PAβN and 1-(1-NP) caused a large increase in the 
fluorescence reading across all treatments (figure 3.5 purple and green bars). As observed 
in SL1344 this suggests the presence and activity of RND type efflux pumps.  
 
3.3.4 One Dimensional Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis (SDS-
PAGE) 
One dimensional SDS-PAGE was performed on OMPs extracted from SL1344 and 14028S 
grown to mid-log phase in a low CHG/BZC concentration, in order to determine if biocide 
exposure caused alterations in OMP composition. Figure 3.6 shows the protein bands 
present in untreated and CHG/BZC treated SL1344 and 14028S cells. The same starting 
concentration (20 µg/ 20µL) of each sample was loaded on to the gel and protein bands 
were stained with colloidal coomassie stain. 
Figure 3.6 shows that there was no definitive absence of existing bands or appearance of 
new bands in either strain after exposure to CHG or BZC. The intensity of two bands was 
reduced after SL1344 was grown to mid-log phase in the presence of 0.0004 % CHG 
(indicated by red arrows in figure 3.6). The molecular weights (MW) of the two bands 
showing reduced intensity are approximately 25 and 50 kDa. Proteins from the omp family 
present in S. Typhimurium vary in MW and are all around 40 kDa, with the exception of 
OmpW which has a MW of 22.96 kDa. This value is quite close in MW to the approximate 
MW of one of the OMPs observed here. It is possible that the 25 kDa band is representative 
of OmpW, a porin present in the outer membrane. Reduced expression of porins (i.e. 
reduced band intensity on a gel) may result in reduced accumulation of a biocide in the cell, 
and a possible increase in the MIC or MBC for that biocide.  The outer membrane proteins 
SmvA (associated with acriflavine efflux) and TolC (an outer membrane efflux system 
protein) are 52.14 and 53.68 kDa in size respectively. They are therefore close in MW to the 
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50 kDa protein observed here. However it is not clear why efflux associated protein 
production would be reduced after biocide exposure, considering the fact that efflux assay 
data was indicative of increased efflux activity. It is possible that the protein band observed 
here does not represent either of these proteins. Further sequencing and proper 
identification of proteins with reduced band intensity would provide further information on 
the effect of biocide exposure on OMP composition. 
 
 
 
 
 
 
 
 
Figure 3.6: Outer membrane protein bands observed in SL1344 & 14028S either grown to 
mid-log phase in low concentrations of CHG/BZC or untreated 
 
Red arrows indicate reduction in band intensity 
 
3.3.5 Flow cytometry 
Biocide-treated and untreated bacteria were stained with PI and BOX and separated 
according to their light scattering and fluorescent properties. The level of uptake of each 
dye and the corresponding fluorescent signal provided information on the amount of 
damage to the cell as a result of biocide exposure, and the number of cells alive, damaged 
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or dead. Figure 3.7 (a) shows the distribution of untreated and ethanol-killed (positive 
control) SL1344 cells. This figure demonstrates the position on the plot of ‘live’ (untreated) 
and ‘dead’ (ethanol-killed) cells and illustrates how the quadrants defining live, dead or 
damaged cells were chosen. Figures 3.7 (b) and (c) show the distribution of SL1344 (b) and 
14028S (c) cells after 5 min exposure to a low concentration of CHG or BZC (0.0004 % CHG 
and BZC for SL1344 and 0.0001 % CHG and 0.0004 % BZC for 14028S) and staining with PI 
and BOX, and a table of statistics adapted from those calculated using FACSDiva software.  
Figure 3.7 (b) shows that untreated SL1344 cells did not accumulate large amounts of PI or 
BOX indicating that they were undamaged. This was also reflected in the statistics that 
show that 97.0 % of cells appeared in Q3-1. A change in the population was clearly 
observed after 5 min exposure of SL1344 to 0.0004 % CHG. As shown in the statistics table 
in figure 3.7 (b), 96.0 % of cells appeared in Q1-1, indicating that a large proportion of the 
population was damaged after biocide exposure. However only 1.60 % of cells appeared in 
Q2-1 (dead), indicating that exposure to this concentration did not kill a large number of 
cells after 5 min. Exposure of SL1344 to 0.0004 % BZC also resulted in damage to the 
population with 23.8 % of cells appearing in Q1-1 after 5 min exposure. However 75.4 % of 
the population appeared in Q3-1 suggesting they were not damaged by 5 min exposure to 
0.0004 % BZC. It is possible that this population that were exposed to the biocide but not 
damaged were responsible for the elevated MIC and MBC values observed in section 3.3.2.  
Sorting of these cells in to FACSflow buffer and determination of the MIC and MBC of CHG 
and BZC would confirm this. As observed in strain SL1344, exposure of 14028S to 0.0001 % 
CHG or 0.0004 % BZC for 5 min resulted in some damage to the population, but the 
majority of cells remained in Q3-1 (92.0 % and 88.8 % respectively) (figure 3.7c). As with 
strain SL1344, it is possible that biocide-exposed cells present in Q3-1 (undamaged) could 
be the population responsible for the elevated MIC and MBC values observed in section 
3.3.2.
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Q1: Damaged cells (membrane potential lost, membrane intact)  
Q2: Dead (ruptured membrane) 
Q3: Alive (minimal uptake of dyes) 
 
Figure 3.7 (a): Distribution of untreated or ethanol-killed SL1344 cells stained with PI and BOX 
Treatment % of events in Q1-1 % of events in Q2-1 % of events in Q3-1 
Untreated 2.10 0.20 97.0 
80 % Ethanol 1.40 78.6 3.5 
PI 
B
O
X 
 
PI 
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X
 
Untreated (control) Ethanol-killed              
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Q1: Damaged cells (membrane potential lost, membrane intact) 
Q2: Dead (ruptured membrane) 
Q3: Alive (minimal uptake of dyes) 
 
 
Figure 3.7 (b): Distribution of untreated or 0.0004 % CHG/BZC treated SL1344 stained with PI and BOX 
 
 
Treatment % of events in Q1-1 % of events in Q2-1 % of events in Q3-1 
Untreated 2.10 0.20 97.0 
0.0004 % CHG 96.0 1.60 2.40 
0.0004 % BZC 23.8 0.70 75.4 
   
0.0004 % CHG 0.0004 % BZC Untreated 
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Q1: Damaged cells (membrane potential lost, membrane intact)  
Q2: Dead (ruptured membrane) 
Q3: Alive (minimal uptake of dyes) 
 
 
Figure 3.7 (c): Distribution of untreated or 0.0001 % CHG/0.0004 % BZC treated 14028S stained with PI and BOX 
Treatment % of events in Q1-1 % of events in Q2-1 % of events in Q3-1 
Untreated 1.20 0.10 98.3 
0.0001 % CHG 7.60 0.20 92.0 
0.0004 % BZC 10.8 0.30 88.8 
   
0.0004 % BZC 0.0001 % CHG Untreated 
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3.3.6 Light scattering experiments 
Biocide-treated and untreated cells were passed through an N4 Plus Dynamic Light Scattering 
machine to determine if bacterial aggregates were present in any samples. Table 3.12 shows 
the mean particle sizes in untreated SL1344 and 14028S cells and cells treated with CHG or BZC 
at the minimum bactericidal concentration. 
Table 3.12: Mean particle size (nm) for untreated and biocide-treated SL1344 & 14028S cells. 
N=3 
 
Strain Treatment  Mean particle diameter (nm) (range) 
SL1344 Untreated 749 (60.20) 
 0.010 % CHG 978 (187.70)* 
 0.003 % BZC 771 (231.60) 
14028S Untreated 700 (117.20) 
 0.006 % CHG 902 (299.60) 
 0.008 % BZC 771 (170.80) 
 
* = significantly different (p≤0.05) from untreated 
 
 
There was no significant difference (p≤0.05) in mean particle size after treatment of 14028S 
with 0.006 % CHG or 0.008 % BZC (table 3.12). This suggests that exposure to these biocides at 
the concentration tested for 15 min did not result in the formation of bacterial aggregates. 
Similarly, exposure of SL1344 to 0.003 % BZC did not result in any significant change in particle 
size (p≤0.05). However, exposure of SL1344 to 0.010 % CHG resulted in a significant increase in 
particle size. This suggests that exposure to 0.010 % CHG may cause the formation of bacterial 
aggregates in this strain. The approximate diameter of a single Salmonella bacterium is 0.5-0.7 
µM (500-700 nm). This correlates with the mean particle diameter observed in untreated 
samples (~700 nm) in the case of both strains and suggests few, if any aggregates present in 
the untreated sample. The mean particle diameter of 978 nm observed after exposure of 
SL1344 to 0.010 % CHG is therefore unlikely to represent bacterial aggregates and is more 
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likely to represent the association of 1-2 cells that may be growing or dividing. Is it therefore 
also unlikely that CHG efficacy would be affected in this case. 
 
3.3.7 Microarray  
Microarray experiments were carried out after exposure of SL1344 and 14028S to CHG (0.0004 
% for SL1344, 0.0001 % for 14028S and BZC (0.0004 %) with a view to finding a potential 
marker gene that was significantly up or down-regulated in both strains and both biocide 
treatments.   
Table 3.13 shows the numbers of genes significantly up-regulated that were common to both 
strains (same treatment) and common to CHG and BZC (same strain). 
Table 3.13: Numbers of genes significantly up/down-regulated (p≤0.01) for each treatment 
and number of genes common to both strains/treatments 
 
Strain Treatment No. of genes 
significantly 
up-regulated 
No. of genes 
significantly 
down-regulated 
No. of genes 
common to 
other strain 
No of genes 
common with 
other biocide 
SL1344 0.0004 % CHG 109 91 4 31 
 
18 
 0.0004 % BZC 310 268 24 
14028S 0.0001 % CHG 84 76 4 
 0.0004 % BZC 177 195 24 
 
SL1344 and 14028S responded quite differently to CHG and BZC treatment at the gene 
expression level, as they only had 4 significantly changed genes in common after CHG exposure 
and 24 significantly changed genes in common after BZC exposure (Table 3.13). Thirty one 
common genes were altered in expression after exposure of strain SL1344 to CHG and BZC, 
and 18 genes after exposure of strain 14028S to CHG and BZC. The relatively small numbers of 
genes common to both biocides suggests that the effect each biocide has on the bacterial cell 
is different. Figure 3.8 shows the distribution of significantly up or down-regulated genes for 
each treatment. 
SL133 0.0004 % BZC 
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Figure 3.8: The distribution of genes significantly up or down-regulated after exposure of 
SL1344 and 14028S to a low concentration of CHG or BZC 
 
Figure 3.8 shows that in both strains and both treatments, the largest proportion of genes with 
a significant change in expression were those involved in metabolic processes, e.g. kinases, 
glycotransferases, dehydratases, dehydrogenases. A large number of genes with unknown 
function were also significantly up or down-regulated. Exposure to BZC resulted in a greater 
overall number of significantly altered genes in comparison to CHG exposure (figure 3.8, table 
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3.13). The proportions of genes within each functional group did not differ substantially across 
strains and treatments, suggesting that the general response to each biocide by each strain 
may be similar, despite the individual genes responsible for this response differing between 
each strain and treatment.  
Results from other experiments in this chapter indicated potential up-regulation of efflux 
activity as a result of biocide exposure, as well as potential formation of bacterial aggregates as 
a result of CHG exposure. Changes in the expression of genes that could potentially be 
associated with these responses were searched for in the microarray data. Changes in 
membrane associated genes were also searched for as CHG and BZC both primarily cause 
damage to the bacterial membrane. Table 3.14 shows key genes that were up or down-
regulated and could possibly be associated with results observed in other experiments in this 
chapter. 
 
Table 3.14: Fold changes in genes associated with transport, membrane, efflux, aggregation, 
metabolism and regulation 
 
↑ = up-regulated   ↓ = down-regulated 
Gene name Fold Change Function Possible explanation 
Transport 
potE  9.06 ↑ in SL1344 BZC Putrescine-ornithine 
antiporter 
 
Putrescine is 
involved in cell 
proliferation and 
growth in E. coli 
(Tabor and Tabor, 
1984) 
potA 1.60 ↑ in 14028S 
CHG 
Spermidine/putresene 
transport ATP-binding protein 
(ABC family)  
 
ybhR 1.64 ↑ in SL1344 BZC Putative transport protein Transport of 
compounds for 
metabolic processes 
 
dcuA 
 
dcuB 
 
4.50 ↑ in 14028S BZC 
 
6.74 ↑ in SL1344 BZC 
 
Anaerobic C4-dicarboxylate  
transporter 
Anaerobic  
respiration – energy 
production 
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dcuC 
 
4.56 ↑ in 14028S BZC 
ydeY 2.07 ↑ in SL1344 BZC Putative sugar transport 
protein 
 
Transport of sugars 
for respiration 
ego 2.80 ↑ in SL1344 
CHG 
Putative ABC-type aldose 
transport ATPase component 
 
glpF 2.80 ↑ in 14028S 
CHG 
Glycerol uptake facilitator 
protein 
Uptake of glycerol as 
a source of 
carbohydrate for 
energy production 
Membrane associated 
blc 2.00 ↑ in SL1344 
CHG and BZC 
 
Lipoprotein Membrane integrity 
spr 2.22 ↑in SL1344 BZC Putative outer membrane 
lipoprotein 
 
nlpI 1.65 ↑ in SL1344 BZC Lipoprotein 
 
ybfN 1.63 ↑ in SL1344 
CHG 
 
Putative lipoprotein 
rfaZ 1.35 ↑ in 14028S 
CHG 
 
LPS core biosynthesis protein Structural integrity 
and protection of 
membrane 
wzzE 1.22 ↑ in 14028S 
CHG 
 
LPS core biosynthesis protein 
tolA 0.79 ↑ in SL1344 
CHG 
 
Inner membrane integrity Inner membrane 
integrity 
ompW 6.80 ↑ in 14028S BZC Outer membrane protein Possible porin – 
biocide removal 
yhbV 4.22 ↑ in 14028S BZC Putative membrane protein Membrane 
integrity/biocide 
removal 
Efflux 
ybhS 1.80 ↑in SL1344 BZC Putative ABC superfamily 
membrane protein 
 
Removal of biocide 
from the cell 
sfbB 1.27 ↑ in 14028S 
CHG 
Putative ABC transport system 
ATPase component 
 
ydgF 2.00 ↑ in 14028S 
CHG 
Multidrug efflux system 
protein MdtJ  
 
mdfA 1.40 ↑ in 14028S 
CHG 
1.70 ↑ in 14028S BZC 
Multidrug translocase – similar 
to E. coli PMF pump 
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acrD 1.76 ↑ in 14028S BZC Putative efflux pump 
 
emrD 0.75 ↓ in SL1344 BZC  Multidrug resistance protein D 
 
Aggregation 
fimZ 0.67 ↓ in SL1344 BZC Regulator of FimA (major 
fimbriae protein) 
De-repression of 
fimA expression and 
increase in fimbriae  
Metabolic 
hycA 13.8 ↑ in 14028S BZC Formate hydrogenlyase 
regulatory protein 
Anaerobic 
respiration 
component – 
conversion of 
formate to CO2 and 
H2 
 
hybB 
 
9.93 ↑ in 14028S BZC Hydrogenase-2 large subunit Anaerobic 
metabolism, 
generation of 
transmembrane 
proton motive force 
hybA 
 
6.79 ↑ in 14028S BZC Hydrogenase-2 small protein 
hybC 
 
6.69 ↑ in 14028S BZC Hydrogenase-2 large subunit 
hybD 6.74 ↑ in 14028S BZC Hydrogenase-2 component 
protein 
 
adhE 6.44 ↑ in 14028S BZC 
3.15 ↑ in SL1344 BZC 
 
Alcohol dehydrogenase Fermentation of 
pyruvate to generate 
NAD+ (i.e. energy) 
pflF 
 
1.68 ↑ in SL1344 
CHG 
Putative pyruvate formate 
lyase 
 
yhhX 1.45 ↑ in SL1344 
CHG 
 
Putative dehydrogenase 
crp 1.27 ↑ in SL1344 
CHG 
cAMP receptor protein Energy production in 
the absence of 
glucose 
 
glpA 6.13 ↑ in 14028S 
CHG 
Anaerobic glycerol 3-
phosphate dehydrogenase 
subunit A 
 
Anaerobic 
respiration 
garK 4.11 ↑ in 14028S 
CHG 
 
Glycerate kinase I Catalyses ADP 
production 
dgoK 3.65 ↑ in 14028S 
CHG 
2-oxo-3-deoxygalaconate 
kinase 
 
Anaerobic 
metabolism 
components 
dgoA 6.91 ↑ in SL1344 BZC 2-oxo-3-deoxygalaconate-6-
phosphate 
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aldolase/galacatonate 
dehydratase 
Regulatory 
acrR 0.60 ↓ in 14028S BZC acrAB operon repressor De-repression of 
acrAB genes and 
increased efflux 
gene expression 
 
soxS 0.40 ↓ in 14028S BZC Regulator of oxidative stress 
genes 
Up-regulation of 
oxidative stress 
genes 
 
ynaF 1.45 ↑ in SL1344 BZC Putative universal stress 
protein 
Stress response 
 
As shown in table 3.14 sugar transporters were up-regulated in both strains and treatments, 
suggesting that during CHG and BZC exposure there is an up-regulation of genes associated 
with the generation of energy for further cellular processes. Numerous efflux-associated genes 
also underwent significant changes in expression after exposure to both biocides, correlating 
with the efflux assay experiments which were suggestive of increased efflux activity. acrR -  a 
regulator of the acrAB operon of efflux-associated genes was down-regulated, which may have 
resulted in de-repression of this operon, and increased expression of efflux associated genes to 
remove biocide from the bacterial cell. A large number of genes associated with anaerobic 
metabolism were up-regulated, suggesting that during biocide exposure, both strains switch to 
anaerobic respiration, and also suggesting that there was an increased requirement for energy 
production.  Several genes encoding lipoproteins and membrane proteins were up-regulated. 
Considering the fact that CHG and BZC primarily cause damage to the bacterial cell membrane, 
genes encoding membrane proteins may have been up-regulated to improve membrane 
integrity in the presence of the biocide. However there did not appear to be any significant up-
regulation of lipid synthesis genes. The regulatory gene fimZ was the only gene associated with 
aggregation that was significantly altered as a result of biocide exposure. Down-regulation of 
fimZ may have resulted in the increased expression of fimA and therefore the increased 
production of aggregative fimbriae. However this was only observed in strain 14028S exposed 
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to BZC. Down-regulation of soxS was observed in 14028S exposed to BZC. This may have 
resulted in de-repression of genes associated with counteracting oxidative stress inflicted on 
the cell as a result of biocide exposure.  The up-regulation of efflux-associated genes, and 
membrane-associated genes may have contributed to the elevated MIC and MBC values 
observed in the biocide exposure experiments in tables 3.4 and 3.5. 
The microarray experiments did not identify a marker gene that was common to both strains 
and both treatments, but did identify genes that may have contributed to the elevated MICs 
and MBCs observed, and the possible increased efflux activity observed. Six genes (ydgF, blc, 
hycA, hybB, acrR, ompW) were investigated using real-time PCR (Table 3.15). 
 
3.3.8 Real-time PCR 
Six genes were selected from microarray data and their expression in biocide-treated bacteria 
was compared with that in untreated bacteria. ydgF, blc, hycA, hybB, acrR and ompW were 
chosen either due to a large change in their expression after biocide exposure in the 
microarray experiments or due to possible association with other results obtained e.g. efflux 
up-regulation, elevated MICs/MBCs. Tables 3.15 and 3.16 show the changes in gene expression 
of the selected genes after growth of SL1344 (a) or 14028S (b) to mid-log phase in the 
presence of a low CHG/BZC concentration. 
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Table 3.15: Fold changes in gene expression after exposure of strain SL1344 to 0.0004 % CHG 
or BZC. N=3 
 
↑ = up-regulated   ↓ = down-regulated    FC = Fold Change 
Gene Treatment FC in microarray FC qPCR ± SD 
ydgF 0.0004 % CHG 
0.0004 % BZC 
1.58 ↑ 
1.80 ↑ 
1.33 ± 0.10 ↑ 
2.52 ± 0.53 ↑ 
blc 0.0004 % CHG 
0.0004 % BZC 
1.82 ↑ 
2.00 ↑ 
4.64 ± 0.00 ↑ 
6.83 ± 0.06 ↑ 
hycA 0.0004 % CHG 
0.0004 % BZC 
1.19 ↑ 
1.02 ↑ 
1.43 ± 0.22 ↑ 
2.42 ± 1.41 ↑ 
hybB 0.0004 % CHG 
0.0004 % BZC 
1.95 ↑ 
2.97 ↑ 
1.20 ± 2.29 ↑ 
0.97 ± 0.26 ↑ 
acrR 0.0004 % CHG 
0.0004 % BZC 
1.87 ↓ 
1.17 ↓ 
132. ± 0.22 ↓ 
2.39 ± 0.71 ↓ 
ompW 0.0004 % CHG 
0.0004 % BZC 
2.14 ↑ 
2.34 ↑ 
3.20 ± 0.84 ↑ 
4.14 ± 0.22 ↑ 
 
The greatest change in gene expression occurred in acrR after exposure of SL1344 to 0.0004 % 
CHG, where a 132 fold down-regulation of this gene was observed (table 3.15).  acrR is a 
potential repressor of the acrAB operon which encodes genes associated with efflux. Down-
regulation of this gene may therefore result in loss of repression of efflux, and possible 
increased efflux of the biocide from the cell. This level of down-regulation was not observed in 
acrR after exposure of SL1344 to 0.0004 % BZC. The greatest up-regulation in gene expression 
after biocide exposure was observed in blc (6.83 fold) after exposure of SL1344 to 0.0004 % 
BZC. Blc is a putative lipoprotein and may therefore be involved in the maintenance of 
membrane integrity or removal of biocide from the bacterial cell. The remaining changes in 
gene expression ranged between 4.64 and 1.33 fold. 
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Table 3.16: Fold changes in gene expression after exposure of 14028S to 0.0001 % CHG or 
0.0004 % BZC. N=3 
 
↑ = up-regulated   ↓ = down-regulated   FC = Fold Change 
n/a – change in this gene was not provided in raw microarray data  
 
Gene Treatment FC in microarray FC qPCR ± SD 
ydgF 0.0001 % CHG 
0.0004 % BZC 
2.00 ↑ 
2.88 ↑ 
1.35 ± 0.45 ↑ 
2.14 ± 0.76 ↑ 
blc 0.0001 % CHG 
0.0004 % BZC 
1.21 ↑ 
1.10 ↑ 
2.76 ± 0.42 ↑ 
1.94 ± 0.74 ↑ 
hycA 0.0001 % CHG 
0.0004 % BZC 
n/a 
13.8 ↑ 
0.99 ± 0.87 ↑ 
14.4 ± 0.16 ↑ 
hybB 0.0001 % CHG 
0.0004 % BZC 
5.10 ↑ 
9.90 ↑ 
11.8 ± 0.91 ↑ 
10.5 ± 0.93 ↑ 
acrR 0.0001 % CHG 
0.0004 % BZC 
1.30 ↓ 
1.76 ↓ 
148.7 ± 0.53↓ 
1.87 ± 1.19 ↓ 
ompW 0.0001 % CHG 
0.0004 % BZC 
4.44 ↑ 
5.76 ↑ 
6.80 ± 0.23 ↑ 
9.95 ± 0.42 ↑ 
 
The greatest change in gene expression occurred in acrR, after exposure of strain 14028S to 
0.0001 % CHG (Table 3.16). A 148.7 fold down-regulation of this gene was observed. This 
suggests that exposure to a low concentration of CHG can result in common responses 
between both strains. The greatest up-regulation was observed in hybB after exposure to both 
CHG and BZC (table 3.16). The hybB gene encodes the large subunit of the hydrogenlyase-2 
enzyme. HybB is involved in anaerobic metabolism and its up-regulation may result in 
increased production of transmembrane proton motive force required for biocide efflux. hybB 
was not up-regulated to the same level in SL1344 (table 3.15).  A 14.4 fold up-regulation of the 
hycA gene was also observed after 14028S exposure to 0.0004 % BZC (table 3.16). HycA is a 
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formate hydrogenlyase regulatory protein and may be associated with HybB.  The remaining 
changes in gene expression ranged between 9.95 and 0.99 fold (table 3.16). 
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3.4 Discussion 
The MIC and MBC values obtained for S. enterica strains SL1344 and 14028S were considerably 
lower than the concentrations currently used in commercial products. CHG is used in 
mouthwash at 0.2 % and in alcohol based hand rubs at 1 % (Lai et al., 2012). The MICs 
obtained here were 0.003 % and the MBCs 0.01 % or less for SL1344 and 14028S. This suggests 
that the strains used here were highly susceptible to the in-use concentrations of CHG. Condell 
et al., (2012a) looked at the MIC of chlorhexidine for SL1344 using a broth dilution method, 
like the one used in the experiments in this chapter, and found that it was 0.0004 %. This is 
approximately 10-fold lower than the MIC determined here and confirms this strains’ high 
susceptibility to the biocide. BZC is used at a concentration range of up to 0.5 % in strong 
cleaning products. The MICs and MBCs obtained for both Salmonella strains were considerably 
lower than this (0.003 – 0.008 %). This shows that both strains were highly susceptible to this 
biocide at the in-use concentration. Condell et al., (2012a) also looked at the susceptibility of a 
different serovar of Salmonella (Hvittingfoss S41) to BZC and found that the MIC was 0.0015 %. 
This value was close to the MICs for BZC of the strains used here. Morrissey et al., (2014) 
defined the ‘cut-off’ MIC for BZC- resistant Salmonella spp. as 128 mg/L (0.0128 %). This value 
is much greater than the MIC values observed here, suggesting SL1344 and 14028S are not 
resistant to BZC. The initial susceptibility of all strains tested provided a good comparison point 
for any reduced susceptibility observed after biocide exposure.  
Exposure of strains SL1344 and 14028S to a range of low concentrations of CHG and BZC 
(0.00001 – 0.0004 %) resulted in an increase in the MIC and MBC of both biocides of up to 100 
fold. These increases were highly reproducible and provided a useful initial marker of 
resistance that was obtainable within a 24 h period. The broth dilution method used also 
allowed for the testing of multiple strains and biocides at one time, making this technique very 
high throughput. Previous work has been carried out looking at single and repeat exposure of 
Pseudomonas aeruginosa to chlorhexidine diacetate (Thomas et al., 2000). Thomas et al., 
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(2000) reported that single exposure of Ps. aeruginosa to a residual (sub-lethal) concentration 
of chlorhexidine diacetate resulted in an increase in the MIC of this biocide. An increase in MIC 
has also been observed by Escalada et al., (2005) in E. coli exposed to the biocide triclosan. 
However, neither of these studies report such an increase in MBC as here observed with S. 
enterica serovar Typhimurium. Thomas et al., (2000) also reported that the increased MIC for 
chlorhexidine diacetate observed after a single exposure was not stable and did not result in 
any antibiotic cross-resistance. This correlates with the unstable increases in MIC and MBC 
observed here in strains SL1344 and 14028S. Mavri et al., (2013) reported adaptation to BZC 
and chlorhexidine diacetate in Campylobacter jejuni and Campylobacter coli that was stable for 
10 passages in biocide-free broth. However this adaptation was achieved through step-wise 
subculturing of the bacteria through increasing concentrations of the biocide, rather than after 
a single exposure.  
 
Exposure of S. enterica serovar Typhimurium to low CHG and BZC concentrations resulted in a 
significant decrease in the zone of inhibition size (mm) for the antibiotics ciprofloxacin and 
ceftriaxone. Koljalg et al., (2002) reported a relationship between chlorhexidine susceptibility 
and decreased susceptibility/resistance to antibiotics. They investigated the susceptibility of 
clinical isolates of Gram-negative bacteria including E. coli, Ps. aeruginosa and Klebsiella 
pneumoniae to chlorhexidine and several antibiotics, one of which was ciprofloxacin. They 
reported that K. pneumoniae with decreased chlorhexidine susceptibility was also clinically 
resistant (according to the National Committee for Clinical Laboratory Standards) to several 
antibiotics including imipenem, cefotaxime, gentamicin and ciprofloxacin. This suggests that 
there may be a common mechanism responsible for reduced susceptibility to both 
chlorhexidine and ciprofloxacin. This mechanism may have been triggered here in strains 
SL1344 and 14028S during 5 min exposure to the range of low CHG concentrations tested, 
resulting in an increase in CHG and BZC MIC and MBC and changes in the zone of inhibition size 
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for the antibiotics ciprofloxacin and ceftriaxone. Koljalg et al., (2002) did not speculate as to a 
possible mechanism associated with decreased susceptibility to multiple antimicrobial 
products. However the qPCR data generated in this chapter is suggestive of increased efflux 
activity as a result of down-regulation of the regulatory gene acrR. Mavri et al., (2013) 
reported reduced susceptibility to ciprofloxacin as a result of BZC exposure in Campylobacter 
spp. which correlates with what was observed here in Salmonella, and they attributed this to 
the up-regulation of more than one type of efflux system, and also to thickening of the cell 
envelope. 
Tattawasart et al., (1999) speculated that alterations to the bacterial cell envelope may be 
responsible for the resistance to triclosan and some antibiotics that they observed in 
chlorhexidine diactetate-resistant Ps. stutzeri. It is possible that changes to the cell envelope 
may have contributed to the decreased susceptibility to both CHG and BZC observed here in 
SL1344 and 14028S after a single exposure to these biocides. In contrast to this Braoudaki and 
Hilton (2004) suggested that mechanisms of resistance to more than one antimicrobial may 
not be non-specific like cell envelope changes. They found that BZC-resistant Salmonella 
enterica serovar Virchow were also resistant to chlorhexidine but chlorhexidine-resistant 
isolates were not resistant to BZC, suggesting the application of a specific mechanism involving 
alteration of a particular cellular target rather than a non-specific mechanism designed to 
remove the antimicrobial from the cell. 
Changes to the cell envelope may also encompass alterations in OMP composition as a result 
of biocide exposure. Condell et al., (2012b) investigated total protein changes in triclosan-
sensitive and triclosan-adapted (>1000 fold increase in MIC) S. enterica serovar Typhimurium 
using one and two dimensional SDS-PAGE. They did not observe any significant changes in 
protein composition when comparing the wild type and adapted strains using one dimensional 
SDS-PAGE. This correlates with what was observed here after exposure of SL1344 and 14028S 
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to a low concentration of CHG and BZC. However Condell et al., (2012b) did observe numerous 
changes in total protein composition when using two dimensional SDS-PAGE, suggesting that 
one dimensional SDS-PAGE may be limited in its sensitivity. Interestingly, a large number of 
proteins that were up-regulated were involved in glycolysis and the generation of energy (e.g. 
GarL AtpA, GapA). This was also observed here in genes associated with energy generation in 
the microarray work carried out (e.g hybB, garL, agp, atpG). Zhang et al.,(2011) looked at the 
effect of phenol exposure on E. coli and observed changes in 9 different proteins using SDS-
PAGE and Western blotting, one of which was the porin OmpA. Rushdy et al., (2013) also used 
SDS-PAGE to identify changes in OMPs in 5 MDR clinical isolates of S. enterica and found loss of 
OmpF in all 5. This protein was however present in the reference strain (14028). OmpF is also a 
porin and may therefore have been lost to reduce the access of antimicrobials to the bacterial 
cell.  Karatzas et al., (2008) also found reduced levels of OmpA, C and F in multiple antibiotic 
resistant S. enterica serovar Typhimurium isolates that had been exposed to 4 disinfectants. 
However Mavri et al., (2013) found that loss of OMPs in C. coli was actually associated with 
very weak adaptive resistance to the biocides tested, so it may not necessarily be associated 
with reduced biocide susceptibility. This may be the reason why there was no loss of protein 
expression observed in the one-dimensional SDS-PAGE carried out here.  Microarray and qPCR 
work carried out here showed an increase in the expression of ompW after biocide exposure. It 
is possible that OmpW may be involved in the efflux of compounds from the cell, hence its 
increased expression. No significant alteration in the expression of any other omp genes was 
observed in the microarray work. However it is worth noting that an alteration in gene 
expression does not always directly correlate with the amount of the corresponding protein 
present.  The limited exploration of OMP changes carried out here just using one dimensional 
SDS-PAGE means that protein identity was not determined, and detailed conclusions about 
alterations in the OMP profile after exposure to a low concentration of CHG/BZC cannot be 
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drawn. Further experiments using two-dimensional SDS-PAGE or Western blotting may provide 
more detail on the OMP profile. 
Pagedar et al., (2011) reported adaptation to BZC and ciprofloxacin and consequent cross-
resistance to other antimicrobials in Ps. aeruginosa. They speculated that efflux pump activity 
was responsible for the adaptation observed and confirmed this by reducing adaptation using 
the efflux pump inhibitor 2, 4 dinitrophenol. They also reported that efflux pump inhibition 
was more effective in isolates that were originally non-resistant to BZC and ciprofloxacin, again 
suggesting that efflux pump activity was likely to be responsible for the adaptation and cross- 
resistance. It is possible that the reduced susceptibility to CHG and BZC observed here in 
strains SL1344 and 14028S was due to efflux pump activity, especially due to the fact that 
decreased accumulation of Hoechst dye was observed in CHG and BZC-treated cells in the 
efflux assay experiments, and furthermore due to >100 fold down-regulation of acrR in the 
microarray experiments.   
Pagedar et al., (2012) also used ethidium bromide accumulation and fluorescence to measure 
the efflux activity in BZC-resistant and non-BZC resistant E. coli strains. They found the same 
level of efflux up-regulation in both resistant and non-resistant strains after BZC exposure. This 
suggests that efflux up-regulation was not just a characteristic of strains adapted to a biocide 
but also a response observed in non-resistant strains as a result of exposure. This finding 
correlates with the work carried out here, as both SL1344 and 14028S were not biocide-
adapted strains and demonstrated a potential increase in efflux activity as a result of biocide 
exposure. Pagedar et al., (2012) also investigated the level of efflux pump activity up-
regulation in E. coli strains adapted to the antibiotic ciprofloxacin and found between 16 and 
50 % up-regulation despite antibiotic resistance commonly being attributed to more specific 
mechanisms. The reduced antibiotic susceptibility observed in S. enterica strains SL1344 and 
14028S after exposure to low CHG and BZC concentrations could therefore be attributed to 
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efflux pump up-regulation. In contradiction to this Naparstek et al., (2012) reported reduced 
susceptibility to chlorhexidine in Klebsiella pneumoniae but were not able to link it to efflux 
pump activity. They found that high chlorhexidine MICs were independent of the expression of 
cepA, acrA and kdeA efflux pump genes. This suggested that efflux activity was not necessarily 
the most likely reason for reduced biocide susceptibility, and this must be taken in to account 
when considering the increased MICs and MBCs observed here in SL1344 and 14028S. 
The AcrAB-TolC tri-partite efflux system is the major multidrug efflux pump present in 
Salmonella species and has been shown to be over-expressed in response to low doses of 
biocides  (Karatzas et al., 2007, Randall et al., 2007). The expression of other efflux systems 
such as AcrEF and AcrD can also mediate multidrug-resistance. Whitehead et al., (2011) 
described the up-regulation of efflux activity in response to the biocides Trigene and Superkill 
at the in-use concentration (1%) using the same method used in this chapter. They attributed 
this up-regulation to the increased expression of the regulatory gene marA, and acrF. They 
concluded that the AcrEF-TolC efflux system was responsible for the up-regulated efflux 
activity. The biocide Superkill contains a mix of aldehydes and QACs. Considering the fact that 
BZC (tested here) is also a QAC, there is the possibility that the up-regulation of efflux 
observed in Salmonella strains SL1344 and 14028S could also be due to increased expression 
of the AcrEF-TolC efflux system. The efflux pump inhibitor PAβN blocks the function of RND 
transporters and its use resulted in the increased accumulation of Hoechst dye in strain 
SL1344. This again suggests that an RND transporter system such as AcrEF-TolC may be up-
regulated in the presence of BZC. In further support of an RND transport system being involved 
in the potential increase in efflux activity observed here, the regulatory gene acrR (regulates 
the acrAB operon involved in efflux (Kumar and Schweizer, 2005) was significantly down-
regulated in both SL1344 and 14028S after exposure to a low CHG concentration. Down-
regulation of this gene may result in decreased regulation of the acrAB operon and increased 
efflux activity. 
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Exposure of S. enterica serovar Typhimurium strain SL1344 to CHG at the minimum 
bactericidal concentration (0.01 %) resulted in a significant increase in mean particle size (nm). 
However the observed particle size after CHG exposure was too small (978 nm) to correspond 
to the formation of bacterial aggregates. Aggregate formation in Salmonella species has been 
observed by other groups. White et al., (2008) investigated Salmonella morphotypes under 
conditions of stress and found that when under stress Salmonella form a red, dry and rough 
morphotype where they express an increased number of aggregative fimbriae. This 
morphotype has been associated with reduced susceptibility to the biocide sodium 
hypochlorite. An increase in the formation of bacterial aggregates could reduce the efficacy of 
a particular biocide. Bacteria frequently exist in biofilms in vivo and the aggregative phenotype 
associated with biofilms has been shown to cause a reduction in biocide efficacy (Wong et al., 
2010a, Wong et al., 2010b). However in the case of CHG, exposure did not appear to result in 
the formation of bacterial aggregates and biocide efficacy was therefore unlikely to be 
reduced. It is also worth noting that a statistically significant change in particle size only 
occurred in SL1344 after exposure to CHG, but elevated CHG and BZC MICs and MBCs were 
observed in both SL1344 and 14028S after CHG and BZC exposure, so it is unlikely that 
aggregate formation is a key reason behind the level of MBC increases observed in this study. 
In addition, microarray experiments did not show significant changes in the expression of 
genes associated with aggregation (e.g. fim genes or csg (curli-associated) genes) after CHG 
exposure.  
The flow cytometry work carried out indicated that 5 min exposure of SL1344 and 14028S to a 
low concentration of CHG and BZC resulted in damage to > 50 % of the population, but did not 
result in a large amount of cell death. The lack of cells present (< 3 %) in Q2-1 (dead) suggested 
that a significant proportion of the population may have survived, and that some of these 
surviving cells may be responsible for the high MICs and MBCs observed in section 3.3.2. It of 
course cannot be ascertained from the flow cytometry plots alone whether or not those cells 
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that were damaged would ultimately recover from the damage or die. Whitehead et al., (2011) 
used flow cytometry to look at S. enterica serovar Typhimurium cells exposed to a low 
concentration of the biocides Superkill, Trigene, AQAS and Virkon for 5 hours. They reported a 
mixture of live, damaged and dead cells after exposure – much like what was observed with 
SL1344 and 14028S here. Whitehead et al., (2011) sorted cells that maintained an intact 
membrane and membrane potential (i.e. alive) and found that these cells showed no 
alteration in susceptibility to antibiotics tested and that there was no significant difference in 
the number of cells in the ‘live’ quadrant after these survivors were re-challenged with the 
same concentration of biocide as before. This correlates with the phenotype stability test data 
obtained here, in that there were no stable changes observed in the susceptibility of surviving 
organisms.  However due to the fact that cell sorting was not performed here, a direct 
comparison cannot be made. Whitehead et al., (2011) successfully used flow cytometry and 
cell sorting to identify mutants with stable antibiotic resistance after 5 h exposure of S. 
enterica serovar Typhimurium to Superkill and Trigene at the in-use concentration. This 
highlights the usefulness of the technique in the identification of organisms that survive 
biocide exposure, where techniques such as a suspension test may not as they require the 
recovery of organisms on rich media over a 24 h period. 
A large number of experimental techniques were employed in order to determine if exposure 
of S. enterica strains SL1344 and 14028S to low concentrations of CHG and BZC resulted in a 
change in antimicrobial susceptibility of surviving organisms. Potential markers of biocide 
resistance identified included significant increases in the MIC and MBC of both CHG and BZC, 
increased efflux activity, up-regulation of genes associated with efflux (microarray, qPCR), 
survival of bacterial cells (i.e. cells in ‘live’ quadrant) after biocide exposure.  The use of strains 
SL1344 and 14028S resulted in the acquisition of highly reproducible MIC, MBC and antibiotic 
susceptibility data, suggesting that S. enterica serovar Typhimurium may be a useful model 
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organism in the prediction of bacterial resistance to biocides and cross resistance to 
antibiotics.  
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Chapter Four: Burkholderia lata strain 383 as a model 
bacterium for predicting biocide resistance 
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4.1 Introduction 
Burkholderia species are a common problem in both the clinical and industrial environments. 
Their intrinsic resistance to multiple antimicrobials makes Burkholderia infections in 
immunocompromised individuals (particularly those with cystic fibrosis) difficult to treat, and 
has also resulted in increasingly frequent isolation of numerous Burkholderia species from 
pharmaceutical and cosmetic products. The most commonly isolated Burkholderia species in 
both the clinic and pharmaceutical products are members of the Burkholderia cepacia complex 
(Bcc). 
 
4.1.1 The Burkholderia cepacia complex  
The Bcc currently comprises at least 17 closely related Gram-negative, non-fermenting, motile 
rods (Rushton et al., 2013). An isolates position in the Bcc is determined via sequencing of the 
recA gene and through multi-locus sequence analysis. Bcc species have been isolated from 
numerous environments including freshwater, soil and plant rhizospheres (Mahenthiralingam 
et al., 2008). They have been used as bio-pesticides to prevent the spread of fungal disease in 
plants in some cases (Torbeck et al., 2011). However they are best known for their roles as 
opportunistic pathogens in disease development and as major contaminants of disinfectants, 
cosmetics and pharmaceuticals (Sousa et al., 2011). 
Some Bcc species have unique metabolic features that include the ability to degrade 
carcinogenic or toxic products such as polycyclic aromatic compounds and other constituents 
of crude oil (Torbeck et al., 2011). This makes them a useful candidate for bioremediation 
processes but also makes them difficult to eliminate from pharmaceutical products as they are 
able to metabolise a range of carbon sources. They can also remain viable in stressful 
conditions, such as low nutrients and the presence of antimicrobials or organic solvents, and 
can survive in water for many months (Torbeck et al., 2011). There is therefore a high risk to 
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patients/users if these organisms are present at any stage of the manufacturing process of 
pharmaceutical products (e.g. process water, manufacturing equipment). 
 
 
4.1.2 Burkholderia in the clinical environment  
Bcc bacteria cause infection in 2-8 % of cystic fibrosis (CF) patients (Lipuma, 2010) with 
Burkholderia cenocepacia and Burkholderia multivorans being responsible for 85-97 % of 
infections (Drevinek et al., 2008). The primary route of transmission is through direct 
interpersonal contact or through contact with body perspiration, although Bcc can also be 
transmitted via contact with hard surfaces (Torbeck et al., 2011). Nosocomial (hospital-
acquired) Burkholderia infection in non-CF patients has been observed due to the use of 
contaminated ultrasound gels (Jacobson et al., 2006) and the use of contaminated 
chlorhexidine solution (0.5 %) before blood transfusions (Garcia-Erce et al., 2002). 
Pulmonary colonisation by Bcc bacteria, via adhesion to lung epithelial cell receptors and 
invasion via intracellular vacuoles or epithelial translocation, may persist for years and can 
cause severe deterioration of patient health. Virulence factors such as lipases, 
metalloproteinases and LPS induce an inflammatory response, damage the epithelial cell layer 
and can inhibit proper formation of tight junctions between epithelial cells (McClean and 
Callaghan, 2009). Patients may develop ‘Cepacia syndrome’, characterised by severe 
necrotising pneumonia and acute pulmonary deterioration, which can cause death within 
weeks.  
Antibiotic combination therapy (may include tobramycin, ciprofloxacin, ceftazidime, 
imipenem, meropenem, co-trimoxazole) is used to clear early infection in CF patients (Rose et 
al., 2009) but is often ineffective due to the intrinsic resistance to multiple clinically used 
antibiotics that Bcc species possess (Jassem et al., 2014, Aaron et al., 2000). Multiple drug 
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resistance (MDR) in CF isolates is defined as resistance to all agents belonging to at least two of 
three antibiotic classes (Bazzini et al., 2011).   
 
4.1.3 Burkholderia in the industrial environment 
As well as their role as opportunistic pathogens Bcc members are contaminants of home and 
personal care (HPC) products. Contaminated sterile solutions, pharmaceuticals, cosmetics, 
disinfectants and preservatives are considered major sources of Bcc infections acquired 
worldwide (Torbeck et al., 2011, Jimenez, 2004). B. cepacia is one of the most frequently 
isolated organisms in pharmaceutical samples around the world (Jimenez, 2004) although 
many of these reports have not accurately determined the Bcc species identity. Bcc 
contamination has resulted in the recall of large numbers of cosmetic products. Between 1994 
and 1998 B. cepacia contamination was the cause of 33 % (19/55) of recalled cosmetic 
products in the United States (Wong et al., 2000) and 4 % (1/24) of recalled contaminated 
cosmetics in the EU between 2005 and 2008 (Lundov and Zachariae, 2008). Bcc species have 
also been isolated from fuel samples (White et al., 2011). Contamination of fuels can lead to 
deterioration of the fuel due to accumulation of bacteria, degradation of fuel additives and 
production of corrosive metabolic by-products. Burkholderia spp. contamination has been 
attributed to a number of things by manufacturers including inadequate cleaning, use of 
unsuitable water, inadequate storage/sterilisation of products and incorrect efficacy testing 
(Torbeck et al., 2011). Of further concern is that Bcc species have been found to contaminate 
products containing BZC, CHG, hydrogen peroxide, sodium hypochlorite, cetylpyridinium 
chloride, citric acid and more (Torbeck et al., 2011). All of these compounds are usually 
employed due to their bacteriostatic or bactericidal activity. Considering the extent to which 
Bcc species are capable of growing in the presence of antimicrobials and considering the fact 
that finished product testing is not always reliable in determining product efficacy it would be 
very useful to establish a standard protocol to predict biocide resistance in these organisms. 
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4.1.4 Mechanisms of resistance in Burkholderia 
Antimicrobial resistance in Burkholderia has frequently been attributed to the presence and 
expression of RND type efflux pumps (Rushton et al., 2013, Bazzini et al., 2011). These efflux 
pumps have contributed to resistance to chloramphenicol, quinolones and tetracyclines in 
planktonic B. thailandensis cells (Biot et al., 2011), as well as chlorhexidine tolerance in 
planktonic and sessile B. cenocepacia cells (Coenye et al., 2011). 
Biofilm formation and cell wall impermeability (George et al., 2009, Drevinek et al., 2008) are 
further mechanisms that contribute to the intrinsic antimicrobial resistance observed in 
Burkholderia species. No correlation between antimicrobial susceptibility and the ability to 
form a biofilm has been found amongst Bcc species, although Burkholderia spp. present in 
biofilm formation have been found to be more tolerant to certain biocides (e.g. chlorhexidine, 
hydrogen peroxide) than their planktonic counterparts (Coenye et al., 2011, Peeters et al., 
2008). It has also been reported that chlorhexidine concentrations as high as 0.1 - 0.2 % have 
had no effect on B. cepacia biofilms (Miyano et al., 2003). 
As a result of the presence of these intrinsic resistance mechanisms Bcc bacteria may need to 
be exposed to at least 25 times the MIC of an antimicrobial to achieve killing, and some in-use 
concentrations of biocides such as chlorhexidine (used at 0.1 – 4 %) may not be high enough to 
achieve killing (Rose et al., 2009). It would therefore be particularly useful to be able to predict 
resistance to antimicrobial products in these bacteria. 
 
4.1.5 Predicting antimicrobial resistance in Burkholderia lata 
B. lata was identified as a new species within the Bcc in 2009 (Vanlaere et al., 2009) through 
the use of multi-locus sequence typing (MLST) analysis and recA gene sequencing. It forms part 
of a distinct MLST cluster known as group K (figure 4.1).  Strain 383 (used throughout this 
work) is the type strain and was originally recovered from forest soil in Trinidad in 1958 
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(Vanlaere et al., 2009). A large proportion of B. lata isolates are recovered from industrial 
samples or the environment with fewer being clinical isolates (Vanlaere et al., 2009). B. lata 
strain 383 was selected for use in this work due to the fact that its genome had been fully 
sequenced and that previous biocide susceptibility and gene expression work had been 
successfully carried out using this strain (Rushton et al., 2013, Rose et al., 2009).  
 
 
Figure 4.1: A phylogenetic tree derived from recA sequence analysis of established Bcc 
species and taxon K strains (B. lata in red bracket) adapted from (Vanlaere et al., 2009). 
 
4.1.6 Aims 
The principle aim of this chapter was to determine if short-term exposure of B. lata strain 383 
to a low concentration of CHG or BZC resulted in a change in biocide/antibiotic susceptibility in 
surviving organisms. Further aims were to assess the suitability of B. lata strain 383 as a model 
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organism for the prediction of biocide/antibiotic resistance and to assess the 
efficacy/practicality of the chosen techniques employed to measure antimicrobial resistance. 
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4.2 Materials & Methods 
4.2.1 Suspension testing 
In order to determine the effect of contact time on biocide efficacy, suspension tests were 
carried out according to the BS EN 1276 (2009) protocol described in chapter 2 section 2.7.1. 
Biocides were used at the minimum bactericidal concentration (CHG – 0.4 %, BZC 0.05 %). 
 
4.2.2 Antimicrobial susceptibility testing  
4.2.2.1 Baseline data 
The MIC and MBC of CHG and BZC were determined following the BS EN ISO: 20776-1 (2006) 
protocol as described in chapter 2 sections 2.4 and 2.5. Susceptibility to the following 
antibiotics was also determined following the BSAC disk diffusion protocol (Andrews, 2009) 
described in section 2.6: ciprofloxacin (1 µg), ceftazidime (30 µg), tobramycin (10 µg), 
imipenem (10 µg) and meropenem (10 µg). These antibiotics were selected due to their 
potential use in the treatment of Burkholderia infection (Rose et al., 2009). 
 
4.2.2.2 Antimicrobial susceptibility of biocide-exposed organisms 
B. lata strain 383 was exposed to a range of low CHG and BZC concentrations (0.005 – 0.04 %) 
for 5 min according to the BS EN: 1276 (2009) suspension testing protocol described in chapter 
2 section 2.7.2. A 5 min exposure time and a 0.005 – 0.04 % concentration range were chosen 
in order to leave sufficient surviving organisms for further susceptibility testing (i.e. a 2-3 log10 
reduction in CFU/mL was observed). After neutralisation, the neutralised suspension was 
centrifuged at 5000 x g for 10 min and the resulting supernatant discarded. The remaining 
pellet was re-suspended in 10 mL TSC buffer. This suspension was then used in the 
determination of the MIC, MBC and antibiotic susceptibility of surviving organisms as 
described previously in chapter 2 sections 2.4, 2.5 and 2.6. In order to determine the 
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reproducibility of any changes in antibiotic susceptibility observed, the above experiment was 
performed on 4 separate occasions over a one year period. 
 
4.2.2.3 Phenotype stability testing 
The stability of any changes in antibiotic susceptibility observed after 5 min biocide exposure 
was determined via the continuous 24 h subculture of surviving organisms through TSB +/- a 
0.005 % CHG or BZC. This concentration was chosen as it resulted in changes in antimicrobial 
susceptibility in survivors. The detailed method is described in chapter 2 section 2.8. Antibiotic 
susceptibility after 1, 5 and 10 subcultures was determined following the BSAC disk diffusion 
protocol (Andrews 2009), fully described in section 2.6. 
 
4.2.3 Efflux assays 
B. lata strain 383 was grown to mid-log phase (OD600 0.5-0.6) in BSB supplemented with 0.005 
% BZC or CHG, or in biocide-free BSB. To ensure the correct growth phase had been reached 
the OD600 of a 1 mL aliquot of each culture was read using an Ultrapro 3000 
spectrophotometer (GE Healthcare, Buckinghamshire, UK). The accumulation of Hoechst dye 
was measured in treated and un-treated cells as an indication of the level of efflux activity 
taking place in the cell. This was also measured in the presence/absence of two EPIs: verapamil 
(50 mg/L) or phenyl-arginine-beta-napthylamide (PAβN) (10 mg/L) to confirm efflux activity 
was taking place in the cells. The method based on that used by Whitehead et al. (2011) is 
described fully in chapter 2 section 2.9. The toxicity of the EPIs was determined prior to 
performing the efflux assay (chapter 2, section 2.9). 
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4.2.4 Real-time PCR 
4.2.4.1 Genes of interest 
Real time PCR reactions were carried out to identify changes in the expression of specific genes 
after B. lata exposure to 0.005 % CHG and BZC, with a view to identifying a marker gene for 
biocide resistance. The genes selected had previously been identified to be up-regulated after 
exposure to antibiotics, preservatives or biocides (Sass et al., 2011, Rose et al., 2009). Table 4.1 
shows a list of Burkholderia genes investigated. These genes were chosen due to their 
presence in the outer membrane or putative contribution to efflux of antimicrobial 
compounds from the bacterial cell. 
 
Table 4.1 Genes investigated using real-time PCR 
Gene Name Putative 
function 
Response observed by global gene expression 
analysis using microarrays or gene mutagenesis 
studies 
 
B. cenocepacia antimicrobial resistance target genes 
BCAM_0925 Outer 
membrane 
protein that is 
part of an RND 
efflux pump 
12-fold up-regulated after exposure to 0.05 mM 
chlorpromazine and mutation of the gene results in 
increased chlorhexidine susceptibility (Sass et al., 
2011); 8-fold up-regulated after exposure to 
chlorhexidine (Rose, H. and Mahenthiralingam, E., 
unpublished data) 
 
BCAS_0081 ABC transporter Up-regulated in an antibiotic resistant clinical clone 
of B. cenocepacia J2315 and mutation of the gene 
results in an increased chlorhexidine susceptibility 
(Sass et al., 2011); 6.8-fold up-regulated after 
chlorhexidine exposure ( Rose, H. and 
Mahenthiralingam, E.,unpublished data) 
 
BCAM_2551 Multi-drug efflux 
transport protein 
CeoA 
 
296-fold up-regulated in a derivative adapted to 
trimethoprim sulfamethoxazole (Sass et al., 2011) 
BCAS_0167 Squalene-
hopene cyclase 
Up-regulated 4.36 -fold after exposure to 0.05 mM 
chlorpromazine and mutation of the gene results in 
increased chlorhexidine susceptibility (Sass et al., 
121 
 
 
 
4.2.4.2 Primers 
Universal primers were designed so that the gene of interest could be amplified in numerous 
Burkholderia species including B. lata, B. ambifaria, B. cepacia, B. cenocepacia, B. multivorans, 
B. phymatum and B. mallei.  The relevant gene sequence for each species was obtained from 
www.Burkholderia.com (accessed 11/03/2014) and sequences were aligned using molecular 
evolutionary analysis software (MEGA 5; http://www.megasoftware.net accessed 11/03/2014) 
Primers were designed to selected regions of homology using Primer 3 software 
(http://bioinfo.ut.ee/primer3-0.4.0 accessed 11/03/2014) and their specificity for each 
Burkholderia gene target tested using the In Silico PCR tool (http://insilico.ehu.es/PCR 
accessed 11/03/2014). The metabolism-associated gene phaC (BCAL1861) was selected as a 
reference control gene as it has been shown to remain stable under a variety of growth 
conditions (Sass et al., 2013) and has also been successfully used in the validation of B. lata 
global gene expression in response to preservative exposure (Rushton et al., 2013). All primers 
were synthesised by and purchased from Invitrogen, Paisley, UK. Primers sequences are listed 
in table 4.2. 
 
 
2011) 
 
BCAL1663 PrkA family 
serine protein 
kinase 
Up-regulated in stationary phase (8- fold), low 
oxygen (8- fold), and heat stress (2 -fold) (Sass et 
al., 2013)  
 
B. lata 383 antimicrobial target gene 
Bcep18194_B1327 MFS_1 
transporter 
4.7 - fold up-regulated in derivative adapted to 
blend of  
methylisothiazolinone/chloromethylisothiazolinone  
(M-CMIT) preservative  (Rushton et al., 2013) 
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4.2.4.3 Real-time PCR conditions 
Reactions were performed in triplicate under conditions described in chapter 2 section 2.13 
using the annealing temperatures listed in table 4.2. Data analysis was carried out using the 
Pfaffl method (Pfaffl, 2001) described  in chapter 2 section 2.14. (See appendix file name: 
chapter 4 appendix data > real_time_PCR for raw data). 
 
Table 4.2 Primers for real-time PCR 
 
Primer Name Primer (Forward and Reverse)  
5’ – 3’ 
Product size (bp) Annealing 
temperature (°C) 
phaC (control) AAGCGTTCGACAAGGTCAAG 218 Multiple 
GTTCACCGACGAGATGTTGA 
 
BCAM_0925 CTGGCGCACGATGTTC 120 67.0 
ATGCCGTACTGCGCTTC 
BCAS_0081 TTCGACGGGCTGAACCT 214 59.4 
GCAGCAGCGAGGTATCCT 
BCAM_2551 TCGGTGTCGCCGATCTAC 338 65.2 
TCGACGACGAACACGAACT 
BCAS_0167 CCTGATGATGCATTTCATGGAC 368 67.0 
ACGCGACCTTGTACATCGAG 
BCAL1663 GTTCAAGGCGCCGATCA 162 67.0 
TCGTTGTTGCGGTTGTTG 
Bcep18194_B1327 GAGGTGGAGATGACCGAATC 206 63.2 
GAGGTGGAGATGACCGAATC 
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4.2.5 Light scattering experiments 
To determine if bacterial aggregates were present in biocide-treated or untreated samples a 
series of experiments measuring particle size were carried out using an N4 Plus dynamic light 
scattering machine that measured the diameter of different particles present in each sample. 
These experiments are described in detail chapter 2 section 2.10. Strain 383 was exposed to 
0.4 % CHG and 0.05 % BZC for 15 min. Untreated cells were suspended in diH20. 
 
4.2.6 Statistical tests 
A Students t-test was used to compare MIC, MBC and zone of inhibition values before and 
after biocide exposure and to compare fluorescence values between biocide-treated and 
untreated cells in efflux assay experiments. A one-way ANOVA test was used when comparing 
zone of inhibition values obtained from the phenotype stability tests and particle size values 
from light scattering experiments. 
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4.3 Results 
 
4.3.1 Suspension testing 
Strain 383 was exposed to CHG and BZC at the minimum bactericidal concentration to 
determine the effect of contact time on biocide efficacy and to determine the time period 
taken for all bacteria to be killed at this concentration. The efficacy and toxicity of the 
neutraliser to strain 383 was determined before the suspension tests were performed. Table 
4.3 shows the neutraliser efficacy and toxicity data. The neutraliser was considered non-toxic if 
≤ 1 log10 reduction in CFU/mL (compared to the control) was observed after exposure, and 
considered effective if ≤ 1 log10 reduction in CFU/mL was observed in the presence of biocide 
and neutraliser (according to the BS EN 1276 2009 suspension testing protocol). 
 
Table 4.3: Neutraliser efficacy and toxicity data 
 
Treatment Mean log CFU/mL ± SD 
Control (diH20) 8.56 ± 0.00 
Neutraliser 8.52 ± 0.01 
CHG 0.00 ± 0.00 
BZC 0.00 ± 0.00 
CHG + Neutraliser 8.20 ± 0.02 
BZC + Neutraliser 8.20 ± 0.28 
 
Table 4.3 shows that the neutraliser was both non-toxic to strain 383 and effective in 
neutralising CHG and BZC. 
Figure 4.2 shows the effect of contact time on the efficacy of 0.05 % BZC and 0.4 % CHG. The 
dilutions performed throughout the suspension test resulted in a 4.2 log10 limit of detection. 
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Figure 4.2: log10 CFU/mL of B. lata strain 383 after exposure to 0.05 % BZC and 0.4 % CHG. 
Contact times of 1, 2.5, 4, 5, 10, 30 and 60 min. N=3 
 
Red dashed line indicates the maximum log10 reduction which could be determined based on a 
4.2 log10 limit of detection 
Figure 4.2 shows that after 4 min exposure to 0.05 % BZC a 1 log10 reduction in CFU/mL was 
observed.  The greatest reductions in log10 CFU/mL occurred between 4 and 5 min of exposure 
to 0.05 % BZC. After 5 min exposure a 4.2 log10 reduction was observed. This was the 
maximum log10 reduction that could be determined based on the limit of detection and 
corresponded to a plate count of zero.  The greatest log10 reduction after exposure of strain 
383 to 0.4 % CHG occurred between 4 and 5 min (~ 1.7). After 60 min exposure to 0.4 % CHG a 
4.2 log10 reduction in CFU/mL was observed. 
 
4.3.2 Antimicrobial susceptibility testing 
The MIC and MBC of CHG and BZC were determined before and after exposure to a range of 
low CHG and BZC concentrations. These values were compared to determine whether short 
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term exposure to a low biocide concentration resulted in a change in susceptibility to that 
biocide and other antimicrobials in surviving organisms. Susceptibility to a range of clinically 
relevant antibiotics was also determined before and after biocide exposure. 
 
4.3.2.1 Changes in minimum inhibitory and minimum bactericidal concentrations 
The MIC and MBC values obtained before and after exposure to a range of low concentrations 
of CHG and BZC are shown in table 4.4(a) and 4.4 (b). 
 
Table 4.4 (a): MIC and MBC values of CHG and BZC after 5 min exposure of B. lata strain 383 
to a range of low CHG concentrations. N=3   
 
* = value is significantly different from baseline value (p≤0.05) 
CHG concentration (%) 
MIC/MBC (%) Baseline 0.040 0.010 0.005 
CHG MIC ± SD 0.07 ± 0.00 0.15 ± 0.00* 0.30 ± 0.09* 0.30 ± 0.09 
CHG MBC ± SD 0.40 ± 0.60 0.20 ± 1.00 0.40 ± 0.02 0.40 ± 0.20 
BZC MIC ± SD 0.05 ± 0.05 0.20 ± 0.00* 0.10 ± 0.00* 0.30 ± 0.10* 
BZC MBC ± SD 0.05 ± 0.05 0.50 ± 0.20* 0.60 ± 0.30* 0.50 ± 0.20* 
 
Five min exposure of strain 383 to low concentrations of CHG resulted in small increases in the 
MIC and MBC for both biocides tested. The greatest increase was observed in the MBC for BZC 
after exposure to 0.01 % CHG, (0.60 %) indicating that exposure to one particular biocide can 
result in a change in the MBC of another biocide in the case of this strain (Table 4.4 (a)).  The 
MBC for CHG did not increase after exposure to any of the low CHG concentrations tested 
suggesting that exposure of B. lata strain 383 to low CHG concentrations does not consistently 
result in an increase in the MIC and MBC of the biocide tested. 
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Table 4.4 (b): MIC and MBC values of CHG and BZC after 5 min exposure of B. lata strain 383 
to a range of low BZC concentrations. N=3  
 
*= value is significantly different from baseline (p≤0.05) 
 
BZC concentration (%) 
MIC/MCB (%) Baseline 0.045 0.010 0.005 
BZC MIC ± SD 0.05 ± 0.05 0.25 ± 0.00* 0.30 ± 0.10* 0.40 ± 0.00* 
BZC MBC ± SD 0.05 ± 0.05 0.20 ± 1.00 0.78 ± 0.20* 0.26 ± 0.10* 
CHG MIC ± SD 0.07 ± 0.00 0.08 ± 0.00 0.10 ± 0.00* 0.30 ± 0.09* 
CHG MBC ± SD 0.40 ± 0.60 0.10 ± 0.20 0.30 ± 0.00 0.40 ± 0.00 
 
The greatest increase was observed in the MBC for BZC after 5 min exposure to 0.01 % BZC 
(table 4.4 (b)). The MBC for CHG did not increase after exposure to any of the BZC 
concentrations tested. This was also observed after 5 min exposure to a range of low CHG 
concentrations (table 4.4 (a)). There did not appear to be a distinct relationship between the 
fold increase in MIC/MBC observed and the concentration of biocide tested. 
 
4.3.2.2 Changes in antibiotic susceptibility 
Clinical susceptibility to a range of antibiotics was determined before and after 5 min exposure 
of strain 383 to a range of low CHG and BZC concentrations.  Table 4.5 shows the mean zone of 
inhibition sizes before and after biocide exposure and the clinical susceptibility to each 
antibiotic according to BSAC breakpoints for Pseudomonas spp. (Andrews, 2009) (none 
available for Burkholderia spp. so the breakpoints for the most closely related species were 
used). 
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Table 4.5: Mean zone of inhibition sizes (mm) for a range of clinically relevant antibiotics after exposure of B. lata strain 383 to low concentrations of CHG 
and BZC. N=3 
S=sensitive  I=intermediate  R=resistant (based on clinical breakpoints for Pseudomonas species provided in the BSAC disk diffusion protocol (Andrews, 2009)) 
*value is significantly different from baseline (p≤0.05) 
 
 Mean zone of inhibition size (mm) ± SD 
Antibiotic Baseline 0.04% 
CHG 
0.01% 
CHG 
0.005% 
CHG 
0.045% 
 BZC 
0.01%  
BZC 
0.005% 
BZC 
Ciprofloxacin 
(1µg) 
30.0S 
± 0.00 
11.3R* 
± 1.20 
17.3I* 
± 0.60 
26.3S* 
± 2.10 
12.0R* 
± 1.00 
28.0S 
± 7.80  
28.3S 
± 1.52 
Tobramycin 
(10µg) 
7.30R 
± 1.20 
9.00R 
± 1.00 
4.30R 
± 3.80 
11.6R 
± 1.53 
8.00R 
± 0.00 
0.00R* 
± 0.00 
8.60R 
± 0.58 
Ceftazidime 
(30µg) 
40.3S 
± 0.60 
33.3S* 
± 1.20 
30.0S* 
± 0.00 
30.3S* 
± 3.10 
39.0S 
± 1.00 
36.0S* 
± 4.60 
30.0S* 
± 2.64 
Imipenem 
(10µg) 
24.0S 
± 0.00 
15.0R* 
± 3.0 
30.7S* 
± 2.10 
19.3I* 
± 1.20 
16.0R* 
± 1.00 
18.0I* 
± 0.00 
19.0I* 
± 2.00 
Meropenem 
(15µg) 
40.7S 
± 1.20 
37.0S 
± 1.00 
35.3S* 
± 1.52 
33.0S* 
± 1.73 
35.5S* 
± 1.00 
33.0S* 
± 1.00 
34.0S* 
± 1.00 
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Clinical susceptibility (according to BSAC breakpoints for Pseudomonas spp.) to the antibiotics 
meropenem, tobramycin and ceftazidime did not change after 5 min exposure to a range of 
low concentrations of CHG or BZC despite significant decreases in the mean zone of inhibition 
size observed. After 5 min exposure to 0.04 % CHG and 0.045 % BZC strain 383 changed from 
sensitive to resistant to imipenem and ciprofloxacin (based on BSAC clinical susceptibility 
breakpoints for Pseudomonas spp. (Andrews, 2009)). Intermediate (neither sensitive nor 
resistant) susceptibility to imipenem was observed in strain 383 after 5 min exposure to 0.005 
% CHG, 0.01 % BZC and 0.005 % BZC. Intermediate susceptibility to ciprofloxacin was observed 
after 5 min exposure to 0.01 % CHG. 
 
4.3.2.3 Phenotype stability testing 
The stability of the observed change (from sensitive to resistant) in susceptibility to imipenem 
(10 µg) and ciprofloxacin (1 µg) was tested via the continuous 24 h subculture of surviving 
organisms in the presence/absence of 0.005 % CHG and BZC. Tables 4.6 (a) and (b) show the 
mean zone of inhibition sizes observed for imipenem and ciprofloxacin after 1, 5 and 15 
subcultures in TSB +/- 0.005 % CHG or BZC. 
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Table 4.6 (a): Mean zone of inhibition sizes (mm) for imipenem and ciprofloxacin after 5 min exposure of B. lata strain 383 to 0.005 % CHG and after 1, 5 and 
10 subcultures through TSB +/- 0.005 % CHG. N=3 
S=sensitive  I=intermediate  R=resistant (based on clinical breakpoints for Pseudomonas species provided in the BSAC disk diffusion protocol (Andrews, 2009)) 
*value is significantly different from baseline (p≤0.05) SC = subculture 
 
  
                           Mean zone of inhibition size (mm) 
                      ± SD 
   
Antibiotic Baseline Initial 5 min 
exposure 
1 SC 
(no CHG) 
5 SCs 
(no CHG) 
10 SCs 
(no CHG) 
1 SC 
(CHG) 
5 SCs 
(CHG) 
10 SCs 
(CHG) 
Imipenem (10 µg) 24.0S 
± 0.00 
15.6R* 
± 4.20 
24.0S 
± 1.00 
21.6S 
± 0.19 
24.3S 
± 1.15 
14.3R* 
± 0.58 
18.6I* 
± 0.21 
21.6S 
± 0.58 
Ciprofloxacin (1 µg) 30.0S 
± 0.00 
11.3R* 
± 2.31 
28.0S 
± 1.00 
31.0S 
± 0.22 
30.0S 
± 4.36 
7.60R* 
± 1.15 
11.3R* 
± 1.15 
11.6R* 
± 0.58 
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Table 4.6 (b): Mean zone of inhibition sizes (mm) for imipenem and ciprofloxacin after 5 min exposure of B. lata strain 383 to 0.005 % BZC and after 1, 5 and 
10 passages through TSB +/- 0.005 % BZC. N=3 
S=sensitive  I=intermediate  R=resistant (based on clinical breakpoints for Pseudomonas species provided in the BSAC disk diffusion protocol (Andrews, 2009)) 
*value is significantly different from baseline (p≤0.05) SC = subculture 
 
 
 
 
 
 
 
 
Mean zone of inhibition size (mm) 
± SD 
Antibiotic Baseline Initial 5 min 
Exposure 
1 SC 
(no BZC) 
5 SCs 
(no BZC) 
10 SCs 
(no BZC) 
1 SC 
 (BZC) 
5 SCs 
 (BZC) 
10 SCs 
 (BZC) 
Imipenem (10 µg) 24.0S 
± 0.00 
16.0R* 
± 1.00 
24.0S 
± 1.53 
24.0S 
± 4.00 
25.3S 
± 3.06 
13.6R* 
± 0.58 
17.0I* 
± 3.45 
25.6S 
± 1.15 
Ciprofloxacin (1 µg) 30.0S 
± 0.00 
11.3R* 
± 0.58 
26.3S 
± 1.15 
29.0S 
± 3.45 
37.3S* 
± 4.04 
7.30R* 
± 1.53 
9.00R* 
± 1.00 
13.0S* 
± 3.60 
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After 1 subculture (24 h) in the absence of CHG or BZC, strain 383 lost the resistance to both 
ciprofloxacin and imipenem initially observed after 5 min biocide exposure (tables 4.6 (a), (b)). 
After 5 subcultures in the presence of 0.005 % CHG and BZC, clinical resistance to ciprofloxacin 
was maintained and intermediate susceptibility to imipenem was observed. After 10 
subcultures in the presence of 0.005 % CHG surviving bacteria remained resistant to 
ciprofloxacin, whereas resistance to imipenem was lost (table 4.6 (a)). After 10 subcultures of 
survivors in the presence of 0.005 % BZC resistance to both antibiotics was lost (table 4.6 (b)). 
All clinical antibiotic susceptibilities observed were based on the BSAC clinical breakpoints for 
Pseudomonas spp. (Andrews, 2009). 
 
4.3.2.4 Data reproducibility 
In order to determine the reproducibility of the changes in antibiotic susceptibility observed in 
strain 383 after 5 min biocide exposure, antibiotic susceptibility tests were performed in 
triplicate on four separate occasions over a one year time period. Table 4.7 shows the mean 
zone of inhibition sizes for 5 clinically relevant antibiotics observed after exposure to 0.005 % 
CHG or BZC on 4 separate occasions. A 5 min exposure of strain 383 to 0.005 % CHG or BZC 
resulted in clinical resistance to imipenem and ciprofloxacin (table 4.7, repeat 1) according to 
the BSAC disk diffusion protocol interpretation for Pseudomonas (Andrews, 2009) on only 1 of 
the 4 occasions on which the experiment was performed.  There were no changes in clinical 
susceptibility to tobramycin, meropenem or ceftazidime observed on any of the 4 occasions, 
despite significant reductions in zone of inhibition size (p≤0.05) having been observed (table 
4.7). These results suggest that a 5 min exposure to a low concentration of CHG and BZC can 
have an effect on susceptibility to imipenem and ciprofloxacin in B. lata strain 383. This change 
in susceptibility did not appear to be reproducible suggesting that any changes that do occur 
as a result of exposure to CHG or BZC at 0.005 % are not stable. 
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Table 4.7: Mean zone of inhibition sizes (mm) of a range of clinically relevant antibiotics after 5 min exposure of B. lata strain 383 to 0.005 % CHG and 
BZC 
S = sensitive  I = intermediate        R= resistant   *value is significantly different from baseline (p≤0.05) 
Cip = ciprofloxacin  Tob = tobramycin  Ceft = ceftazidime  Imi = imipenem  Mem = meropenem 
                                         Mean zone of inhibition size (mm) ± SD  
Antibiotic 
(separate  
repeats) 
Baseline 0.005% CHG 
(1) 
0.005% CHG 
(2) 
0.005% CHG 
(3) 
0.005 % CHG 
(4) 
0.005% BZC 
(1) 
0.005% BZC 
(2) 
0.005% BZC 
(3) 
0.005 % BZC 
(4) 
Cip (1µg) 30.0S 
± 0.00 
11.3R* 
± 2.31 
24.0S 
± 0.00 
20.0S* 
± 3.00 
29.0S 
± 1.00 
12.0R* 
± 1.53 
24.0S* 
± 3.00 
28.5S 
± 2.00 
29.0S 
± 1.00 
Tob (10µg) 7.30R 
± 1.20 
9.00R 
± 0.00 
4.30R 
± 1.70 
11.6R 
± 2.50 
8.0R 
± 0.00 
8.00R 
± 0.00 
0.00R * 
± 0.00 
8.60R 
± 1.20 
8.00R 
± 0.00 
Cef (30µg) 40.3S 
± 0.60 
33.3S * 
± 1.60 
30.0S * 
± 3.00 
30.3S * 
± 3.50 
34.5S* 
± 4.38 
39.0S 
± 1.00 
36.0S * 
± 3.60 
30.0S * 
± 4.40 
32.5S* 
± 23.1 
Imi (10µg) 24.0S 
± 0.00 
15.0R 
± 4.20 
27.3S 
± 2.50 
25.0S 
± 0.00 
21.0S 
± 2.00 
16.0R 
± 0.58 
30.0S* 
± 4.30 
29.0S* 
± 2.00 
24.0S 
± 0.00 
Mem (15µg) 40.7S 
± 1.20 
37.0S 
± 2.30 
35.3S * 
± 1.15 
33.0S * 
± 3.00 
39.0S 
± 4.00 
40.7S 
± 3.30 
35.5S * 
± 4.00 
34.0S * 
± 3.20 
39.2R 
± 1.15 
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4.3.3 Efflux assays 
The accumulation of fluorescent Hoechst dye was measured in B. lata strain 383 cells grown to 
mid-log phase in the presence/absence of 0.005 % CHG or BZC, and in the presence/absence of 
2 different EPIs. This gave an indication of the level of efflux activity taking place in the 
bacterial cell as a result of biocide exposure.  The toxicity of the EPIs was tested prior to their 
use in the efflux assay and both were found to be non-toxic to strain 383 at the concentrations 
used. Toxicity testing data is shown in table 4.8. An EPI was considered to be non-toxic if ≤ 1 
log10 reduction in CFU/mL was observed after exposure 
 
Table 4.8: Toxicity of EPIs to strain 383 
 
 
EPI Concentration  
(mg/L) 
log CFU/mL  
before 
log CFU/mL  
after EPI 
Log CFU/mL 
after diH20 
Verapamil 50 8.20 ± 0.00 7.20 ± 0.44 7.95 ± 0.35 
PAβN 10 8.90 ± 0.00 8.10 ± 0.24 8.87 ± 0.77 
 
 
Figure 4.3 shows the mean fluorescence values in biocide-treated and untreated cells in the 
presence/absence of verapamil (50 mg/L) or PAβN (10 mg/L). 
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Figure 4.3: Mean fluorescence values observed in untreated and biocide-treated B. lata strain 
383 in the presence/absence of 2 different efflux pump inhibitors. N=3 
 
*CHG-treated significantly different from untreated (p≤0.05) 
 
B. lata strain 383 cells grown to mid-log phase in the presence of 0.005 % CHG accumulated 
significantly less (p≤0.05) Hoechst dye than untreated cells, as indicated by the lower 
fluorescence reading (figure 4.3, blue bars).  This reduced accumulation of Hoechst dye may 
have occurred as a result of increased efflux pump activity or up-regulation of efflux associated 
genes. Cells grown in the presence of 0.005 % BZC accumulated less Hoechst dye than 
untreated cells but there was no statistically significant difference in fluorescence observed 
(figure 4.3). This suggests that the presence of 0.005 % BZC may not have a significant effect 
on the efflux activity taking place in the cell. The addition of either verapamil (50 mg/L) or 
PAβN (10 mg/L) resulted in a large increase in fluorescence in both biocide-treated and 
untreated B. lata strain 383 cells, suggesting that some inhibition of the efflux of Hoechst dye 
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was taking place. The fact that this effect was observed in the presence of both EPIs suggests 
that more than one type of efflux pump may be contributing to Hoechst dye efflux, as 
verapamil specifically inhibits ABC transporters and PAβN inhibits RND type pumps. The 
increase in fluorescence observed after the addition of both EPIs in the case of 0.005 % CHG –
treated cells was significantly lower (p≤0.05) than that observed in untreated cells (figure 4.3), 
again suggesting that greater efflux pump activity was taking place in the CHG-treated cells. 
There was no significant difference in fluorescence observed after the addition of EPIs when 
comparing untreated and BZC-treated cells. 
 
4.3.4 Real-time PCR 
Real time PCR reactions were carried out to identify changes in the expression of specific genes 
after growing B. lata strain 383 to mid-log phase in 0.005% CHG or BZC, with a view to 
identifying a marker gene for biocide resistance.  Table 4.9 shows the mean fold changes in the 
expression of selected genes after biocide exposure. The greatest fold changes in expression 
were observed in an outer membrane protein (BCAM_0925) and in an ABC transporter 
(BCAS_0081) (table 4.9). Fourteen-fold changes in expression or less were observed in the 
remaining 4 genes investigated. Changes in the expression of genes BCAM_0925 and 
BCAS_0081 were further observed using RNA extracted from bacterial cells that were exposed 
to 0.005% CHG or BZC for 5 min. There were no changes in gene expression observed after 5 
min exposure to 0.005 % CHG or BZC (table 4.9). 
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Table 4.9: Mean fold changes in gene expression after B. lata strain 383 was grown to mid-exponential phase in 0.005 % CHG or BZC (N=3) and mean fold 
change in expression in genes BCAM_0925 and BCAS_0081 after 5 min biocide exposure (N=3) 
Gene Name Mean fold change in 
expression  
Control vs. 0.005 % CHG 
Mean fold change in 
expression 
Control vs. 0.005 % BZC 
Mean fold change in 
expression 
0.005 % CHG (5min) 
Mean fold change in 
expression 
0.005 % BZC (5min) 
BCAM_0925 0.27 43.41 0.14 0.05 
BCAS_0081 102.30 37.99 0.01 0.12 
BCAM_2551 2.54 3.98 n/a n/a 
BCAS0167 0.44 0.97 n/a n/a 
Bcep18194_B1327 0.23 0.05 n/a n/a 
BCAL1663 14.72 3.68 n/a n/a 
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4.3.5 Light scattering experiments 
Biocide-treated and untreated cells were passed through an N4 Plus Dynamic Light Scattering 
machine to determine if bacterial aggregates were present in any samples. Table 4.10 shows 
mean particle sizes in untreated samples and cells treated with CHG or BZC at the minimum 
bactericidal concentration. 
Table 4.10: Mean particle size (nm) for untreated and biocide-treated B. lata strain 383 cells. 
N=3 
 
* = significantly different (p≤0.05) from untreated 
 
Treatment  Mean particle diameter (nm) (range) 
Untreated 722.50 (30.00)  
0.40 % CHG 1129.8 (285.2) * 
0.05 % BZC 611.60 (52.50) * 
 
After exposure to 0.4 % CHG (15 min) there was a significant increase in mean particle 
diameter observed in comparison to untreated cells. There was also a much larger range 
(285.2) after exposure to CHG, suggesting a greater variance in particles sizes.  It is possible 
that the increase in mean particle diameter may have been observed due to the aggregation of 
cells in response to biocide exposure. The formation of aggregates may restrict the access that 
a biocide or antibiotic has to the bacterial cell and may therefore result in reduced 
susceptibility to that biocide or antibiotic. This suggests a possible reason for the reduced 
susceptibility to ciprofloxacin and imipenem observed after 5 min biocide exposure. However 
after exposure to 0.05 % BZC there was a significant decrease in mean particle diameter in 
comparison to untreated cells.  This may have been due to damage to the cells and release of 
cellular material.  Despite the fact that both CHG and BZC primarily cause damage to the 
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bacterial cell membrane, the response of strain 383 in terms of aggregation appears to differ 
for each biocide. 
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4.4 Discussion 
B. lata strain 383 was exposed to low concentrations of CHG and BZC in order to determine if 
short-term biocide exposure resulted in reduced antimicrobial susceptibility in surviving 
organisms. The reproducibility of the data obtained was assessed in order to determine the 
suitability of strain 383 as a model organism for predicting biocide resistance. 
No significant change in the biocide susceptibility profile of strain 383 was observed after 5 
min exposure to low concentrations of CHG and BZC. Thomas et al., (2000) observed stable 
chlorhexidine diacetate resistance in Ps. aeruginosa after 24 h exposure to 1 µg-1 and 
speculated that contact time may affect the mechanisms employed by the bacterial cell to 
counteract the antimicrobial, and therefore may affect the susceptibility profile of any 
surviving organisms. Possible aggregate formation was observed as a result of exposure to 
CHG for 15 min, but not after BZC exposure. The formation of aggregates has been observed in 
B. cenocepacia as a result of high levels of free iron (Fe3+ , 10 and 100 µM) present in the 
sputum of CF patients (Berlutti et al., 2005). A more stressful, iron-depleted environment was 
not associated with aggregate formation in this case. There does not appear to be a definitive 
relationship between biocide exposure and aggregate formation in B. lata strain 383, although 
a stressful, nutrient-depleted environment has been demonstrated to cause the formation of 
aggregates in other bacterial species such as Salmonella Typhimurium (White et al., 2008, 
White et al., 2006). Kaplan et al., (2012) showed that exposure to low concentrations (up to 1 x 
MIC) of β-lactam antibiotics resulted in bacterial aggregation and biofilm formation in 
Staphylococcus aureus, which they suggested may promote antibiotic resistance in a clinical 
setting. The small changes observed in the MIC and MBC of CHG and BZC observed here after 5 
min exposure to low biocide concentrations could be explained in part by the formation of 
aggregates in a response similar to that demonstrated in S. aureus. 
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Changes in susceptibility to the antibiotics imipenem and ciprofloxacin were observed after 
exposure to CHG and BZC. However these changes were not observed consistently across all 
four repeats of the experiment, nor were they stable in the absence of either biocide. This 
highlights the need to assess the reproducibility of the data obtained over time, as well as the 
stability of any altered susceptibility observed. It is also worth noting that the method used to 
determine antibiotic susceptibility may affect the data obtained. Although the BSAC 
methodology (Andrews, 2009) was strictly followed, Schuurmans et al., (2009) found that 
antibiotic MIC values could vary by a factor of up to 8 if small alterations were made in the 
method used to determine them. This reiterates the requirement for a standard protocol for 
susceptibility measurement. Larsen et al., (1993) observed phenotypic variability when single 
colonies of B. cepacia were used experimentally. In the work carried out here the test 
inoculums were based on broth culture instead of single colonies which rules out this 
phenotypic variability. It was difficult to determine the clinical significance of the observed 
reduced zone of inhibition sizes due to the fact that the BSAC protocol does not provide 
susceptibility breakpoints for Burkholderia species. If one uses the breakpoints available for 
Pseudomonas aeruginosa (Andrews, 2009) clinical resistance to ciprofloxacin and imipenem 
would only have been observed on one out of the four occasions. The mechanisms of action of 
imipenem and ciprofloxacin differ considerably. Imipenem inhibits bacterial cell wall synthesis 
via the binding of penicillin binding proteins, preventing peptidoglycan formation (Sawasdidoln 
et al., 2010), whereas ciprofloxacin inhibits DNA synthesis via the inhibition of the enzyme DNA 
gyrase that unwinds double-stranded DNA (Lunn et al., 2010). This suggests that the 
mechanisms behind the reduced susceptibility observed are likely to be non-specific. 
A very small number of studies have been carried out investigating the effect of biocide 
exposure on the antimicrobial susceptibility of surviving Burkholderia species. Rose et al., 
(2009) investigated biocide and antibiotic susceptibility of 12 species of the Bcc complex 
including B. lata strain 383 and reported no correlation between CHG and BZC susceptibility 
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and antibiotic susceptibility. They did not however investigate the direct effect of biocide 
exposure on antibiotic susceptibility. Rushton et al., (2013) investigated the effect of 
adaptation of B. lata strain 383 to various preservatives on susceptibility to other 
antimicrobials. They reported that strain 383 adapted to methylisothiazolinone (MIT), 
methylisothiazolinone-chloromethylisothiazolinone (M-CMIT), benzisothiazolinone (BIT) and 
benzethonium chloride (BC) was cross-resistant to other preservatives and showed increased 
tolerance to chloramphenicol and fluoroquinolones. They attributed M-CMIT tolerance and 
fluoroquinolone resistance to up-regulated efflux pump activity. It is possible that the changes 
in susceptibility to ciprofloxacin and imipenem observed in the work carried out here could be 
due to up-regulated efflux pump activity as a result of CHG/BZC exposure.  
A change in antibiotic susceptibility with no change in biocide susceptibility has been observed 
by Christensen et al., (2011) in Listeria monocytogenes after exposure to triclosan. They 
reported a 16-fold decrease in gentamicin susceptibility after exposure to a sub-lethal 
concentration of triclosan, despite observing no change in susceptibility to triclosan itself. 
Gentamicin resistant organisms were also resistant to other aminoglycosides. In contrast to 
this Birošová et al., (2009) reported that after 30 min exposure of S. enterica to sub-MIC 
concentrations of triclosan, there was no alteration in biocide or antibiotic susceptibility. 
Whitehead et al., (2011) observed that a single (5 h) exposure to cationic biocides (including a 
QAC and ‘Superkill’ – a mix of QACs) or triclosan at the in-use concentration (1 %) selected for 
multiple drug resistant surviving organisms. The above mentioned studies did not make a 
comparison between baseline susceptibility data and change in susceptibility profile after 
biocide exposure, therefore making the reproducibility of their observations difficult to 
determine. 
It is important to consider the stability of a change in susceptibility as it raises questions about 
the selection effect of a given biocide (Knapp et al., 2013). In the work carried out here the 
reduced antibiotic susceptibility was not maintained in the absence of either biocide. However 
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in the presence of 0.005 % CHG or BZC the decreased zones of inhibition did not revert back to 
baseline values after ten passages. It appears that the selective pressure for reduced antibiotic 
susceptibility (i.e. biocide exposure) was required for the maintenance of decreased zones of 
inhibition. 
 
The greatest changes in gene expression after exposure of strain 383 to 0.005 % CHG or BZC 
were observed in genes BCAM_0925 and BCAS_0081. These encode an outer membrane 
protein and an ABC transporter respectively, both of which could contribute to the efflux of 
antimicrobial compounds from the bacterial cell (Buroni et al., 2009). Efflux has been 
described as an important non-specific mechanism that can reduce the intracellular 
concentration of unrelated antimicrobials (Maillard and Denyer, 2009) and such is a likely 
candidate to explain a change in susceptibility profile. Bazzini et al., (2011) recently observed 
the effect of deleting the RND-4 and RND-9 efflux systems in B. cenocepacia. They reported 
that a double mutant had a 4 – 16 fold increase in susceptibility to antibiotics tested, including 
ciprofloxacin. This suggests a potential role for these efflux systems in antimicrobial 
susceptibility, and may in part explain what has been observed here with exposure of strain 
383 to CHG and BZC, particularly as changes in susceptibility to more than one antimicrobial 
were observed. Sass et al., (2011) looked at global gene expression in B. cenocepacia strain 
J2315 in relation to spontaneous antibiotic resistance and exposure to the cationic antibiotic 
potentiator chlorpromazine. Up-regulation of BCAM_0925 was observed in response to 
chlorpromazine exposure, and its subsequent deletion resulted in increased susceptibility to 
azithromycin and chlorhexidine. BCAS_0081 is composed of an ATP binding cassette and 
transmembrane components that possess homology to the Escherichia coli mdlB gene which 
has been associated with multiple drug resistance. Deletion of BCAS_0081 resulted in 
increased susceptibility to tetracycline and chlorhexidine but not to other antibiotics tested, 
including ciprofloxacin and imipenem. The susceptibility profiles of strain 383 and B. 
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cenocepacia strain J2315 appear very different, making comparisons between the two difficult 
to make. The findings of Rushton et al., (2013) do however correlate well the work carried out 
here, as they demonstrated the role of efflux in preservative resistance in B. lata which also 
lead to stable, elevated fluoroquinolone resistance. It is worth noting that only a small number 
of genes that could have played a role in the change in susceptibility profile observed were 
investigated, and that perhaps a wider range of B. lata genes should be investigated in order to 
establish a genuine effect of biocide exposure.  
 
When establishing a standard protocol predictive of bacterial biocide resistance it is essential 
to ensure reproducibility of the findings made. Despite following standard assays for the 
determination of the MIC, MBC and antibiotic susceptibility profile, the data obtained using B. 
lata strain 383 were not reproducible. This suggests that this bacterium may not be an 
appropriate model organism to use in the generation of predictive markers of biocide 
resistance.
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Chapter Five: Protocol validation 
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5.1 Introduction 
5.1.1 Background 
The principle aim of this work was to design a standard protocol that allows the prediction of 
biocide resistance and antibiotic cross-resistance in bacteria. Chapters 3 and 4 involved the 
assessment of a variety of techniques in their ability to generate practical markers of biocide 
resistance and antibiotic cross-resistance in S. enterica serovar Typhimurium and B. lata. 
Important factors considered when assessing these techniques included test practicality (i.e. 
how high throughput the test was), cost of the test, usefulness of the technique (i.e. how much 
data was obtained) and most importantly the reproducibility of the data obtained. Table 5.1 
summarises the advantages and disadvantages of each of the techniques explored in chapters 
3 and 4, taking in to account the results obtained in these chapters. 
 
Table 5.1: Advantages & disadvantages of techniques employed to identify resistance 
markers in survivors of biocide exposure (based on data obtained in chapters 3 and 4) 
 
Experimental technique Advantages Disadvantages 
Changes in MIC and MBC  High throughput, data within 
24h, good initial indication of 
resistance, reproducible for S. 
enterica strains, low cost 
 
Non-reproducible for 
Burkholderia lata– choice 
of model organism 
important 
Changes in antibiotic 
susceptibility 
High throughput, data within 
24 h, disk diffusion method 
low in cost. Good initial 
marker of antibiotic cross- 
resistance 
 
Disk diffusion zones of 
inhibition not always 
relevant to clinical change 
in susceptibility. Not 
reproducible for B. lata, no 
Burkholderia spp. 
breakpoints available 
 
Phenotype stability tests Give an idea of stability of 
changes observed – 
determines if susceptibility 
change is transient/stable 
No details on what 
changes have taken place 
in cells present in 
population 
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Efflux assays Good start point if one 
observes reduced biocide 
susceptibility– more likely to 
be a non-specific mechanism 
such as efflux rather than a 
specific mutation. Efflux 
pump inhibitors may give 
indication of which pumps 
responsible for efflux 
 
Long preparation time   
Real-time PCR Useful if one has identified 
specific genes potentially 
involved in resistance 
already, cheaper than 
microarray 
 
Relatively expensive, not 
useful if no knowledge of 
genes potentially involved 
in resistance. DNA/RNA 
prep time consuming if 
you have a large sample 
number 
 
Microarray See genome wide changes  - 
most likely to identify marker 
gene(s) 
 
Expensive, long 
preparation time, data 
analysis is time consuming, 
may require professional 
biostatistician 
 
One dimensional SDS-PAGE Good starting point for 
observation of outer 
membrane protein changes 
Expensive, time 
consuming, 1 dimension 
does not provide info on 
protein identity. Semi-
quantitative 
 
Flow cytometry 
 
Allows the observation of 
viable but non culturable cells 
that may not appear in 
suspension test due to 
dilution 
 
Susceptibility of surviving 
cells not apparent until 
they are further sorted and 
tested, and some may not 
be recoverable 
 
5.1.2 Principle of validation 
In the literature, validation of a protocol often involves the comparison of data generated from 
the new protocol with data from an existing, validated standard (Ebentier et al., 2013, 
Lofstrom et al., 2012, McCabe et al., 2011). However due to the fact that there is no existing 
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standard protocol for predicting biocide resistance that could be used as a comparison point, 
validation here focused on data repeatability (data variability between biological replicates 
from the same experiment) and reproducibility (variability between data generated from 
experiments performed on separate occasions) .  Validation of a particular technique involved 
the execution of the experiment on at least 3 separate occasions (each using 3 biological 
replicates) over a 6 month period of time using a variety of biocidal products and bacterial 
strains. It was important that the technique could be employed to predict resistance to 
multiple biocidal products using several different bacterial species, as different products have 
different applications and target organisms. 
In order for a technique to be validated for use in the prediction of bacterial biocide resistance 
and antibiotic cross-resistance, repeatable and reproducible data had to be obtained. For 
example, if a clinical change in antibiotic susceptibility was observed (i.e. a bacterium became 
clinically resistant to a particular antibiotic after exposure to a biocidal product), this change 
needed to be observed in all 3 biological replicates in that individual experiment, as well as on 
each separate occasion on which the experiment was carried out.  
 
5.1.3 Techniques chosen for use in validation  
Due to the low cost of pre and post- biocide exposure MIC and MBC determination (following 
the BS EN ISO: 20776-1 (2006) protocol), and the possibility of testing a large number of 
bacterial strains and biocidal products within a 24 h period (table 5.1), this technique was 
selected for use in validation experiments. Antibiotic susceptibility testing following the BSAC 
disk diffusion method (Andrews, 2009) was also selected for use in validation experiments as it 
was a useful and high throughput technique that allowed the determination of antibiotic cross-
resistance as a result of biocide exposure. Both these techniques were also chosen due to the 
fact that they provided useful initial information on biocide and antibiotic resistance in 
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surviving organisms, particularly in the case of S. enterica serovar Typhimurium, that could 
then be followed up with more time consuming and costly techniques such as efflux assays or 
real-time PCR. 
 
5.1.4 Aims 
The principle aim of this chapter was to validate pre and post- biocide exposure MIC, MBC and 
antibiotic susceptibility determination as a practical technique in the prediction of biocide 
resistance and antibiotic cross-resistance in bacteria. Further aims were to determine if 
exposure of S. enterica serovar Typhimurium, Ps. aeruginosa, Klebsiella pneumoniae and B. 
cepacia to Corsodyl mouthwash, Dermax therapeutic shampoo or eye make-up remover 
resulted in a change in biocide and/or antibiotic susceptibility in surviving organisms.  
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5.2 Materials & Methods 
 
5.2.1 Bacterial strains 
In addition to S. enterica strains SL1344 and 14028S used in chapter 3, a further 3 strains were 
used in the validation experiments. These were Burkholderia cenocepacia (UL2P), Klebsiella 
pneumoniae (UL13) and Pseudomonas aeruginosa (UL-7P) and were selected in agreement 
with Unilever SEAC, Colworth, UK. All 3 were selected as challenge organisms due to their 
routine use, propagation and handling in Unilever laboratories. They were originally isolated 
from household product contamination. Tested strains are listed in table 5.2. 
Table 5.2: Strains used in validation experiments 
 
Strain Source 
Burkholderia cenocepacia (UL2P) Unilever SEAC, Colworth, UK 
Klebsiella pneumoniae (UL13) Unilever SEAC, Colworth, UK 
Pseudomonas aeruginosa (UL-7P) Unilever SEAC, Colworth, UK 
SL1344 See chapter 2 table 2.1 
14028S See chapter 2 table 2.1 
 
5.2.2 Culture and storage of bacteria 
All strains used in validation experiments were cultured on TSA or in TSB at 37°C (± 1 °C) as 
described in chapter 2 section 2.1. All strains were stored at -80 °C (± 1 °C) as described in 
chapter 2 section 2.1. 
 
5.2.3 Biocides and neutraliser 
As well as CHG and BZC (described in chapter 2 section 2.2), 3 further biocidal products were 
tested. These were Corsodyl Mouthwash (0.2 % w/v CHG), Eye Make-up Remover (0.1 % 
biocide (confidential)) and Dermax Therapeutic Shampoo (0.5 % w/w BZC).  These products 
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were chosen following discussions and in agreement with Unilever SEAC. Their selection was 
based on the fact that they are commonly used home and personal care products and all 
contain either CHG or BZC, which were both tested in previous chapters. The neutraliser used 
was of the same composition as that described in chapter 2 section 2.3. Neutraliser efficacy for 
mouthwash, shampoo and eye make-up remover, and toxicity towards strains UL2P, UL13 and 
UL-7P was determined as described in chapter 2, sections 2.3.2 and 2.3.1 respectively. 
 
5.2.4 Suspension testing 
Suspension tests were performed to determine the efficacy of each product when tested at 
the lowest concentration attained during product use (I.e. the concentration of the product 
after any dilution by the consumer as a result of the product application). These 
concentrations were agreed with Unilever SEAC. Suspension tests were carried out according 
to the BS EN 1276 protocol (2009) described in detail in chapter 2 section 2.7. Further 
suspension tests were then performed in order to determine a concentration of each product 
that would leave sufficient surviving organisms for further antimicrobial susceptibility testing 
(i.e. a concentration that resulted in a 1-3 log10 reduction in CFU/mL). 
 
5.2.5 Suspension test conditions  
The suspension test conditions used were chosen in order to reflect parameters used in 
practice as closely as possible. Test (lowest attainable) concentrations were calculated using 
dilution factors for each product provided by Unilever SEAC. These dilution factors were based 
on the product application and how it was used by the consumer.  A contact time of 1 min was 
chosen for all products as an estimation of the length of time spent using the product by the 
consumer in order to reflect in-use conditions as accurately as possible. Table 5.3 shows the 
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contact times and calculated test concentrations (based on dilution factors provided by 
Unilever SEAC) for each product tested. 
 
Table 5.3: Initial & test (lowest attainable) concentrations & contact times for Corsodyl 
mouthwash, Dermax shampoo & eye make-up remover 
 
Product Concentration of 
active agent 
contained in product 
(%) 
Dilution 
due to 
product 
use 
Test (lowest 
attainable) 
concentration 
(%) 
Contact 
time 
(min) 
Corsodyl Mouthwash 0.20 CHG 1:40 0.005 1.00 
Dermax Shampoo 0.50 BZC 1:100 0.005 1.00 
Eye make-up remover 0.10 Biocide None 0.100 1.00 
 
5.2.6 Antimicrobial susceptibility testing 
5.2.6.1 Baseline data 
The MIC and MBC of each biocidal product were determined for all 5 strains following the BS 
EN ISO: 20776-1 (2006) protocol described in chapter 2 sections 2.4 and 2.5. The MIC and MBC 
of CHG and BZC were also determined for strains UL2P, UL13 and UL-7P following the same 
protocol. Clinical susceptibility to a range of antibiotics was determined for strains UL2P, UL13 
and UL-7P  following the BSAC disk diffusion protocol (Andrews, 2009) described in chapter 2 
section 2.6. As previously stated in chapter 4, the BSAC protocol does not provide susceptibility 
breakpoints for Burkholderia spp. Breakpoints for Pseudomonas spp. were therefore used 
instead in the case of strain UL2P (B. cenocepacia). The antibiotics tested for each strain are 
shown in table 5.4. Selected antibiotics represented different antibiotic classes in order to 
determine the effect of biocide exposure on susceptibility to multiple classes of antibiotic. 
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Table 5.4: Antibiotics tested for strains UL2P, UL13, UL-7P, SL1344 & 14028S 
 
Strain Antibiotics tested 
B. cenocepacia (UL2P) ceftazidime (30 µg), ciprofloxacin (1 µg), 
meropenem (15 µg), imipenem (10 µg), 
tobramycin (10 µg) 
 
K. pneumoniae (UL13) ceftazidime (30 µg), ampicillin (10 µg), 
ciprofloxacin (1 µg), chloramphenicol (50 µg), 
ceftriaxone (30 µg) 
 
Ps. aeruginosa (UL-7P) imipenem (10 µg), ceftriaxone (30 µg), 
meropenem (15 µg), tobramycin (10 µg), 
aztreonam (30 µg) 
 
SL1344 As described in chapter 3 section 3.2.2.1 
14028S As described in chapter 3 section 3.2.2.1 
 
5.2.6.2 Antimicrobial susceptibility of biocide-exposed organisms 
All 5 strains were exposed for 1 min (reflective of in-use conditions) to a concentration of each 
biocidal product that resulted in a 1-3 log10 reduction in CFU/mL, following the BS EN 1276 
(2009) suspension testing protocol fully described in chapter 2 section 2.7.2. All 5 strains were 
also exposed to CHG and BZC for 1 min at the same concentration as that present in each 
biocidal product. Temperature was maintained at 20 °C throughout the experiment using a 
water bath.  
After neutralisation the neutralised suspension was centrifuged at 5000 x g for 10 min, and the 
supernatant discarded.  The remaining cell pellet was then re-suspended in 10 mL TSC buffer. 
This suspension was then used in the determination of the biocidal product MIC, MBC and 
antibiotic susceptibility of surviving organisms as described in chapter 2 sections 2.4, 2.5 and 
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2.6. In order to determine the reproducibility and repeatability of the data obtained, the above 
experiment was performed on 3 separate occasions (each using 3 biological replicates) over a 
6 month period.  
 
5.2.7 Statistical analysis 
A Students t-test was used to compare MIC, MBC and antibiotic zone of inhibition sizes before 
and after biocide exposure.  
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5.3 Results 
5.3.1 Neutraliser toxicity and efficacy 
The toxicity of the neutraliser to strains UL13, UL-7P and UL2P, and efficacy of the neutraliser 
in neutralising Corsodyl mouthwash, Dermax shampoo and eye make-up remover were tested 
prior to the suspension tests being carried out. The neutraliser was considered non-toxic if ≤ 1 
log10 reduction in CFU/mL was observed after exposure to the neutraliser (compared to 
control). The neutraliser was considered effective if ≤ 1 log10 reduction in CFU/mL was 
observed in the presence of biocide and neutraliser (according to BS EN 1276 2009 guidelines). 
Tables 5.5 and 5.6 show neutraliser toxicity and efficacy data for strains UL2P, UL13 and UL-7P 
(tests performed for SL1344 and 14028S in chapter 3) and mouthwash, shampoo and eye 
make-up remover. 
 
Table 5.5: Neutraliser toxicity data for strains UL2P (B. cenocepacia), UL13 (K. pneumoniae) 
and  UL-7P (Ps. aeruginosa). N=3  
 
Treatment Mean Log CFU/mL ± SD 
Control (diH20) UL2P: 8.78 ± 0.00 
UL13: 9.07 ± 0.00 
 UL-7P: 8.95 ± 0.00 
Neutraliser UL2P: 8.24 ± 0.24 
UL13: 8.93 ± 0.06 
 UL-7P: 8.85 ± 0.06 
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Table 5.6: Neutraliser efficacy data for Corsodyl mouthwash, Dermax shampoo & eye make-
up remover using strain SL1344. N=3 
 
Treatment Mean Log CFU/mL ± SD 
Control (diH20) 8.60 ± 0.00 
Corsodyl mouthwash 0.00 ± 0.00 
Corsodyl + neutraliser 8.09 ± 0.05 
Dermax shampoo 6.09 ± 0.00 
Shampoo + neutraliser 8.10 ± 0.07 
Eye make-up remover 5.35 ± 0.40 
Eye make-up remover  
+ neutraliser 
8.40 ± 0.04 
 
Tables 5.5 and 5.6 show that the neutraliser was not toxic to any strain, and that it was 
effective in neutralising Corsodyl mouthwash, Dermax shampoo and eye make-up remover. 
 
5.3.2. Suspension tests 
Suspension tests were carried out in order to determine the efficacy of each biocidal product 
when tested at the lowest concentration attained during product use (0.1 % make-up remover, 
0.005 % shampoo and mouthwash – see table 5.3) and a contact time of 1 min. Table 5.7 
shows the log10 reduction in CFU/mL after exposure of all 5 strains to each biocidal product, 
and to CHG and BZC at the same concentration as that contained within the product. The 
dilutions performed during suspension testing resulted in a 4 log10 limit of detection. 
As shown in table 5.7, 1 min exposure to Corsodyl mouthwash (0.005 %) resulted in a 4 log10 
reduction in CFU/mL in all strains tested. This was the maximum log10 reduction that could be 
determined due to the 4 log10 limit of detection, and corresponded to a plate count of 0. One 
min exposure to CHG at the same concentration contained within the mouthwash (0.005 %) 
resulted in a ~ 3 log10 reduction in CFU/mL, leaving some surviving organisms in each strain. 
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This suggests that Corsodyl mouthwash was more effective after 1 min against each strain in 
comparison with CHG alone when tested at the same concentration. One min exposure to 
Dermax shampoo (0.005 %) only resulted in a 1.78-2.34 log10 reduction in CFU/mL in all strains 
tested, whereas exposure to BZC at the same concentration contained within the shampoo 
(0.005 %) resulted in a 4 log10 reduction in all strains except B. cenocepacia (1.92 log10 
reduction after exposure to 0.005 % BZC). This suggests that the efficacy of the BZC present in 
the shampoo may be reduced by the other components of the shampoo, as BZC alone was 
much more effective against all strains (except B. cenocepacia). One min exposure of all strains 
to eye make-up remover resulted in a 2.26 – 4 log10 reduction across all strains. Exposure of all 
strains to 0.1 % biocide (contained within the eye make-up remover) resulted in a 1.97 – 3.17 
log10 reduction in CFU/mL. There was very little difference between log10 reductions observed 
after exposure to the make-up remover and biocide alone suggesting that the efficacy of the 
biocide contained within the make-up remover was not affected by the other components of 
the product. 
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Table 5.7: log10 reductions in CFU/mL of strains SL1344, 14028S, K. pneumoniae, B. 
cenocepacia & Ps. aeruginosa after 1 min exposure to mouthwash, shampoo & eye make-up 
remover at the lowest concentration attained during product use. N=3 
 
1 4.00 log10 reduction is the limit of detection and corresponds to a plate count of 0. 
 
 
Further suspension tests were then performed to identify concentrations of each biocidal 
product and CHG/BZC that resulted in a 1-3 log10 reduction in CFU/mL after 1 min exposure. A 
1-3 log10 reduction in CFU/mL left a sufficient number of surviving organisms for use in post-
exposure susceptibility tests. The chosen concentrations are shown in table 5.8. 
 
Log10 reduction ± SD 
Strain Corsodyl 
(0.005 %)  
CHG 
(0.005 %)  
Shampoo 
(0.005 %) 
BZC 
(0.005 %)  
Make-up  
Remover 
(0.1 %) 
Biocide 
(0.1 %) 
SL1344  4.001   
± 0.00 
 3.20 
 ± 0.20 
2.08  
± 0.00 
4.00  
± 0.00 
3.12  
± 0.10 
2.33  
± 0.14 
 
14028S 4.00 
± 0.00 
 3.20 
 ± 0.20 
2.34 
± 0.11 
4.00  
± 0.00 
3.36 
± 0.17 
2.20 
± 0.09 
 
Klebsiella 4.00   
± 0.00 
 3.90 
 ± 0.60 
1.78 
± 0.04 
4.00 
 ± 0.00 
3.15 
± 0.08 
2.18 
± 0.17 
 
B. cenocepacia 4.00 
± 0.00 
 3.80 
 ± 0.60 
2.27 
± 0.38 
1.92 
 ± 0.50 
2.26 
± 0.33 
1.97 
± 0.34 
 
Ps. aeruginosa 4.00 
± 0.00 
 3.80 
 ± 0.02 
2.01 
± 0.03 
4.00 
 ± 0.00 
4.00 
± 0.00 
3.17 
± 0.34 
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Table 5.8: Concentrations of products and CHG/BZC for use in antimicrobial susceptibility 
testing 
 
Biocidal  
product 
Concentration 
contained 
within product 
Concentration of 
product/active 
biocide resulting in 1-
3 log10 reduction (%) 
Dilution due to 
product use 
Test 
concentration 
(%) * 
Corsodyl 
mouthwash 
0.2 % CHG 0.0005 1:40 0.0000125 
Dermax 
Shampoo 
0.5 % BZC 0.0015 1:100 0.000015 
Eye make-up 
remover 
0.1 % biocide 0.1  None 0.1 
* Concentrations used in antimicrobial susceptibility testing 
 
As shown in table 5.8 the test concentrations of each product used (column 5) are 
considerably lower than the concentrations contained within Corsodyl mouthwash and 
Dermax shampoo (column 2). However, concentrations needed to be reduced so that a 
sufficient number of surviving organisms remained for further susceptibility testing for the 
purpose of protocol development. 
 
5.3.3 Antimicrobial susceptibility testing 
The susceptibility of surviving organisms to each biocidal product or CHG/BZC alone and a 
range of antibiotics was tested after exposure of each strain to each biocidal product, in order 
to determine if exposure to any of the biocidal products resulted in a change in antimicrobial 
susceptibility in the survivors. Each experiment was performed on three separate occasions 
over a 6 month period in order to assess the repeatability and reproducibility of the data when 
using this technique in the identification of surviving organisms with altered antimicrobial 
susceptibility. Table 5.9 shows the baseline and post-exposure MIC and MBC values after 1 min 
exposure of all 5 strains to eye make-up remover (0.1 %). 
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Table 5.9: Baseline & post-exposure MIC and MBC values after 1 min exposure of SL1344, 14028S, K. pneumoniae, B. cenocepacia & Ps. aeruginosa to eye 
make-up remover (undiluted) carried out on 3 separate occasions over a 6 month period. 
 
* = significantly different from baseline value (p ≤ 0.05) 
1 each MIC/MBC value is the mean of 3 biological replicates  
MIC/MBC ± SD 
Strain Baseline  
MIC (%) 
MIC 11 
(%) 
MIC 2  
(%) 
MIC 3  
(%) 
Baseline 
MBC (%) 
MBC 1  
(%) 
MBC 2  
(%) 
MBC 3  
(%) 
SL1344 0.003  
± 0.00 
0.006  
± 0.00* 
0.003 
± 0.00 
0.003 
± 0.00 
> 0.05 
± 0.00 
> 0.05 
± 0.00 
> 0.05 
± 0.00 
> 0.05 
± 0.00 
 
14028S 0.003  
± 0.00 
0.006  
± 0.00* 
0.006 
± 0.00* 
0.006 
± 0.00* 
> 0.05 
± 0.00 
> 0.05 
± 0.00 
> 0.05 
± 0.00 
> 0.05 
± 0.00 
 
K. pneumoniae 0.012  
± 0.00 
0.012  
± 0.00 
0.012  
± 0.00 
0.012  
± 0.00 
> 0.05 
± 0.00 
> 0.05 
± 0.00 
> 0.05 
± 0.00 
> 0.05 
± 0.00 
 
B. cenocepacia 0.012  
± 0.00 
0.012  
± 0.00 
0.012  
± 0.00 
0.012  
± 0.00 
> 0.05 
± 0.00 
> 0.05 
± 0.00 
> 0.05 
± 0.00 
> 0.05 
± 0.00 
 
Ps. aeruginosa 0.012  
± 0.00 
0.012  
± 0.00 
0.012  
± 0.00 
0.012  
± 0.00 
> 0.05 
± 0.00 
> 0.05 
± 0.00 
> 0.05 
± 0.00 
> 0.05 
± 0.00 
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As shown in table 5.9, statistically significant changes (p ≤ 0.05) in the MIC of eye make-up 
remover were observed on all 3 occasions for strain 14028S and on 1 occasion for strain 
SL1344. However despite being statistically significant, these changes in MIC were very small, 
particularly in comparison to those observed in SL1344 and 14028S after exposure to low 
concentrations of CHG/BZC (0.00001 – 0.0004 %) (Chapter 3, tables 3.5 & 3.6). It was not 
possible to ascertain if there were changes in the MBC of this product as viable cells from all 5 
strains remained in the highest testable concentration of eye make-up remover (0.05 %). What 
is clear from table 5.9 is that the resulting mean MIC values were highly repeatable (indicated 
by low SD values) and that mean MIC values were reproducible across all 3 separate 
experiments. This suggests that determination of the MIC/MBC before and after biocide 
exposure is a useful and valid technique for use in the prediction of biocide resistance in the 5 
organisms tested. 
Table 5.10 shows the mean zone of inhibition sizes observed for a range of antibiotics before 
and after 1 min exposure of all 5 strains to make-up remover (0.1 %). As shown in table 5.10, 
there was no clinical change in susceptibility to any of the antibiotics tested after 1 min 
exposure to make-up remover, in the case of all 5 strains (according to BSAC susceptibility 
breakpoints for Enterobacteriaceae/Pseudomonas spp). In the case of some strains and 
antibiotics, statistically significant changes in the zone of inhibition size were observed but this 
did not correspond to a clinical change in susceptibility (e.g. ciprofloxacin and SL1344, 14028S; 
ceftazidime and Klebsiella pneumoniae). As previously discussed in detail in chapter 4, it was 
not possible to directly determine if clinical changes in susceptibility were observed in B. 
cenocepacia, as there were no available breakpoints provided for this species in the BSAC 
protocol, and clinical susceptibility was therefore based on Pseudomonas spp.  
Carrying out this experiment on 3 separate occasions over a 6 month period also allowed for 
an assessment of the reproducibility of the results obtained. It is clear from table 5.10 that the 
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post-exposure antibiotic susceptibility data was reproducible across all three separate 
experiments, validating this technique for the determination of antibiotic cross-resistance as a 
result of biocide exposure in the 5 organisms tested here. 
Biocidal product/biocide concentrations that resulted in a 1-3 log10 reduction in CFU/mL were 
0.0005 % Corsodyl mouthwash, 0.0005 % CHG, 0.0015 % Dermax shampoo, 0.0015 % BZC and 
0.1 % biocide (equivalent to biocide concentration in make-up remover). As shown in table 5.3, 
Corsodyl mouthwash and Dermax shampoo undergo a 1:40 and 1:100 dilution respectively as a 
result of product use by the consumer (eye make-up remover is not diluted). This means that 
final exposure concentrations of mouthwash/CHG and shampoo/BZC in this case were 
0.0000125 % and 0.000015 % respectively (no dilution for eye make-up remover) (see table 
5.8). The final concentrations of Corsodyl mouthwash and Dermax shampoo tested were 
therefore considerably lower than the original product concentration in table 5.8. This was due 
to the fact that lower biocide concentrations were required to leave a sufficient number of 
surviving organisms for post-biocide exposure testing. This had to be considered when 
analysing the data obtained. 
The resulting MIC/MBC and antibiotic susceptibility values for each strain and each biocidal 
product and active biocide are shown in the appendix (file name: appendix data for chapter 5). 
No significant changes in clinical antibiotic susceptibility were observed after exposure of all 5 
strains to the 3 biocidal products and equivalent concentrations of CHG or BZC (according to 
BSAC antibiotic susceptibility breakpoints for Enterobacteriaceae/Pseudomonas spp.) with the 
exception of tobramycin resistance observed in 1/3 occasions in B. cenocepacia after exposure 
to Dermax shampoo. 
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Table 5.10: Baseline & post-exposure mean zone of inhibition values (mm) after 1 min exposure of SL1344, 14028S, K. pneumoniae, B. cenocepacia & Ps. 
aeruginosa to eye make-up remover (undiluted) carried out on 3 separate occasions over a 6 month period. 
 
Green = clinically sensitive   Red = clinically resistant (according to BSAC antibiotic susceptibility breakpoints for Enterobacteriaceae (SL1344, 14028S, 
Klebsiella) or Pseudomonas spp. (B. cenocepacia, P. aeruginosa)) 
* = significantly different from baseline value p ≤ 0.05  
Mean zone of inhibition size (mm) ± SD 
Strain Antibiotic Baseline Post- exposure 1 Post- exposure 2 Post- exposure 3 
SL1344 Chloramphenicol (50 µg) 28.7 ± 1.2 28.0 ± 0.0 28.0 ± 0.0 27.8 ± 1.2 
 Ampicillin (10 µg) 31.7 ± 0.6 28.3 ± 1.5* 30.0 ± 0.0 31.0 ± 0.0 
 Ciprofloxacin (1 µg) 32.0 ± 1.7 28.0 ± 0.0* 31.3 ± 0.6 30.0 ± 0.0 
 Ceftriaxone (30 µg) 34.3 ± 2.1 36.3 ± 1.5 32.0 ± 0.0 34.0 ± 0.0 
 Piperacillin (30 µg) 29.0 ± 1.0 29.7 ± 1.5 29.0 ± 0.0 29.0 ± 0.0 
      
14028S Chloramphenicol (50 µg) 27.7 ± 0.6 27.3 ± 0.6 27.5 ± 1.2 28.1 ± 0.8 
 Ampicillin (10 µg) 31.0 ± 1.7 29.7 ± 0.6 30.1 ± 0.7 29.9 ± 1.3 
 Ciprofloxacin (1 µg) 31.3 ± 1.2 27.0 ± 1.0* 28.5 ± 0.5 30.0 ± 0.0 
 Ceftriaxone (30 µg) 33.7 ± 0.6 30.7 ± 0.6* 33.0 ± 0.0 31.4 ± 0.6 
 Piperacillin (30 µg) 29.7 ± 0.6 29.8 ± 0.6 29.0 ± 0.0 29.0 ± 0.0 
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 K. pneumoniae Ceftriaxone (30 µg) 35.7 ± 0.6 34.7 ± 0.6 34.2 ± 0.6 33.6 ± 0.5 
 Ampicillin (10 µg) 0.00 ± 0.0 0.00 ± 0.0 0.00
 ± 0.0 0.00 ± 0.0 
 Ciprofloxacin (1 µg) 27.3 ± 1.2 26.3 ± 0.6 27.0 ± 0.0 25.8 ± 0.6 
 Chloramphenicol (50 µg) 25.3 ± 0.6 26.7 ± 0.4 26.3 ± 1.2 26.0 ± 0.0 
 Ceftazidime (30 µg) 32.3 ± 0.6 31.0 ± 0.6* 30.0 ± 0.0* 31.4 ± 0.4 
      
Ps. aeruginosa Imipenem (10 µg) 26.7 ± 0.6 22.7 ± 0.6 25.0 ± 0.0 27.3 ± 0.3 
 Ceftazidime (30 µg) 22.3 ± 1.2 23.0 ± 1.0 22.0 ± 0.0 23.0 ± 0.0 
 Meropenem (15 µg) 33.0 ± 1.0 33.0 ± 2.0 32.0 ± 0.0 33.1 ± 1.3 
 Tobramycin (10 µg) 28.3 ± 2.1 29.0 ± 2.6 28.5 ± 1.5 29.0 ± 0.0 
 Aztreonam (30 µg) 12.0 ± 0.0 10.7 ± 1.5 10.3
 ± 1.2 10.0 ± 0.0 
      
B. cenocepacia Imipenem (10 µg) 35.3 ± 1.2 34.0 ± 0.0 35.0 ± 0.0 34.2 ± 1.4 
 Ceftazidime (30 µg) 25.3 ± 0.6 27.5 ± 0.5 26.5 ± 1.5 27.7 ± 0.9 
 Meropenem (15 µg) 36.0 ± 0.0 35.0 ± 0.0 36.0 ± 0.0 36.0 ± 0.0 
 Tobramycin (10 µg) 20.0 ± 1.0 19.5 ± 0.5 20.0 ± 0.0 20.5 ± 0.0 
 Ciprofloxacin (1 µg) 19.0 ± 0.6 19.0 ± 0.0 19.0 ± 0.0 19.0 ± 0.0 
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5.4 Discussion 
SL1344, 14028S, Ps. aeruginosa, B. cenocepacia and K. pneumoniae were exposed to Corsodyl 
mouthwash, Dermax shampoo, eye make-up remover and CHG or BZC at the same 
concentration contained within the biocidal product in order to validate the determination of 
the MIC/MBC and antibiotic susceptibility of surviving organisms as a practical technique in the 
prediction of biocide resistance. 
Despite no significant changes in clinical antibiotic susceptibility as a result of biocide exposure 
in any strains tested, reduced antibiotic susceptibility has been observed as a result of biocide 
exposure in Ps. aeruginosa by other groups (Tandukar et al., 2013, D'Arezzo et al., 2012). 
Tandukar et al., (2013) observed increased resistance to the antibiotics penicillin G, 
ciprofloxacin and tetracycline as a result of long-term exposure to BZC (added to growth 
media) which they attributed to degradation of the antibiotic (penicillin G) and efflux pump 
activity. It is worth noting that the data obtained by Tandukar et al., (2013) was as a result of 
step-wise, long-term BZC exposure whereas the data obtained in this chapter was as a result of 
a single exposure, taking in to account realistic parameters such as contact time and possible 
product dilution through product use. D’Arezzo et al., (2012) observed cross- resistance to 6 
antibiotics including ciprofloxacin in a triclosan-adapted strain of Ps. aeruginosa. However this 
data was also obtained as a result of step-wise adaptation of Ps. aeruginosa to triclosan, and is 
therefore not directly comparable to the data obtained in this chapter. When predicting 
bacterial biocide resistance it is important to consider the application of the product and 
potential in-use contact time in order to create realistic test parameters.  This was considered 
here when testing Corsodyl mouthwash, Dermax shampoo and make-up remover and may 
provide more realistic susceptibility data in surviving organisms than stepwise adaptation 
experiments that do not necessarily consider realistic parameters when it comes to exposure 
time and concentration. MIC/MBC and antibiotic susceptibility values were highly repeatable 
and reproducible across separate experiments performed over a 6 month period suggesting 
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that determination of the MIC/MBC and antibiotic susceptibility following standard protocols 
(BS EN ISO: 20776-1 (2006) and BSAC protocol (Andrews, 2009) respectively)) before and after 
biocide exposure is a valid and practical technique for use in the prediction of bacterial biocide 
resistance. 
Very little investigation in to the relationship between biocide and antibiotic susceptibility in 
Klebsiella spp. has been carried out. Data obtained in this chapter indicated that 1 min 
exposure to the three biocidal products tested here did not have an effect on the antibiotic 
susceptibility of surviving organisms, nor on the MIC/MBC of the biocidal product itself 
(appendix file name: appendix data for chapter 5). Abuzaid et al., (2012) investigated the 
relationship between biocide and antibiotic susceptibility in K. pneumoniae isolates. They 
found that strains that carried the efflux pump genes cepA and qacE showed reduced 
susceptibility to the biocides CHG and BZC but were not resistant to any antibiotics tested. This 
suggests there may not be a common mechanism present that could confer cross-resistance to 
antibiotics after biocide exposure. The lack of investigation in to the effect of biocide exposure 
on antibiotic susceptibility in this species suggests that Klebsiella spp. may not be an ideal 
model organism for use in the prediction of biocide resistance. However the data obtained 
using this organism was highly reproducible and consistent across repeats, indicating that 
MIC/MBC and antibiotic susceptibility determination following standard protocols is a practical 
technique for biocide resistance determination. 
Large increases (up to 100-fold) in MIC/MBC were observed in SL1344 and 14028S after 
exposure to low CHG/BZC concentrations (chapter 3, tables 3.5 & 3.6). Such increases were not 
observed in this chapter after 1 min exposure to Corsodyl mouthwash, Dermax Shampoo and 
eye make-up remover. However the concentrations and contact time used in this chapter 
differ from those used in chapter 3 (5 min, 0.00001 – 0.0004 % CHG/BZC) and therefore may 
not have resulted in the same response at the cellular level. Biocide exposure and antibiotic 
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cross resistance in Salmonella species has been described by Condell et al., (2012a), 
Whitehead et al., (2011), Randall et al., (2007)  and Braoudaki and Hilton (2004) and has been 
discussed in detail in chapter 3 section 3.4. More importantly, the data obtained for both 
Salmonella enterica strains across experimental repeats in both chapter 3 and this chapter is 
highly reproducible, even when separate experiments were performed over a 6 month period 
of time. This confirms the validity of MIC/MBC and antibiotic susceptibility determination 
before and after exposure to a particular biocide for use in the prediction of biocide resistance. 
These data also further confirm that Salmonella enterica serovar Typhimurium may be a useful 
model organism in the prediction of biocide resistance. 
Alterations in clinical susceptibility to the antibiotics ciprofloxacin and imipenem were 
observed in B. lata in chapter 4 (table 4.5) after 5 min exposure to 0.005 % CHG and BZC but 
no changes in clinical antibiotic susceptibility were observed here in B. cenocepacia after 
exposure to Corsodyl mouthwash or eye make-up remover. Susceptibility to tobramycin was 
altered from sensitive to resistant on 1 out of 3 occasions after exposure to Dermax shampoo 
(appendix file name: appendix data for chapter 5). This isolated change in susceptibility 
appears to confirm the lack of data reproducibility when using Burkholderia spp. as a model 
organism for predicting biocide resistance and antibiotic cross-resistance (Knapp et al., 2013). 
Rose et al., (2009) investigated biocide and antibiotic susceptibility of B. cenocepacia and 
found that despite being resistant to multiple antibiotics, there was no direct correlation 
between biocide susceptibility and antibiotic susceptibility in this species of Burkholderia 
which correlates with the findings in this chapter. The effect of biocide exposure on the 
susceptibility of Burkholderia species has been investigated by Knapp et al., (2013) and 
Rushton et al., (2013) and is discussed in detail in chapter 4 section 4.4. Data obtained using B. 
cenocepacia was generally reproducible across separate repeats with the exception of 1 
clinical change in tobramycin susceptibility, whereas there was considerable variability in 
antibiotic susceptibility after biocide exposure was observed in B. lata. These findings suggest 
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that Burkholderia spp. may not be an appropriate model organism for use in the prediction of 
biocide resistance and antibiotic cross-resistance. Furthermore the lack of clinical antibiotic 
susceptibility breakpoints for Burkholderia spp. available in the BSAC protocol also makes this 
species a less favourable model organism for resistance prediction. 
The principle aim of this chapter was to validate the use of MIC, MBC and antibiotic 
susceptibility determination before and after biocide exposure, for use in the prediction of 
bacterial biocide resistance. MIC, MBC and antibiotic susceptibility values for Corsodyl 
mouthwash, Dermax shampoo, eye make-up remover, CHG and BZC were repeatable between 
biological replicates and reproducible between separate repeat experiments at the 
concentrations tested in 4 out of 5 strains. The reproducibility of the data across all strains 
(except B. cenocepacia) and experiments indicates that MIC, MBC and antibiotic susceptibility 
determination (following standard protocols (BS EN ISO: 20776-1 (2006) and BSAC protocol 
(Andrews, 2009) respectively))  is a practical and high throughput technique that provides 
useful initial information in the prediction of bacterial biocide resistance.
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Chapter Six: General discussion 
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The principle aim of this project was to use a variety of experimental techniques to explore a 
range of practical markers of biocide resistance and antibiotic cross-resistance with a view to 
developing a step-by-step protocol that allows the prediction of bacterial biocide resistance. 
With this in mind a number of techniques were used, including MIC/MBC/antibiotic 
susceptibility determination, efflux assays, SDS-PAGE, real-time PCR, and microarray, and their 
ability to generate practical markers of biocide resistance, their cost effectiveness and their 
ability to generate repeatable and reproducible data was determined. 
 
6.1 Protocol design 
As previously mentioned (chapter 1, section 1.3) the BPR now states that manufacturers of 
biocidal products must provide information on the likelihood of resistance development to 
their product. With this in mind there is a requirement for a standard protocol that allows the 
prediction of resistance, using high throughput and effective techniques that allow the 
manufacturer to provide this type of data promptly (SCENIHR, 2010). 
 
6.1.1 Protocol consideration 
The protocol designed here is based on the comparison of baseline (pre-biocide exposure) and 
post-biocide exposure data, and this principle was validated using MIC/MBC and antibiotic 
susceptibility determination (chapter 5). The protocol provides logical steps to take in order to 
firstly identify changes in biocide/antibiotic susceptibility as a result of biocide exposure 
(predict resistance) and secondly identify further resistance markers and possible mechanisms 
behind the observed changes. It also takes in to account how high throughput a technique is, 
how practical the technique is and the cost of each technique. Table 6.1 provides a comparison 
of the techniques explored in terms of practicality, cost, and ease of use (i.e. the amount of 
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training/knowledge required to successfully use the technique). The table helps provide the 
rationale behind the order of the techniques used in the step-by-step protocol. 
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Table 6.1: Comparison of practicality, cost and complexity of techniques explored throughout project 
 
Technique Practicality Approximate/Predicted cost Complexity/Ease of use 
MIC/MBC determination High throughput, data within 24 h, 
96 well plate easy to set up 
Can test multiple 
species/biocides/concentrations at 
once 
~£1 per 96 well MIC plate+ lid 
Media cost dependent on test 
bacterium. TSA/TSB  ~£40/500g 
Approx cost per sample (MIC): 
£1.10 (plate + media). Note can 
run multiple samples per plate to 
reduce cost per sample 
Approx cost per sample (MBC): 50 
p (based on 1 TSA plate per 
sample) 
 
Straightforward, follow step by 
step ISO:20776-1protocol, data 
easy to interpret 
 
Antibiotic susceptibility testing High throughput, data within 24 h, 
disk diffusion protocol allows testing 
of 6 antibiotics per plate.  
Antibiotic disks £11-15 for 50 
depending on which antibiotic is 
required 
Iso-sensitest agar ~£200 per 500g.  
Approx cost per sample (testing 6 
antibiotics on one plate): £2.00 
 
Straightforward, follow step by 
step BSAC disk diffusion protocol, 
clinical breakpoints provided 
make data easy to interpret 
Phenotype stability testing New data generated after every 
subculture (every 24 h). High 
throughput, large data set obtained 
over chosen test period. Valuable 
info on stability of change. 
Subcultures + MIC/MBC tests easy 
to perform 
Dependent on duration of stability 
testing/number of samples. 
E.g. One strain, 2 biocides uses 
approximately 14 96 well plates 
over a 7 day period - cost ~£14. 
Media cost dependent on test 
bacterium. TSA/TSB  ~£40/500g 
Approx cost for one strain, 2 
Simple technique, requires 
MIC/MBC and antibiotic 
determination every 24 h. 
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biocides over 7 days (including 
MIC/MBC determination, 
antibiotic testing): £25 
 
Efflux assay Simple but time consuming set-up 
(takes 3-6 h for bacteria to reach 
mid-log phase depending on 
species). Once set up, data obtained 
within 3 min from plate reader, little 
data manipulation required to 
generate meaningful data. Despite 
long set-up can read several plates 
rapidly, allowing multiple 
strains/biocides to be tested at once 
Black 96 well plate for 
fluorescence reading ~ £1.50 for 
plate + lid (1 strain + 2 biocides 
per plate) 
Hoechst dye £36.60/100 mg – 2 
tubes required for all reactions 
performed in this project (3 
strains, 3 treatments per strain) 
Approx cost per sample (one 
strain untreated/CHG treated/BZC 
treated): £ 25 i.e. plate + dye 
assuming 3 biological replicates 
per treatment 
 
Based on changes in fluorescence 
readings obtained from different 
samples – data easy to analyse. 
Simple biocide exposure followed 
by staining with fluorescent dye 
Protein assay (SDS-PAGE) Limited info on protein identity 
using one dimension only (used 
here). Long prep time – protein 
extraction, purification, 
quantification. Electrophoresis, 
staining, de-staining and 
visualisation also time consuming. 
Further work required for more 
informative data to be obtained (e.g. 
protein sequencing, western blot) 
Extraction, electrophoresis and 
staining reagents are costly but 
can be purchased in bulk and used 
for multiple samples  
Pre-cast gel £13 – can run one 
strain + 3 treatments per gel 
Approx cost per individual sample 
(i.e. one strain untreated, CHG 
treated, BZC treated): £30-35, 
includes gel and all purification, 
electrophoresis and staining 
components 
 
Previous training in gel 
electrophoresis, loading gels, 
staining and visualising gels may 
be required for efficient use of 
technique and ease of data 
interpretation (although not 
essential). Knowledge of 
approximate protein molecular 
weights may assist in data analysis 
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Real-time PCR RNA extraction simplified by use of 
step-by-step kit, but time consuming 
especially if large sample number. A 
large number of PCR reactions can 
be run at once (max 96), run time 
approx 3.5 hours, so 2 -3 runs can be 
completed in one day. Data analysis 
straightforward. 
Kits expensive but allow large 
number of samples to be 
processed 
Extraction kit: £322 (but variable 
depending on kit choice), allows 
50 preps 
cDNA synthesis kit: £298 for 100 
reactions 
SYBR Green kit: £140 for 200 25 µL 
runs 
In this project use of qPCR 
machine £5 per run 
Approx cost per sample: £15 -20 
(includes extraction, cDNA 
synthesis, SYBR Green and use of 
machine and accounts for 
variability in cost of kits) 
 
Previous training in primer design, 
RNA extraction and setting up PCR 
reactions essential as real-time 
PCR highly sensitive to 
contamination. Training in data 
interpretation, calculation of fold 
changes also essential as more 
than one method available – 
choice of method may affect 
accuracy of fold changes 
calculated e.g. Pfaffl method 
accounts for primer efficiency but 
delta-delta method does not 
Microarray Very time consuming prep – RNA 
extraction, bioanalysis, labelling. 
Generates a very large volume of 
raw data which requires extensive 
analysis. Not a practical choice if you 
require rapid data generation 
SV RNA isolation system £204 for 
50 preps 
Approximate cost of work carried 
out here (includes RNA prep and 
bioanalysis, microarray execution 
and primary data analysis by 
biostatistician: £3000 
Approx cost per strain (i.e. 
untreated, CHG and BZC treated): 
£1500. Based on 8 x 15k array 
slides, i.e. 8 repeats of same gene 
set on one slide 
 
Previous training in running a 
microarray essential, particularly 
labelling and hybridisation steps. 
Good theoretical knowledge of 
how a microarray works also 
required. Extensive training in 
data interpretation/analysis 
required, including training in the 
use of software for microarray 
data analysis e.g. GeneSpring. 
Basic knowledge of how biocidal 
product works/bacterium may 
respond could help with data 
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interpretation 
 
Flow cytometry Preparation may be time consuming 
depending on biocide exposure 
times and bacterial growth 
requirements, but is simple. Instant 
generation of data by flow 
cytometer, analysis may be time 
consuming and data can be difficult 
to interpret. Useful starting point for 
looking at changes in a population as 
a result of exposure 
Propidium iodide: £38.60/ 25 mg 
BOX dye: £147 / 25 mg 
Cost per sample (based on 
staining with PI (5 µg/mL) and BOX 
(10 µg/mL)): ~£1 
 
  
Set up and staining of samples 
straightforward. However 
previous experience/training in 
the use of a flow cytometer is 
essential as well as training in the 
use of accompanying software e.g. 
FACSDiva in order to be able to 
analyse data effectively. 
 
 
176 
 
Figure 6.1 shows the decision tree for risk of emerging resistance. It is based on the protocol 
proposed for current use including the techniques to use and the order they are used, as well 
as points when the user can make an informed decision on the risk of resistance. As shown in 
figure 6.1 a decision on how high the risk of resistance development is can be made using the 
first 3 steps of protocol (MIC/MBC/antibiotic susceptibility, flow cytometry and phenotype 
stability testing). If no changes in the MIC/MBC or antibiotic susceptibility are observed after 
biocide exposure, and flow cytometry experiments do not identify undamaged, surviving cells, 
the risk of resistance development to the biocide is low. If an increase in the MIC or MBC or a 
clinical change in antibiotic susceptibility is observed the stability of this change can inform the 
user on the risk of resistance development. A stable change suggests a high risk of resistance 
development whereas an unstable change suggests a low risk. The steps that follow (efflux 
assay, protein assay, microarray, PCR) can then be used to identify further resistance markers 
and inform the user on potential mechanisms of resistance to the test biocide.  
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Figure 6.1: Decision tree and proposed protocol for the prediction of bacterial biocide resistance
Risk of stable resistance 
development 
Flow cytometry 
Is there an undamaged, surviving population? 
No 
Risk 
Yes 
No 
Phenotype stability testing 
Are the observed changes stable? 
No 
Risk 
Mechanisms Efflux assays 
Does efflux activity increase? 
RISK 
No 
No 
Risk 
No risk of resistance due 
to efflux up-regulation 
Yes 
No 
Yes 
No 
No 
Risk 
No Membrane protein expression 
Change in outer membrane proteins? 
Yes 
Microarray 
Identification of 
potential marker genes 
Real time PCR 
Confirmation of microarray changes  
Identification of marker gene 
What type of pump? 
No risk of resistance due 
to outer membrane 
protein change 
Yes 
Cheap, high throughput,  
rapid, easy to use 
 
Increased cost, less high 
throughput, training 
required 
Expensive, very time 
consuming, extensive 
expertise required 
To include in 
future protocol 
MIC/MBC/antibiotic susceptibility 
Is there an increase in MIC/MBC? 
Is there a change in antibiotic susceptibility? 
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6.1.2 Protocol rationale 
Figure 6.2 is populated with data obtained from chapter 3 in order to demonstrate how the 
protocol can be used to predict resistance development. Techniques that are high throughput 
(i.e. generate a large volume of a data in a short period of time), low in cost per sample and 
simple to execute (i.e. minimal training/knowledge required, if any) are carried out before 
those that are more complex and costly as shown in figures 6.1 and 6.2. MIC, MBC and 
antibiotic susceptibility determination comprise the first step of the protocol as they are high 
throughput, cheap and simple to execute. Furthermore, the elevated MIC and MBC values 
observed when exposing S. enterica serovar Typhimurium strains SL1344 and 14028S to CHG 
and BZC (chapter 3) provided a useful initial resistance marker that could then be further 
explored using different techniques. There is also the potential to start the protocol using flow 
cytometry alongside MIC/MBC/antibiotic susceptibility determination to identify cells within a 
biocide- exposed population that are undamaged after exposure, as these cells may 
demonstrate reduced biocide susceptibility. 
Phenotype stability testing follows MIC/MBC/antibiotic susceptibility determination as it 
establishes whether the increased MIC/MBC or change in antibiotic susceptibility is stable or 
transient. At this point in the protocol a decision can be made on the risk of resistance 
development, based on the stability of the changes observed. Phenotype stability testing is 
also low in cost and high throughput, and successfully established that the increased MIC and 
MBC values observed in SL1344 and 14028S were not stable (chapter 3).  
The techniques that follow phenotype stability testing are less high throughput and may 
require some form of training/knowledge for effective execution.  The suggested order shown 
in figure 6.1 was chosen to first identify a putative mechanism behind the increased MIC/MBCs 
(efflux assay, protein assay) and then to potentially identify a change in a specific gene or 
protein associated with a particular mechanism, thus generating multiple markers of 
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resistance.  Efflux and protein assays were chosen as logical steps following increases in the 
MIC/MBC as bacterial biocide resistance is often associated with mechanisms that remove 
biocide from the cell (i.e. efflux up-regulation) or prevent biocide entering the cell (e.g. 
changes in porins). As discussed in table 6.1, further sequencing of proteins would be required 
to provide more information on protein changes observed. In the work carried out here a 
positive result was obtained for efflux up-regulation in strains SL1344 & 14028S as indicated by 
the decrease in fluorescence after biocide exposure, corresponding to less Hoechst dye 
accumulating within the bacterial cell.  This represented a further resistance marker. 
Efflux assays are followed by either real-time PCR reactions or microarrays, with a view to 
identifying a specific type of efflux pump or a marker gene associated with this efflux up-
regulation. Real-time PCR would be recommended over microarrays as it is less costly, and 
data can be obtained faster. However the use of real-time PCR does require knowledge of 
specific genes that could be associated with resistance.  If this information cannot be acquired 
by the user a microarray exploring genome-wide gene expression is recommended. However 
microarrays are costly and require training and expertise to be performed successfully. 
Microarray therefore appears as a last step in the protocol.  A combination of microarray 
technology and real-time PCR was used to identify down-regulation of the acrR efflux pump 
regulatory gene in SL1344 and 14028S after CHG exposure (chapter 3) which may be 
responsible for the up-regulation in efflux observed in the efflux assays. Down-regulation of 
this gene across both strains made it a useful resistance marker. 
180 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.2: Decision tree and predictive protocol populated with data from chapter 3
No 
Flow cytometry 
A surviving, undamaged population was 
observed in SL1344 & 14028S after exposure 
to low CHG/BZC concentrations 
No 
Risk 
Yes 
No 
Phenotype stability testing 
Increased MIC/MBCs were not stable in 
SL1344 or 14028S in the absence of CHG/BZC 
No 
Risk 
Mechanisms Efflux assays 
Increased removal of Hoechst dye from 
SL1344/14028S after CHG/BZC exposure 
RISK 
No 
No 
Risk 
No risk of resistance due 
to efflux up-regulation 
Yes 
No 
Yes 
No 
No 
Risk 
Membrane protein expression 
More info required on outer 
membrane proteins e.g. sequence 
Yes 
Microarray 
Identification of blc, ompW, hycA, 
hybB, acrR significantly changed 
Real time PCR 
Confirmation of down-regulation of 
acrR after CHG exposure 
Identification of marker gene 
What type of pump? 
No risk of resistance due 
to outer membrane 
protein change 
Yes 
Risk of stable resistance 
development 
MIC/MBC/antibiotic susceptibility 
Increased MICs and MBCs observed in SL1344 & 
14028S after CHG/BZC exposure 
Cheap, high throughput,  
rapid, easy to use 
 
Increased cost, less high 
throughput, training 
required 
Expensive, very time 
consuming, extensive 
expertise required 
Not included 
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6.3 Choice of model organism 
Various species were used in this project including S. enterica serovar Typhimurium, B. lata, B. 
cepacia, K. pneumoniae and Ps. aeruginosa. It was important that the predictive protocol 
designed was suitable for use with multiple bacterial species as different biocidal products 
have different target organisms.  As determined in chapters 4 and 5, Burkholderia spp. were 
not a particularly useful model organism for the prediction of biocide resistance and antibiotic 
cross-resistance due to the lack of repeatable and reproducible data obtained. This was 
observed in antibiotic susceptibility tests using B. lata strain 383 where resistance to imipenem 
and ciprofloxacin as a result of 5 min exposure to 0.005 % CHG/BZC was only observed in 1 out 
of 4 separate repeats of the experiment. Lack of data repeatability was also observed in 
chapter 5 in the validation work carried out using B. cenocepacia, where resistance to 
tobramycin as a result of exposure to Dermax shampoo was observed in only 1 of 3 separate 
repeat experiments. A further limitation to using the BSAC disk diffusion protocol for antibiotic 
susceptibility testing (Andrews, 2009) with Burkholderia spp. was that it does not provide 
clinical breakpoints for these organisms.  However, the data generated from the three 
remaining species was both repeatable and reproducible. This indicates that the protocol 
(figure 6.1, 6.2) is suitable for use with different species of bacteria. S. Typhimurium in 
particular would make a good model organism as all the MIC/MBC and antibiotic susceptibility 
data generated using this organism was highly reproducible. Further tests used to identify 
possible biocide resistance mechanisms and additional markers in this species (efflux assays, 
real-time PCR, microarray) also generated some useful resistance markers, e.g. increased efflux 
of Hoechst dye, down-regulation of the acrR gene as illustrated in figure 6.2. 
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6.4 Using the protocol to determine the risk of resistance development to CHG and BZC  
Changes in biocide susceptibility observed included an increase in the MIC and MBC of CHG 
and BZC for S. enterica serovar Typhimurium strains SL1344 and 14028S. However, phenotype 
stability tests carried out indicated that these increases were not stable in the presence or 
absence of low concentrations (0.0001 – 0.0004 %) of these biocides. A change that is stable in 
the absence of any biocide may indicate the presence of a permanent mutation in a particular 
gene or a permanent alteration to the bacterial cell physiology. A permanent/stable change in 
the bacterial cell as a result of biocide exposure would be associated with a greater risk of 
resistance development compared with a transient, unstable response.  This suggests that 
despite the increases in MIC and MBC observed here, there is not a high risk of stable 
resistance development to CHG and BZC in either Salmonella enterica strain tested, due to the 
transient and unstable nature of the response. Despite the unstable changes observed, further 
tests were performed for the purpose of protocol development. Efflux assays, microarrays and 
real-time PCR indicated that efflux up-regulation (increased Hoechst dye efflux, down-
regulation of acrR) was the putative mechanism behind the increased MIC and MBC values 
observed. This data indicated that despite CHG and BZC generally being used at higher 
concentrations than those tested here, much lower, potentially residual concentrations 
(0.00001 – 0.0004 %) can induce responses such as efflux up-regulation resulting in increases 
in biocide MIC and MBC. The protocol shown in figure 6.1 can therefore be used to test both 
in-use and residual biocide concentrations in order to determine if residual concentrations of 
biocide could be associated with resistance development. However due to the instability of the 
changes observed there is no risk of resistance development to CHG or BZC at the 
concentrations tested. 
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6.5 Protocol limitations and further considerations 
6.5.1 Test conditions 
The repeatability and reproducibility of the data obtained using any standard protocol can be 
affected by test conditions such as temperature, test inoculum preparation and pH. Existing 
protocols such as the BS EN 1276 (2009) suspension testing protocol specify that temperature 
must be maintained at 20 ± 1°C and provide specific instructions on the preparation of the 
diluents used for the test biocide and preparation of the test organism. The BSAC disk diffusion 
(2009) protocol for antibiotic susceptibility testing also specifies that the depth of the Iso-
Sensitest agar used must consistently be 4 ± 0.5 mm so that all antibiotics diffuse evenly in to 
the agar and reproducible results are obtained. To ensure that data obtained using the 
protocol shown here (figure 6.1) were reproducible, the test inoculum was always prepared in 
the same way (see chapter 2 section 2.1) and temperature during biocide exposure was 
maintained at 20 ± 1 °C using a water bath. Controlling these parameters is essential for the 
successful use of the protocol developed here as it minimises the chance of data variability due 
to altered biocide efficacy, either due to temperature fluctuations or differences in the test 
inoculum e.g. variable cell count or presence of aggregates. 
 
6.5.2. Biocide vs. Formulation 
As identified by SCENIHR (2009, 2010)  the vast majority of biocide susceptibility testing is 
carried out using individual biocides rather than formulations. It is important that formulations 
are tested as components of the formulation may affect the efficacy of the biocide contained 
within the product in comparison to the efficacy of the active biocide tested alone.  This point 
was highlighted in preliminary suspension tests performed in chapter 5 (table 5.7) where 
Dermax shampoo (contains 0.5 % BZC) was much less effective in killing test organisms in 
comparison to BZC alone. Factors such as the viscosity of a formulation (e.g. shampoo) may 
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affect the data obtained when using certain techniques to predict resistance.  The protocol 
designed here (figure 6.1) was validated testing both biocides (CHG, BZC) and formulations 
(mouthwash, shampoo, eye make-up remover) with reproducible and repeatable data 
obtained in both cases. To demonstrate the use of the protocol in testing formulations, figure 
6.3 shows the use of the protocol in predicting the risk of resistance development to Dermax 
shampoo using S. enterica strains SL1344 and 14028S as model organisms. As shown in figure 
6.3, there were no increases in the MIC or MBC for Dermax shampoo, nor were there any 
clinical changes in antibiotic resistance observed after exposure to Dermax shampoo. It can 
therefore be concluded that the risk of resistance development in SL1344 and 14028S is low. 
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Figure 6.3: Use of the predictive protocol to determine the risk of resistance development to Dermax shampoo in S. enterica strains SL1344 & 14028S  
Flow cytometry 
No 
Risk 
Yes 
No 
Phenotype stability testing 
No 
Risk 
Mechanisms 
Efflux assays 
RISK 
No 
No 
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No risk of resistance due 
to efflux up-regulation 
Yes 
No 
Yes 
No 
No 
Risk Membrane protein expression Yes 
Microarray Real time PCR 
What type of pump? 
No risk of resistance due 
to outer membrane 
protein change 
Yes 
Risk of stable resistance 
development 
MIC/MBC/antibiotic susceptibility 
No increase in MIC or MBC after exposure of all 
strains to Dermax shampoo 
Cheap, high throughput,  
rapid, easy to use. Cheap, 
high throughput,  
 
Not required 
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6.5.3 Additional techniques and future work 
6.5.3.1 Transferable and acquired resistance 
Multiple drug resistance in bacteria is most often associated with genotypic changes. These 
can be in the form of mutations in genes associated with resistance, e.g. efflux pump genes, 
porins (Svetlikova et al., 2009, Baucheron et al., 2004b) and can also occur when bacteria 
acquire resistance genes present on plasmids or transposons (Popowska and Krawczyk-Balska, 
2013). It is therefore important that predictive protocols are designed with this in mind, 
incorporating techniques that can inform the user of the effect of biocide exposure on gene 
exchange. The protocol designed here (figure 6.1) includes techniques such as real-time PCR 
and microarray which allow the exploration of changes in gene expression as a result of 
biocide exposure. Despite being costly, these techniques are well-established and have been 
successfully used in identifying changes in gene expression that have led to biocide resistance 
(Rushton et al., 2013, Sass et al., 2011, Whitehead et al., 2011). However these techniques 
cannot provide information on the effect of biocide exposure on plasmid transfer and 
therefore the dissemination of resistance genes and acquired MDR. This is also poorly studied 
and is more difficult to incorporate in to a predictive protocol as there are no standard 
techniques available (SCENIHR, 2009). It also must be taken in to consideration that resistance 
genes can be transferred between different bacterial species present in a given environment, 
as well as between the same species (Frye et al., 2011). The use of a particular biocide may 
therefore affect other bacterial species as well as the target organism. The method used must 
be suitable for the testing of multiple biocides and bacterial species and produce reproducible 
data. Such a method should be incorporated in to further developed versions of the protocol 
shown in figure 6.1.   
 
187 
 
6.5.3.2 Mutation 
Mutations in specific genes are often more associated with antibiotic resistance. For example, 
mutations in the QRDRs of genes such as gyrA have been shown to result in resistance to 
quinolone antibiotics in Salmonella species (Webber et al., 2013). However biocide exposure 
can result in the appearance of mutants with reduced biocide tolerance (Whitehead et al., 
2011). It would therefore be useful to include techniques that determine bacterial mutation 
frequency as a result of biocide exposure in future predictive protocols. Although there is no 
current standard technique for the determination of mutation frequency, it has been studied 
by several groups. The technique generally involves the exposure of the test organism to the 
biocide before surviving organisms are plated on to agar containing the same biocide at a 
concentration 2-4 times the MIC. The number of colonies on the plate can then be counted 
and the mutation frequency calculated (Christensen et al., 2011, Randall et al., 2004). The 
mutation frequency without biocide exposure should also be determined alongside this as a 
comparison point. It may also be useful to use a test organism for which the mutation 
frequency is already well-established, so an increase in the mutation frequency is easy to 
interpret.  As this technique appears rapid and straightforward it would make a valuable 
addition to future predictive protocols. 
 
6.5.3.3. Biofilms 
As > 90 % of bacteria are thought to exist in biofilm formation in vivo (Baugh et al., 2013), 
biocide susceptibility testing should be more frequently performed using biofilms (SCENIHR, 
2009). Comparisons between the susceptibility of biofilm and planktonic cells to a particular 
biocide should also be made. The protocol designed here (figure 6.1) was developed using 
planktonic cells only, but tests such as MIC/MBC determination, antibiotic susceptibility 
testing, efflux assays, real-time PCR, SDS-PAGE  and  microarray have been successfully used 
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with biofilms previously (Baugh et al., 2013, Coenye et al., 2011, Pagedar et al., 2011, Caraher 
et al., 2007, Tabak et al., 2007, Svensater et al., 2001) so the protocol would be suitable for 
predicting resistance in biofilm cells although some additional techniques could be added.  Of 
particular interest to investigate would be the effect of biocide exposure on the transfer of 
genetic material between cells present in a biofilm, as biofilms are often composed of 
numerous different bacterial species. The effect of biocide exposure on the ability of bacterial 
cells to form a biofilm should also be investigated as a biocide could both promote biofilm 
formation (as a mechanism to reduce biocide susceptibility) or reduce it (cell damage). Global 
gene expression analysis in biofilm cells would be also be of interest as biofilm cells often exist 
in a dormant state with reduced metabolic activity (Baugh et al., 2013) and resistance marker 
genes in biofilm cells may therefore differ considerably from those in planktonic cells. 
 
6.5.3.4 Fluorescence activated cell sorting (FACS) 
Flow cytometry experiments performed in chapter 3 highlighted that some cells within the 
population exposed to a low concentration of CHG or BZC (0.0001 – 0.0004 %) appear to 
remain undamaged after exposure. FACS allows the sorting and isolation of surviving cells and 
therefore provides the opportunity for further experiments to be performed using these cells. 
Whitehead et al., (2011) successfully used a combination of flow cytometry and FACS to 
identify and isolate multidrug resistant surviving S. enterica serovar Typhimurium isolates after 
biocide exposure. Flow cytometry and FACS could be incorporated in to future predictive 
protocols as a method for isolating surviving organisms before MIC/MBC determination and 
testing for further markers of resistance.  
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6.6 Concluding remarks 
The protocol proposed in figure 6.1 is composed of a range of techniques explored throughout 
this project that successfully generated markers of biocide resistance. The protocol has been 
validated (chapter 5) and produces reproducible data when testing both biocides and biocidal 
formulations. The protocol shown in figure 6.1 is therefore proposed for current use in the 
prediction of bacterial biocide resistance and antibiotic cross- resistance.  
Improvements can be made to this protocol via the incorporation of additional techniques 
including gene transfer analysis, mutation frequency experiments and FACS which will provide 
additional resistance markers. Figure 6.4 shows a possible future protocol incorporating these 
techniques. FACS should be carried out alongside flow cytometry as it allows the sorting and 
isolation of surviving populations observed in flow cytometry experiments. Mutation 
frequency and gene transfer experiments could be carried out following the observation of a 
stable increase in MIC, MBC, and/or antibiotic susceptibility.  
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Figure 6.4: Proposed future predictive protocol incorporating techniques that allow determination of the effect of biocide exposure on gene transfer and 
mutation frequency, as well as the use of FACS to isolate potentially resistant populations
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 Analysed data with a cut off p value of 0.01 
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 14028S 0.0004 % BZC 
 List of all genes in microarray 
 Concentration and purity of RNA extracted 
 
 Real-time PCR 
 Contains standard curves and fold change calculations for all Salmonella 
genes tested 
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